lapatinib has been researched along with Breast Cancer in 1043 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 177 (16.97) | 29.6817 |
| 2010's | 719 (68.94) | 24.3611 |
| 2020's | 147 (14.09) | 2.80 |
| Authors | Studies |
|---|---|
| Acton, DG; Ballard, P; Barlaam, B; Bradbury, RH; Cross, D; Ducray, R; Germain, H; Hudson, K; Klinowska, T; Magnien, F; Ogilvie, DJ; Olivier, A; Ross, HS; Smith, R; Trigwell, CB; Vautier, M; Wright, L | 1 |
| Dayam, R; Gundla, R; Kazemi, R; Muttineni, R; Neamati, N; Sanam, R; Sarma, JA | 1 |
| Byun, JY; Cha, MY; Choi, KJ; Jung, YH; Kang, SJ; Kim, MS; Lee, GS; Lee, HJ; Lee, KO; Park, SB; Song, JY | 1 |
| Bratton, MR; Jones, FE; Klein Stevens, CL; Nguyen, TL; Sfondouris, ME; Sridhar, J; Townley, I | 1 |
| Cao, R; Li, S; Zeng, Y; Zhang, T; Zhong, W | 1 |
| Abd Elmageed, ZY; Abdel Latif, NA; Abdelhafez, OM; Ahmed, EY; Ali, HI; Arafa, RK | 1 |
| Abd El-Karim, SS; Ahmed, NS; Anwar, MM; El-Hallouty, SM; Srour, AM | 1 |
| Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Gan, N; Li, H; Peng, X; Sun, Q; Suo, Z; Zhang, S; Zhao, G; Zhao, L | 1 |
| Ansari, K; Bhan, A; Chen, MY; Jandial, R | 1 |
| Berliere, M; Canon, JL; Dufour, V; Duhoux, FP; Migeotte, A; Taylor, D; van Maanen, A | 1 |
| Arribas, J; Chandarlapaty, S; de Stanchina, E; Ferraro, E; Kulick, A; Lahuerta, EJA; Li, Q; Morales, CB; Razavi, P; Reis-Filho, J; Rosen, N; Ross, D; Safonov, A; Smith, AE; Solit, DB | 1 |
| Andrejic Visnjic, B; Kolarov Bjelobrk, I; Pesic, J; Petrovic, N; Radic, J; Trifunovic, J; Vidovic, V; Vranjkovic, B | 1 |
| Bindhya, S; Ganesan, TS; Joshua, T; Krishnapriya, S; Manasa, P; Murhekar, K; Nagare, RP; Shabna, A; Sidhanth, C; Sneha, S | 1 |
| Bachelot, T; Bailleux, C; Darlix, A; Jacot, W | 1 |
| Bachelot, T; Carbonnaux, M; Dufresne, A; Heudel, PE; Mery, B; Toussaint, P; Trédan, O; Vanacker, H | 1 |
| Lou, G; Qu, Q; Shangguan, C; Yang, C | 1 |
| Armstrong, A; Bliss, JM; Brunt, AM; Bundred, N; Cameron, DA; Cramer, A; Cutress, RI; Dodwell, D; Emson, MA; Evans, A; Hanby, A; Hartup, SM; Horgan, K; McIntosh, SA; Miller, SE; Morden, JP; Naik, J; Narayanan, S; Ooi, J; Porta, N; Rakha, EA; Shaaban, AM; Skene, AI | 1 |
| Chen, T; He, Y; Lu, H; Pang, Z; Wang, Y | 1 |
| Chiotti, K; Korkola, JE; Liby, T; Liu, M; López, CS; Smith, R | 1 |
| Boué, SM; Burow, ME; Davidson, AM; Gupta, A; Khupse, R; Patel, JR; Payton-Stewart, F; Tilghman, SL; Walker, RR; Williams, CC | 1 |
| Conte, PF; Dieci, MV; Girardi, F; Griguolo, G; Guarneri, V; Miglietta, F | 1 |
| Bachelot, T; Carton, M; Cheaib, B; Chevrot, M; Cottu, PH; Courtinard, C; Dalenc, F; Debled, M; Desmoulins, I; Diéras, V; Emile, G; Eymard, JC; Ferrero, JM; Goncalves, A; Jacot, W; Leheurteur, M; Moinard-Butot, F; Mouret-Reynier, MA; Patsouris, A; Petit, T; Pflumio, C; Saint-Martin, C; Uwer, L; Vanlemmens, L | 1 |
| Abuhelwa, AY; Badaoui, S; Danell, NO; Haseloff, M; Hopkins, AM; McKinnon, RA; Modi, ND; Perry, RNA; Rathod, A; Shahnam, A; Sorich, MJ; Swain, SM; Welslau, M | 1 |
| Cortes, J; Dang, C; Gilsenan, A; Hackshaw, MD; Layton, JB; Lee, C; Perez, EA; Singh, J; Wang, K | 1 |
| Agostinetto, E; Awada, A; Bruzzone, M; Ceppi, M; Danielli, L; de Azambuja, E; Kotecki, N; Lambertini, M; Martins-Branco, D; Nader-Marta, G | 1 |
| Alley, SC; Bao, X; Jiang, J; Kumar, V; Lee, AJ; Li, J; Peterson, S | 1 |
| Drover, S; Wiede, LL | 2 |
| Belfiore, A; Bianchini, G; Castagnoli, L; Ciniselli, CM; Coccia-Portugal, MA; Corsetto, PA; Daidone, MG; de Azambuja, E; Di Cosimo, S; Dugo, M; El-Abed, S; Galbardi, B; Gianni, L; Huober, J; Izquierdo, M; Janni, W; Ligorio, F; Loi, S; Lorenzini, D; Michiels, S; Moscetti, L; Nuciforo, P; Pizzamiglio, S; Pruneri, G; Pupa, SM; Salgado, R; Tagliabue, E; Triulzi, T; Verderio, P; Vernieri, C; Vingiani, A | 1 |
| Bowen, J; Ibahim, MJ; Khan, J; Muhamad, M; Raja Sharin, RNFS; Wan Mohamad Zain, WNI | 1 |
| Barbolini, M; Canino, F; Dominici, M; Moscetti, L; Omarini, C; Piacentini, F; Toss, A; Vici, P | 1 |
| Chi, Y; Du, Y; Li, H; Man, X; Shan, C; Shang, M; Tan, Q; Wang, J; Yi, W; Yin, S | 1 |
| Iqbal, H; Khan, NU; Menaa, F; Razzaq, A; Rehman, SU; Webster, TJ; Xiao, R | 1 |
| Adamczyk-Grochala, J; Błoniarz, D; Lewińska, A; Wnuk, M; Wołowiec, S; Wróbel, K | 1 |
| Choi, SH; Choi, SJ; Jang, JK; Jung, KH; Kang, HJ; Kim, DW; Lee, JB; Lee, SS; Park, HJ | 1 |
| Buccinnà, B; Piccinini, M; Ramondetti, C | 1 |
| Chen, D; He, Z; Jiang, G; Li, H; Liu, B; Liu, H; Liu, S; Lyu, H; Ruan, S; Wang, H; Yang, M; Zeng, S; Zheng, G; Zhou, L | 1 |
| Cho, KR; Jung, SP; Kim, CY; Kim, JW; Lee, JH; Lee, NK; Lim, AR; Park, KH; Song, SE; You, JY | 1 |
| Beaumont, H; Chamorey, E; Faye, N; Hsieh, CY; Iannessi, A; Klifa, C | 1 |
| Badwe, R; Bajpai, J; Bhargava, P; Budrukkar, A; Desai, S; Ghosh, J; Gulia, S; Gupta, S; Joshi, S; Kannan, S; Nair, N; Pathak, R; Patil, A; Popat, P; Rath, S; Rathnasamy, N; Sarin, R; Shenoy, R; Shet, T; Wadasadawala, T | 1 |
| Bao, Y; Cai, L; He, X; Li, X; Wang, X; Zhang, Z | 1 |
| Arribas, J; Bernadó-Morales, C; Cordani, M; Diaz, E; Gámez-Chiachio, M; Gassner, K; Hernandez, A; Llobet, FJ; Llobet-Navás, D; Martinez, L; Martinez-Val, J; Molina-Crespo, Á; Moreno-Bueno, G; Ramos-Nebot, C; Rodríguez-Barrueco, R; Rojo-Sebastian, A; Sanchez, L; Sarrió, D; Soriano, M; Triviño, JC | 1 |
| Anderson, J; Antonios, B; Deol, J; Gaikazian, S; Ghimire, B; Gupta, R; Gupta, S; Huben, M; Jaiyesimi, I; Jindal, V; Stender, M | 1 |
| Lin, NU | 1 |
| Acconcia, F | 1 |
| Dong, Z; Fang, Q; Wang, J; Wu, Y | 1 |
| Alba, E; Antolin, S; Barnadas, A; Bonfill, X; Lluch, A; Martin, M; Rodriguez-Lescure, A; Ruiz-Borrego, M; Sanchez-Rovira, P; Servitja, S; Sola, I; Urrutia, G; Vazquez, JC | 1 |
| Cai, Y; Li, W; Liu, X; Yuan, Y | 2 |
| Ballman, KV; Brasó-Maristany, F; Campbell, JD; Carey, LA; Chic, N; Cortés, J; Fernandez-Martinez, A; Hoadley, KA; Krop, I; Llombart-Cussac, A; Nuciforo, P; Pare, L; Partridge, A; Pascual, T; Perou, CM; Prat, A; Rashid, NU; Singh, B; Spears, PA | 1 |
| Anderson, RA; Arecco, L; Ballestrero, A; Bruzzone, M; Cameron, DA; Ceppi, M; de Azambuja, E; Del Mastro, L; Demeestere, I; Di Cosimo, S; El-Abed, S; Franzoi, MA; Lambertini, M; Latocca, MM; Lecocq, C; Massarotti, C; Nuciforo, P; Partridge, AH; Peccatori, FA; Piccart, M; Pistilli, B; Pusztai, L; Rolyance, R; Ruddy, KJ; Saura, C; Sohn, J; Untch, M; Wang, Y | 1 |
| Aspitia, AM; Bliss, J; Cameron, D; Coccia-Portugal, MA; Colleoni, M; de Azambuja, E; Di Cosimo, S; El-Abed, S; Ferro, A; Fielding, S; Gelber, R; Gkolfi, P; Gombos, A; Gomez, H; Huober, J; Kroep, J; Kunz, G; Lerzo, G; Moebus, V; Nuciforo, P; Piccart, MJ; Saura, C; Semiglazov, V; Sohn, J; Townend, J; Tseng, LM; Werutsky, G | 1 |
| Chen, X; Fu, H; Gao, Z; He, Q; Jin, Y; Luo, P; Pan, Z; Wang, X; Xu, B; Xu, Z; Yan, H; Yang, B; Yang, X; Zeng, Y; Zhang, X; Zhang, Y | 1 |
| Aure, MR; Engebraaten, O; Haugen, MH; Hongisto, V; Kristensen, VN; Leivonen, SK; Mælandsmo, GM; Normann, LS; Sahlberg, KK; Tahiri, A | 1 |
| Antao, V; Lamarre, N; Montemurro, F; Peña-Murillo, C; Sanglier, T; Shim, J | 1 |
| Aydiner, A; Dogan, I; Ibis, K; Kizildag, I; Özkurt, S; Saip, P; Vatansever, S | 1 |
| André, T; Cervera, P; Cohen, R; Spitzer, E | 1 |
| Athanasiadis, E; Chalari, A; Chavdoula, E; Kafalidou, A; Klinakis, A; Konstantopoulos, D; Melissa, P; Papafotiou, G; Paschalidis, N; Pateras, IS; Simigdala, N; Sklirou, AD; Trougakos, IP | 1 |
| Abdel-Fattah, MM; Amin, NH; El-Saadi, MT; Mohammed, AA; Said, EG | 1 |
| Banjara, B; Boué, SM; Burow, ME; Davidson, AM; Ohemeng, A; Patel, JR; Tilghman, SL | 1 |
| Abdelgalil, AA; Alkahtani, HM | 1 |
| Gulmez, A | 1 |
| Cao, Y; Qi, T | 1 |
| Arai, N; Ebata, T; Fujii, S; Hattori, N; Kondo, H; Liu, YY; Mukai, H; Takeshima, H; Takeuchi, C; Ushijima, T; Yamashita, S | 1 |
| Camps Maléa, A; Hennequin, C; Rivera, S | 1 |
| Ajayi, RF; Douman, SF; Iwuoha, EI; January, JL; Jijana, AN; Mulaudzi, T; Ngema, NPP; Tshobeni, ZZ | 1 |
| Chang, L; Chen, X; Gao, X; Li, Q; Li, Y; Luo, H; Wei, X; Westover, KD; Zhang, Y; Zhou, Z; Zhu, J | 1 |
| Senkus, E; Stanowicka-Grada, M | 1 |
| Asselain, B; Barraud, S; Bihan, K; Coussy, F; Dumas, E; Gougis, P; Grandal, B; Hamy, AS; Hotton, J; Jochum, F; Laas, E; Pierga, JY; Reyal, F; Savarino, R; Sebbag, C; Spaggiari, E; Spano, JP | 1 |
| Bandos, H; Geyer, CE; Goerlitz, D; Harris, BT; Lucas, PC; Mamounas, EP; Rastogi, P; Robidoux, A; Swain, SM; Tang, G; Wolmark, N | 1 |
| Feng, J; Hu, X; Jiang, Z; Li, H; Li, W; Liu, Y; Ma, F; Ouyang, Q; Tong, Z; Wang, S; Xu, B; Yu, S; Zhu, X; Zou, J | 1 |
| Fang, R; Hazard, SE; Mason, S; Roberts, TM; Sun, B; Wang, Q; Wang, Y; Wilson, RC; Yang, M; Yeh, ES; Zhao, JJ | 1 |
| Belcheva, A; Boone, T; Chang, JC; Creamer, SL; Darcourt, JG; Ensor, JE; Kaklamani, VG; Kuhn, JG; Li, X; Meisel, JL; Niravath, PA; Patel, TA; Qian, W; Rodriguez, AA; Rosato, RR; Schwartz, MR; Zhao, J | 1 |
| Gourd, E | 1 |
| Abu-Irmaileh, B; AbuThiab, T; AlBayyari, S; Hameduh, T; Mubarak, MS; Zalloum, H; Zalloum, W; Zihlif, M | 1 |
| Corral de la Fuente, E; Fernández Abad, M; Martin Huertas, R; Martínez Jáñez, N; Serrano Domingo, JJ | 1 |
| Aghadoukht, A; Baradaran, B; Derakhshani, A; Gholamiyan Moghadam, A; Hajiasgharzadeh, K; Mir, A; Rezaei, Z; Sabri, M; Safarpour, H; Sanati, MA; Vahidian, F | 1 |
| Chattipakorn, N; Chattipakorn, SC; Leemasawat, K; Phrommintikul, A | 1 |
| Cataldo, ML; De Angelis, C; Gutierrez, C; Hilsenbeck, SG; Hoyt, CC; Liu, L; Mao, S; Nagi, C; Nuciforo, P; Osborne, CK; Pavlick, A; Prat, A; Reis-Filho, JS; Rimawi, MF; Roman, K; Schiff, R; Sethunath, V; Trivedi, MV; Tsimelzon, A; Veeraraghavan, J; Wang, C; Wang, T; Weigelt, B; Wolff, AC; Zheng, Y | 1 |
| De Angelis, C; Forero, A; Goetz, MP; Gutierrez, C; Hilsenbeck, SG; Jiralerspong, S; Krop, I; Nanda, R; Nangia, JR; Niravath, P; Osborne, CK; Pavlick, A; Rexer, BN; Rimawi, MF; Schiff, R; Storniolo, AM; Veeraraghavan, J; Wang, T; Wolff, AC | 1 |
| Albanell, J; Almendro, V; Alonso, R; Ametller, E; Bill, A; Bragado, P; Enreig, E; Fernández-Nogueira, P; Fuster, G; Gaither, LA; Gascon, P; Jauregui, P; Lluch, A; López-Plana, A; Mancino, M; Menéndez, S; Moragas, N; Noguera-Castells, A; Recalde-Percaz, L; Rojo, F; Rovira, A; Serrano, L | 1 |
| Brunton, VG; Creedon, H; Culley, J; Kemp, AJ; Klinowska, T; Muir, M; Tracey, N | 1 |
| Díaz-Gil, L; Díaz-Rodríguez, E; Gandullo-Sánchez, L; Ocaña, A; Pandiella, A; Ríos-Luci, C | 1 |
| Ali, AA; Alqhtani, H; Balkrishnan, R; de Lima Lopes, G; Diaby, V; Ko, Y; Palacio, S; van Boemmel-Wegmann, S; Wang, CY | 1 |
| An, J; Bang, S; Canfield, K; Cheng, C; Del Genio, C; DiRenzo, J; Febbraio, M; Feng, WW; Gaur, A; Guo, JY; Kinlaw, WB; Kurokawa, M; Li, J; Powles, RL; Pusztai, L; Robey, RB; Sotiriou, C; Ung, M; Wells, W; Wilkins, O | 1 |
| Hu, Y; Li, X; Luo, N; Zhang, K | 1 |
| Adamo, B; Alarcón, J; Bermejo, B; Brasó-Maristany, F; Chic, N; Ciruelos, E; Cortés, J; Galván, P; Garau, I; Gomis, RR; Gregorio, S; Griguolo, G; Llombart-Cussac, A; López, R; Manso, L; Martínez, E; Martínez, N; Martínez, O; Morales, S; Muñoz, M; Nuciforo, P; Oliveira, M; Paré, L; Pascual, T; Pernas, S; Prat, A; Vidal, M; Villagrasa, P | 1 |
| Lei, L; Wang, XJ; Xu, CW; Yang, L; Yang, ZY | 1 |
| Cheng, H; Ding, J; Huang, G; Li, M; Liu, C; Liu, P; Wang, K; Wang, M; Wang, X; Yao, Y; Ye, M; Yi, J; Zhang, N; Zhang, Y | 1 |
| Blanco-Aparicio, C; Cunningham, D; Eustace, AJ; Hennessy, BT; Kennedy, SP; Martinez, S; Morris, PG; O'Neill, M; Pastor, J; Toomey, S | 1 |
| Hong, R; Jiang, K; Lee, K; Li, Y; Liao, H; Lu, Q; Qin, G; Wang, S; Xia, W; Xu, F; Yuan, H; Zhai, Q; Zhang, J; Zhang, K; Zheng, Q | 1 |
| Ge, R; Ji, X; Li, W; Luo, T; Sang, D; Wang, B; Xie, Y; Yuan, P | 1 |
| Ao, J; Chen, D; Chen, H; Fei, J; Li, F; Luo, Y; Luo, Z; Niu, M; Ren, X; Xiao, ZJ; Yi, J; Yi, Y; Zhang, W | 1 |
| Fu, P; Fu, Z; Huang, X; Jiang, Z; Jin, F; Li, J; Li, W; Li, Y; Sun, C; Wang, B; Wang, H; Wang, J; Wu, H; Yan, M; Yang, F; Yang, M; Yin, Y; Zeng, T; Zhang, J | 1 |
| Gangemi, E; Greco, C; Ippolito, E; La Cesa, A; Matteucci, P; Ramella, S; Santini, D; Santo, B; Silipigni, S | 1 |
| Cao, J; Du, Y; Hu, X; Lin, M; Lin, Y; Tao, Z; Wang, B; Wang, L; Zhang, J; Zhang, S | 1 |
| Bandos, H; Brauer, HA; Geyer, CE; Goerlitz, DS; Harris, BT; Lucas, PC; Mamounas, EP; Rastogi, P; Ren, Y; Robidoux, A; Swain, SM; Tang, G; Wolmark, N | 1 |
| Chintalaramulu, N; Cock, IE; Nguyen, NT; Vadivelu, R | 1 |
| Deutsch, TM; Feisst, M; Fischer, C; Fremd, C; Hartkopf, AD; Nees, J; Pantel, K; Riethdorf, S; Schneeweiss, A; Schütz, F; Trumpp, A; Wallwiener, M | 1 |
| Bueno, C; Carolla, RL; Chen, B; Hillman, DW; Jenkins, RB; Johnson, DB; Leon-Ferre, RA; Moreno-Aspitia, A; Northfelt, DW; Perez, AT; Perez, EA; Zon, RT | 1 |
| Crawford, DR; Ilic, Z; Saxena, AR; Sripada, V | 1 |
| Huang, B; Luo, KQ; Wei, N; Yip, WK | 1 |
| Camidge, DR; Danysh, HE; Hackshaw, MD; Iwata, H; Ladner, A; Powell, CA; Ritchey, ME; Singh, J; Taitt, C | 1 |
| Apostolidou, K; Bartsch, R; Dimopoulos, MA; Le Rhun, E; Preusser, M; Zagouri, F; Zografos, E; Zoumpourlis, P | 1 |
| Dodwell, D; Heudtlass, P; Johnston, S; Marshall, H; Murden, G; Oughton, JB; Passant, H; Pottinger, A; Price, C; Rizwanullah, M; Seligmann, JF; Velikova, G; Wright-Hughes, A | 1 |
| Brugge, JS; Dillon, DA; Lin, JR; Mills, GB; Pathania, S; Poskus, MD; Scott, AL; Selfors, LM; Sorger, PK; Zervantonakis, IK | 1 |
| Goel, AK; Hari, S; Zamre, V | 1 |
| Cella, D; Fallowfield, LJ; Harder, H; May, SF; Schmid, P; Shilling, VM | 1 |
| Hu, Y; Lee, S; Li, L; Lin, L; Schiff, R; Tan, Y; Veeraraghavan, J; Wang, X; Wang, XS | 1 |
| Beaumel, S; Chettab, K; Cleret, A; Conilh, L; Dumontet, C; Duong, MN; Geneste, A; Jordheim, LP; Lachat, M; Matera, EL; Molina, L | 1 |
| Huang, L; Liu, A; Liu, Q; Yang, F; Zhang, J; Zhang, L | 1 |
| Bighin, C; Blondeaux, E; Cardinali, B; Del Mastro, L; Ferreira, AR; Fontana, A; Fregatti, P; Lai, A; Lambertini, M; Minuti, G; Montemurro, F; Mura, S; Poggio, F; Poletto, E; Puglisi, F; Sini, V; Sottotetti, F | 1 |
| Burdaeva, O; Gradishar, WJ; Hegg, R; Im, SA; Iwata, H; Izquierdo, MA; Johnston, SRD; Kenny, S; Kurteva, G; Park, IH; Press, MF; Sarp, S; Simon, SD; Tjulandin, S; Williams, LS | 2 |
| Al-Husein, BA; Alkhalifa, AE; Ayoub, NM; Ibrahim, DR | 1 |
| Ali, A; Ali, SM; Aparicio, S; Chen, BE; Cream, L; Drabick, J; Gelmon, K; Halstead, ES; Leitzel, K; Lipton, A; Maddukuri, A; Mckeone, D; Moku, P; Nagabhairu, V; Nomikos, D; Pancholy, N; Parulekar, WR; Polimera, H; Poulose, J; Shepherd, L; Spiegel, H; Umstead, TM; Virk, S; Zhu, L | 1 |
| Agbor-Tarh, D; Dal Lago, L; de Azambuja, E; Dueck, AC; Gelber, RD; Hilbers, F; Jackisch, C; Jatoi, A; Korde, LA; Moreno-Aspitia, A; Piccart, M; Pondé, N; Sotiriou, C; Werner, O | 1 |
| Ayyamperumal, S; Durai, U; Jubie, S; Latha, S; Prabha, T; Wadhwani, A | 1 |
| Freeman, MR; Hemler, ME; Sharma, C; Steen, H; Yang, W | 1 |
| Ahn, JH; Ahn, SH; Gong, G; Jung, KH; Kim, D; Kim, HH; Kim, JE; Kim, SB; Lee, HJ; Moon, DH; Park, JH; Shin, HJ; Son, BH | 1 |
| Gelmon, KA; Tesch, ME | 1 |
| Fan, Y; Guo, Z; Hu, J; Liang, E; Ma, M; Sui, J; Sun, Y; Wang, J; Yang, L | 1 |
| Bando, H; Homma, M; Ishiguro, H; Kuroi, K; Masuda, N; Morita, S; Ohgami, M; Shimizu, S; Takano, T; Toi, M; Toriguchi, N; Tsuda, M; Yamamoto, N; Yanagita, Y | 1 |
| Pisoni, R; Ramagopalan, SV; Rathore, LS; Ray, J; Sammon, C; Zenin, A | 1 |
| Berry, D; Carey, LA; Dang, C; Fernandez-Martinez, A; Hahn, O; Harris, L; Henry, NL; Hillman, DW; Hoadley, KA; Hudis, C; Huebner, L; Krop, IE; Parker, JS; Partridge, A; Perou, CM; Polley, MY; Shepherd, J; Tolaney, S; Winer, E | 1 |
| AlSultan, D; Ballot, J; Bossenmaier, B; Collins, DM; Crown, J; Davies, AM; Espina, V; Eustace, AJ; Gallagher, WM; Gately, KA; Gaynor, N; Hasmann, M; Hennessy, BT; Holmes, FA; Hughes, C; Le Gal, M; Liotta, L; Madden, SF; Mahgoub, T; O'Byrne, KJ; O'Connor, DP; O'Donovan, N; Toomey, S | 1 |
| Adams, B; Allen, H; Bean, GR; Bosserman, L; Brugge, JS; Calfa, C; Caswell-Jin, JL; Chen, HW; Curtis, C; Dering, J; DiCarlo, B; Dichmann, R; Giuliano, A; Hurvitz, SA; Kennedy, A; Kotler, E; Mani, A; McNamara, KL; Molthrop, D; Patel, R; Perez, A; Press, MF; Slamon, DJ; Zehngebot, L; Zoeller, JJ | 1 |
| Fujii, M; Fujimoto, Y; Haeno, H; Hakozaki, Y; Kashima, Y; Kobayashi, SS; Morita, TY; Mukohara, T; Ohashi, A | 1 |
| Bera, T; Das, A; Shetty, SR; Yeeravalli, R | 1 |
| Ait-Oudhia, S; Franco, YL; Mody, H; Perez, L; Ramakrishnan, V; Vaidya, TR | 1 |
| Li, C; Li, H; Lin, F; Ma, F; Nan, P; Qian, H; Wang, H; Wang, J; Wang, T; Xu, D; Yi, Z; Zhang, J | 1 |
| George Priya Doss, C; Magesh, R; Thirumal Kumar, D; Udhaya Kumar, S | 1 |
| Chen, C; Chen, Q; Cheng, J; Cheng, Y; Feng, J; Geng, C; Gu, Y; Hu, X; Li, H; Li, W; Liu, J; Liu, Q; Lu, J; Luo, T; Ma, F; Ouyang, Q; Qin, S; Shen, K; Sun, T; Tong, Z; Wang, H; Wang, S; Wang, X; Wu, Y; Xu, B; Yan, M; Yang, J; Yin, Y; Yu, Z; Zhang, Q; Zhu, X; Zou, J | 1 |
| Ahmed, S; Diab, AA; El Mahdy, MM; El-Husseiny, N; El-Sherif, AA; El-Shinawi, M; Mohamed, HT; Mohamed, MM; Safwat, G | 1 |
| Alsaleem, M; Arribas, J; Benítez, S; Ciscar, M; Galván, P; Gomez-Miragaya, J; Gonzalez-Suarez, E; Green, AR; Jimenez, M; Lemeer, S; Morancho, B; Mulder, C; Palomeras, S; Pascual, T; Pedersen, K; Pernas, S; Petit, A; Prat, A; Puig, T; Rakha, EA; Santamaria, PG; Sanz-Moreno, A; Soler-Monsó, MT; Viñas, G | 1 |
| Ballman, KV; Chen, B; De Silva, C; Dueck, AC; Goetz, MP; Haddad, TC; Haluska, P; He, J; Hopkins, JO; Linden, H; Northfelt, D; O'Sullivan, CC; Perez, EA; Sparano, JA; Tenner, KS | 1 |
| Alyami, SA; Azad, AKM | 1 |
| Banerji, D; Majumder, A; Moasser, MM; Olshen, A; Sandhu, M; Steri, V | 1 |
| Dietrich, TN; Dinant, C; Egan, D; Hansen, MB; Jäättelä, M; Kallunki, T; Maeda, K; Nielsen, IØ; Postol, M; Puustinen, P; Strauss, R; Tvingsholm, S | 1 |
| Brugge, JS; Dering, J; Hurvitz, SA; Press, MF; Selfors, LM; Slamon, DJ; Zoeller, JJ | 1 |
| Bai, Y; Cheng, Y; Cui, Y; Duan, X; Liu, Q; Liu, Y; Qin, N; Xiang, Q; Xu, L; Zhang, J; Zhang, Z | 1 |
| Aure, MR; Haugen, MH; Hongisto, V; Kristensen, VN; Leivonen, SK; Mælandsmo, GM; Normann, LS; Sahlberg, KK | 1 |
| Kim, S; Kwon, YS; Nam, KS | 1 |
| Borrero-García, LD; Del Mar Maldonado, M; Dharmawardhane, S; Grafals-Ruiz, N; Medina-Velázquez, J; Troche-Torres, AL; Velazquez, L | 1 |
| Austin, E; Kalomeris, T; Larimer, B; Mahmood, U; Nesti, S; Sinevici, N; Wehrenberg-Klee, E | 1 |
| Nycz, J; Wilczok, A; Zajdel, A | 1 |
| Cheng, H; Li, L; Liu, P; Liu, Y; Liu, Z; Rui, C; Sang, X; Tao, Z | 1 |
| Bisagni, G; Cagossi, K; Cavanna, L; Cinieri, S; Conte, P; Dieci, MV; Frassoldati, A; Generali, DG; Gianni, L; Girardi, F; Griguolo, G; Guarneri, V; Miglietta, F; Musolino, A; Piacentini, F; Pinotti, G; Prat, A; Sarti, S | 1 |
| Dinaryanti, A; Kirtishanti, A; Siswodihardjo, S; Sudiana, IK; Suprabawati, DGA | 1 |
| Chen, S; Lensing, MM; Lyu, C; Wagner, KU; Weigel, RJ; Ye, Y | 1 |
| Babcock, D; Boddapati, S; Chin, K; Devlin, K; Esch, A; Garay, JP; Gray, JW; Heiser, L; Hollern, DP; Korkola, JE; Kwon, S; Liby, T; Liu, M; Smith, R; Thompson, W; Watson, SS; Zheng, T | 1 |
| Badiee, A; Jafari, MR; Karimi, M; Mansouri, A; Mehrabian, A; Nikpoor, AR; Sadri, K; Shokooh Saremi, S | 1 |
| Chen, CH; Chen, HF; Chen, JY; Hsu, YM; Huang, CH; Huang, WC; Huynh, TK; Liu, LC; Tu, CY; Wei, YL; Yang, YS; Yao, JH | 1 |
| Agustina, R; Ishimoto, T; Kato, Y; Kido, Y; Masuo, Y; Shinoda, K | 1 |
| Amadori, D; Andreis, D; Cecconetto, L; Donati, C; Fabbri, F; Faedi, M; Fedeli, A; Maltoni, R; Melegari, E; Monti, M; Nanni, O; Passardi, A; Pietri, E; Rocca, A; Sarti, S; Schirone, A | 1 |
| Aiyappa, R; Alexander, A; Ce, A; Correa, M; Desai, K; Kalamdani, A; Kaluve, RS; Korlimarla, A; Lawrence, PV; Manjunath, S; Nair, MG; Patil, S; Prabhu, JS; Prasad, M; Sridhar, TS; Srinath, BS | 1 |
| Jeong, J; Kim, LK; Kim, W; VanHouten, J; Wysolmerski, JJ | 1 |
| Agbor-Tarh, D; Andersson, M; Azim, HA; Bradbury, I; Cufer, T; de Azambuja, E; Di Cosimo, S; Fumagalli, D; Gralow, J; Harris, L; Keane, M; Kroep, J; Moreno-Aspitia, A; Piccart-Gebhart, M; Salman, P; Sarp, S; Simon, SD; Sonnenblick, A; Toi, M; Wolff, AC | 1 |
| Anne Zujewski, J; Azim, HA; De Azambuja, E; Gingras, I; Gnant, M; Gralow, JR; Harris, L; Holmes, E; Inbar, M; Izquierdo, M; Moreno-Aspitia, A; Naume, B; Nguyen, DH; Piccart, MJ; Tomasello, G; Wolff, AC | 1 |
| Chen, Z; Huang, Y; Zhang, L; Zhu, B; Zhu, Y; Zhuo, W | 1 |
| Ci, X; Dong, JT; Fu, L; King, JL; Luo, A; Ma, G; Nahta, R; Qi, L; Wu, Q; Zhang, B; Zhang, S | 1 |
| Bradbury, P; Chia, SK; Eisenhauer, E; Ellard, SL; Gelmon, K; Goodwin, R; Hagerman, L; Kumar, V; Lohrisch, C; Mates, M; Mihalcioiu, C; Miller, WH; Sakashita, S; Taylor, S; Tsao, MS; Wang, T; Welch, S | 1 |
| Arima, N; Hasegawa, S; Kai, Y; Katayama, K; Koga, T; Kurashita, K; Mitsuyama, S; Nishimura, R; Ohi, Y; Okumura, Y; Saimura, M; Saito, T; Shimada, K; Tamura, K; Tanaka, M; Tanaka, T; Teraoka, M; Todoroki, H; Toh, U; Toyoshima, S | 1 |
| Conlon, N; Crown, J; Kolch, W; O'Connor, R; O'Donovan, N; Roche, S; Santra, T | 1 |
| Ali, SM; Aparicio, S; Carney, WP; Chapman, JW; Crescnzo, RJ; Ellis, CE; Gelmon, KA; Ho, D; Huang, J; Leitzel, K; Lipton, A; Nomikos, D; Parulekar, WR; Shepherd, L; Virk, S; Zhu, L | 1 |
| Alladin, A; Burwinkel, B; Garcia, M; Gibson, TJ; Havas, KM; Jechlinger, M; Kafkia, E; Klaus, B; Milchevskaya, V; Patil, KR; Pruneri, G; Radic, K; Rotmensz, N; Schneeweiss, A; Sotillo, R; Stolte, J | 1 |
| Buisseret, L; Ceppi, M; de Azambuja, E; Fumagalli, D; Garaud, S; Ignatiadis, M; Lambertini, M; Salgado, R; Scartozzi, M; Solinas, C; Sotiriou, C; Willard-Gallo, K | 1 |
| Baselga, J; Blackwell, K; Diéras, V; Gianni, L; Green, M; Hoersch, S; Krop, IE; Miles, D; Pegram, M; Verma, S; Welslau, M; Xu, J | 1 |
| Badovinac-Crnjevic, T; Ferrero, JM; Hoersch, S; Kim, SB; Krop, IE; LoRusso, PM; Martin, AG; Smitt, M; Wildiers, H | 1 |
| Aogi, K; Bando, H; Homma, M; Ishiguro, H; Kurosawa, A; Masuda, N; Mitsuhashi, S; Ohgami, M; Toi, M; Toriguchi, N; Tsuda, M | 1 |
| Patra, PK; Sahu, A; Varma, M; Yadav, MK | 1 |
| De Angelis, C; Osborne, CK; Pascual, T; Prat, A; Reis-Filho, JS; Rimawi, MF; Schiff, R; Veeraraghavan, J | 1 |
| Bobos, M; Christodoulou, C; Fountzilas, G; Goudopoulou, A; Kalogera-Fountzila, A; Kalogeras, KT; Karavasilis, V; Kouvatseas, G; Papadopoulos, G; Papandreou, CN; Rallis, G; Razis, E; Samantas, E; Syrigos, KN; Varaki, K | 1 |
| Burugu, S; Chen, B; Gao, D; Gelmon, KA; Kos, Z; Leung, S; Liu, S; Nielsen, TO; Parulekar, WR; Shepherd, L; Virk, S | 1 |
| Breathnach, O; Carr, A; Crown, J; Duke, D; Eustace, AJ; Fay, J; Gallagher, W; Grogan, L; Gullo, G; Hambly, N; Hennessy, BT; Hill, AD; Kay, EW; Kelly, C; Kennedy, MJ; Madden, SF; Milewska, M; Moulton, B; O'Donovan, N; Power, C; Sheehan, KM; Teiserskiene, A; Toomey, S; Walshe, J | 1 |
| Chanrion, M; Dewson, G; Geneste, O; Giner, G; Gong, JN; Gräsel, J; Herold, MJ; Huang, DCS; Lalaoui, N; Lessene, G; Li, X; Lindeman, GJ; Liu, K; Maragno, AL; Merino, D; Pal, B; Schneider, E; Segal, D; Serrano, A; Smyth, GK; Vaillant, F; Visvader, JE; Whittle, JR | 1 |
| Antony, J; El-Bahrawy, M; Gabra, H; Karali, E; Louis, LS; McKie, AB; Okon, IS; Recchi, C; Stebbing, J; Vaughan, S; Zanini, E | 1 |
| Metzger-Filho, O; Winer, EP | 1 |
| Ahmed, S; Andersson, M; Armour, A; Aziz, Z; Briley, LP; Byrne, J; Crescenzo, R; Demetriou, G; Fraser, DJ; Gralow, J; Harris, L; Jackson, N; Jiang, Z; Mehta, A; Parham, LR; Perez, E; Piccart, M; Spraggs, CF; Toi, M; Warren, L; Williams, LS; Zujewski, JA | 1 |
| Chander, H; Kaur, RP; Kumar, V; Ludhiadch, A; Munshi, A; Singla, H | 1 |
| Barni, S; Borgonovo, K; Cabiddu, M; Ghidini, M; Ghilardi, M; Lonati, V; Petrelli, F; Tomasello, G | 1 |
| Chang, MJ; Choi, HD | 1 |
| Blankstein, AR; Chen, Y; Choquette, TR; Dielschneider, RF; Gibson, SB; Henson, ES; Ma, S; Xiao, W | 1 |
| Autret, A; Bertucci, F; Boher, JM; Camerlo, J; Campone, M; Charafe-Jauffret, E; Extra, JM; Gonçalves, A; Guerin, M; Hervieu, A; Isambert, N; Lokiec, F; Pakradouni, J; Provansal, M; Rezai, K; Sabatier, R; Viens, P | 1 |
| Alarcón, J; Bermejo, B; Brase, JC; Cortés, J; Fasani, R; Galvan, P; Garau, I; Holgado, E; Llombart-Cussac, A; López, R; Manso, L; Martínez, E; Martínez, N; Muñoz, M; Nuciforo, P; Oliveira, M; Paré, L; Pascual, T; Pernas, S; Prat, A; Rodrik-Outmezguine, V; Vidal, M; Villagrasa, P | 1 |
| Arteaga, CL; Dugger, TC; Estrada, MV; Formisano, L; Gonzalez Ericsson, PI; Guerrero-Zotano, A; Horak, ID; Hutchinson, KE; Kragh, M; Lantto, J; Pedersen, MW; Red-Brewer, M; Rexer, BN; Sanders, ME; Schwarz, LJ; Young, CD | 1 |
| Cescon, D; El-Hachem, N; Haibe-Kains, B; Lupien, M; Mak, TW; Quevedo, R; Safikhani, Z; Silvester, J; Smirnov, P; Thu, KL | 1 |
| Choi, MR; Clare, SE; Goodman, AM; Halas, NJ; Henderson, L; Neumann, O; Nørregaard, K | 1 |
| Burke, KA; Chang, JC; Contreras, A; De Angelis, C; Forero, A; Fuqua, SAW; Geyer, FC; Goetz, MP; Gutierrez, C; Herrera, S; Hilsenbeck, SG; Kent Osborne, C; Krop, IE; Li, MM; Mayer, IA; Nanda, R; Pareja, F; Pavlick, AC; Reis-Filho, JS; Rimawi, MF; Schiff, R; Wang, T; Weigelt, B; Wolff, AC | 1 |
| Abe, T; Hayashida, T; Kikuchi, M; Kitagawa, Y; Maeda, H; Nagayama, A; Nakashoji, A; Seki, T; Takahashi, M; Toyota, T; Watanuki, R; Yokoe, T | 1 |
| Azim, HA; Baselga, J; Bregni, G; Campbell, C; Colleoni, M; Criscitiello, C; Curigliano, G; de Azambuja, E; de la Pena, L; Di Cosimo, S; Fein, L; Ferro, A; Fumagalli, D; Galli, G; Huober, J; Izquierdo, M; Naume, BJ; Ng, WMJ; Patel, A; Piccart-Gebhart, MJ; Vinholes, J | 1 |
| Bagheri, N; Kosari, S; Madden, R; Peterson, GM; Thomas, J | 1 |
| Hannouf, MB; Nixon, NA; Verma, S | 1 |
| Burki, TK | 1 |
| Ameels, H; Baselga, J; Berghorn, M; Borrego, MR; Bozovic-Spasojevic, I; Bradbury, I; Campbell, C; Chen, DR; de Azambuja, E; Di Cosimo, S; Ewer, M; Fumagalli, D; Harbeck, N; Huober, J; Im, YH; Izquierdo, M; Lambertini, M; Maetens, M; Piccart, M; Ponde, N; Pusztai, L; Rodeheffer, R; Suter, T; Zardavas, D | 1 |
| Gligorov, J; Pivot, X; Richard, S | 1 |
| Chang, DY; Chao, TY; Chen, TW; Cheng, AL; Chow, LW; Consortium, TBC; Hsieh, YY; Huang, SM; Lin, CH; Lu, YS; Yeh, DC | 1 |
| Hirata, M; Nezasa, KI; Shinonome, S; Tanaka, H; Tanaka, Y; Torii, M | 1 |
| Alvarez, JV; Amuchastegui, K; Damrauer, JS; Kroger, BR; Lupo, R; Mabe, NW; Phelps, SN; Walens, A | 1 |
| Tan, Q; Wei, C | 1 |
| Beal, K; Diab, A; Hudis, CA; McArthur, HL; Morikawa, A; Patil, S; Seidman, AD; Wang, R; Yang, J | 1 |
| Dong, D; Guan, M; Liu, X; Niu, R; Shao, J; Tong, Y; Wang, M; Zhang, F; Zhou, Y | 1 |
| Abe, K; Ando, O; Imaoka, T; Karibe, T | 1 |
| Bando, H; Inoue, K; Iwata, H; Kasai, H; Kuroi, K; Masuda, N; Morita, S; Ohno, S; Ohtani, S; Sakurai, T; Takano, T; Toi, M; Yamamoto, N; Yanagita, Y | 1 |
| Ajmal, G; Bonde, GV; Chauhan, S; Mishra, B; Mittal, P; Thokala, S; Yadav, SK | 1 |
| Blohmer, JU; Eggemann, H; Fasching, PA; Fehm, T; Gerber, B; Hanusch, C; Hauschild, M; Huober, J; Jackisch, C; Kunz, G; Loibl, S; Nekljudova, V; Rezai, M; Schem, C; Solbach, C; Tesch, H; Untch, M; von Minckwitz, G | 1 |
| Bucher, E; Chin, K; Dane, M; Gray, JW; Heiser, LM; Jonas, O; Kilburn, D; Korkola, JE; Liby, T; Liu, M; Mills, GB; Nederlof, M; Smith, R; Sudar, D; Tatarova, Z; Thompson, W; Watson, SS; Whitman, M | 1 |
| Ci, B; Fernández, ÁF; Kim, M; Levine, B; Vega-Rubín-de-Celis, S; Xiao, G; Xie, Y; Zou, Z | 1 |
| Arumí, M; Bellet, M; Escrivá-de-Romaní, S; Saura, C | 1 |
| Friberg, LE; Girish, S; Jin, JY; Karlsson, MO; Li, C; Lum, BL; Quartino, A; Schindler, E; Wang, B | 1 |
| Aogi, K; Fukuoka, J; Ito, Y; Kawabata, H; Kimura, H; Matsumoto, K; Nakagawa, K; Nishio, K; Saeki, T; Sakai, K; Sato, K; Takahashi, M; Takano, T; Tamura, K; Tsurutani, J; Yamanaka, T | 1 |
| Autore, F; Barber, PR; Cameron, A; Claus, J; Collu, F; Colomba, A; Fraternali, F; George, R; Hirsch, M; Martin-Fernandez, ML; Ng, T; Ortiz-Zapater, E; Parker, PJ; Patel, G; Roberts, S; Soliman, TN; Vojnovic, B; Weitsman, G; Yarden, Y; Zanetti-Domingues, LC | 1 |
| Brandão, M; El-Hachem, G; Piccart, M; Pondé, N; Werbrouck, E | 1 |
| Duchnowska, R; Jassem, J; Loibl, S | 1 |
| Alexandrova, EM; Garcia, L; Ghaleb, A; Marchenko, N; Yallowitz, A | 1 |
| Hayashida, T; Jinno, H; Kitagawa, Y; Matsumoto, A; Takahashi, M | 1 |
| Barrios, CH; Baselga, J; Bines, J; Boyle, F; Campbell, C; de Azambuja, E; Del Mastro, L; Fumagalli, D; Gelber, RD; Ignatiadis, M; Izquierdo, M; Jackisch, C; Korde, LA; Lambertini, M; Lang, I; Moreno-Aspitia, A; Piccart, M; Pritchard, K; Smith, I; Untch, M; Wolff, AC; Xu, B | 1 |
| Gray, JW; Gu, S; Hu, Z; Ngamcherdtrakul, W; Reda, M; Yantasee, W | 1 |
| Baker, AT; Fernandez, M; Filipovic, A; Green, A; Miele, L; Osipo, C; Peiffer, DS; Rakha, E; Shah, D; Simms, P; Wyatt, D | 1 |
| Baselga, J; de Azambuja, E; Di Cosimo, S; Elemento, O; Fumagalli, D; Harbeck, N; Hatzis, C; Huober, J; Loi, S; Nuciforo, P; Piccart-Gebhart, M; Powles, RL; Pusztai, L; Redmond, D; Sarp, S; Sotiriou, C | 1 |
| Asif, M; Bhadauria, S; Chourasia, MK; Khanna, A; Shrivastava, R; Singh, PK; Trivedi, S | 1 |
| Daniels, B; Girosi, F; Houssami, N; Kiely, BE; Lord, SJ; Pearson, SA; Tervonen, H | 1 |
| Browne, BC; Canonici, A; Collins, DM; Conlon, NT; Crown, J; Gaynor, N; Gullo, G; Ivers, L; O'Brien, NA; O'Donovan, N; Pedersen, K | 1 |
| Canese, R; Casalini, P; Castagnoli, L; Di Nicola, M; Dugo, M; Faraci, S; Iorio, E; Koschorke, A; Morelli, D; Nanni, P; Pupa, SM; Tagliabue, E; Vernieri, C | 1 |
| Boakye-Agyeman, F; Boughey, JC; Dai, Q; Goetz, MP; Hitosugi, S; Hitosugi, T; Karnitz, LM; Kaufmann, SH; Kurmi, K; Larson, TR; Lou, Z; Machida, YJ; Wang, L; Wiese, EK; Yu, J | 1 |
| Kassem, H; Kassem, N; Talima, S | 1 |
| Chang, Y; Han, KC; Lee, JE; Park, KH | 1 |
| Barroso-Sousa, R; Pernas, S; Tolaney, SM | 1 |
| Avogadri-Connors, F; Baselga, J; Berger, MF; Boni, V; Bryce, RP; Cai, Y; Chan, C; Chandarlapaty, S; Cocco, E; Cownie, J; Cutler, RE; Hyman, DM; Javier Carmona, F; Lalani, AS; Loi, S; Montemurro, F; Moriarty, A; Papadopoulos, KP; Razavi, P; Rossi, V; Sarotto, I; Savas, P; Scaltriti, M; Shifman, SG; Solit, DB; Soong, J; Toska, E; Wick, MJ; Won, HH | 1 |
| Browne, BC; Conlon, NT; Crown, J; Espina, V; Eustace, AJ; Gallagher, C; Gallagher, WM; Ginther, C; Holmes, FA; Liotta, LA; Madden, SF; McDermott, MSJ; O'Brien, NA; O'Donovan, N; O'Driscoll, L; O'Leary, P; O'Shaughnessy, J; Rani, S; Slamon, D; Walsh, N; Watson, WR; Zagozdzon, R | 1 |
| Alexander, PB; Chen, J; Chen, R; Ding, Y; Gong, C; Li, QJ; Liang, G; Lin, KH; Song, EW; Sui, P; Wang, QF; Wang, XF; Wood, KC; Xiang, H; Yin, T; Yuan, L | 1 |
| Anders, CK; Copeland, AC | 1 |
| Azim, HA; Baselga, J; Campbell, C; de Azambuja, E; Di Cosimo, S; Gelber, RD; Guillaume, S; Hilbers, FS; Huober, J; Ignatiadis, M; Korde, L; Lambertini, M; Martel, S; Moreno-Aspitia, A; Piccart-Gebhart, M; Schuehly, U; Tenglin, RC | 1 |
| Ismail, P; Jabbarzadeh Kaboli, P; Leong, MP; Ling, KH | 1 |
| Baselga, J | 1 |
| Choi, J; Dann, P; Friedman, PA; Gefter, JV; Jeong, J; Kim, W; Takyar, F; Wysolmerski, JJ | 1 |
| Bines, J; Tevaarwerk, AJ | 1 |
| Couvreur, P; Denis, S; Guillaneuf, Y; Jacobs, M; Lazzari, G; Mougin, J; Mura, S; Nicolas, J; Vinciguerra, D; Zhu, C | 1 |
| Czerniecki, BJ; Ghimirey, N; Koski, GK; Oechsle, C; Showalter, LE; Steele, C | 1 |
| Acevedo, F; Camus, M; Domínguez, F; Galindo, H; López, V; Medina, L; Navarro, ME; Oddó, D; Pérez-Sepúlveda, A; Razmilic, D; Sánchez, C; Villarroel, A | 1 |
| Abraham, J; Ahluwalia, MS; Angelov, L; Barnett, GH; Budd, GT; Chao, ST; Kim, JM; Kotecha, R; Miller, JA; Mohammadi, AM; Moore, H; Murphy, ES; Peereboom, DM; Suh, JH; Vogelbaum, MA | 1 |
| Ahluwalia, MS; Angelov, L; Barnett, GH; Chao, ST; Juloori, A; Kotecha, R; Miller, JA; Mohammadi, AM; Murphy, ES; Parsai, S; Peereboom, DM; Suh, JH; Vogelbaum, MA | 1 |
| Akl, MR; Ayoub, NM; Ebrahim, HY; El Sayed, KA; Goda, AA; Hananeh, WM; Liu, YY; Meyer, SA; Mohyeldin, MM; Nagumalli, SK; Siddique, AB | 1 |
| Hou, S; Lei, H; Li, Q; Liu, F; Liu, H; Liu, S; Wang, D; Wang, S; Wang, T; Wu, Y; Xu, L; Zaky, MY; Zhang, J; Zhang, Y; Zou, K; Zou, L | 1 |
| Barinoff, J; Bauerschlag, DO; Bischoff, J; Costa, SD; Gerber, B; Grischke, EM; Herr, D; Krabisch, P; Kümmel, S; Loibl, S; Lübbe, K; Maass, N; Marmé, F; Müller, V; Mundhenke, C; Nekljudova, V; Schmidt, M; Schumacher, C; Seiler, S; Thill, M; von Minckwitz, G | 1 |
| Chang, JC; Contreras, A; De Angelis, C; Forero, A; Fuqua, SAW; Goetz, MP; Gutierrez, C; Herrera, S; Hilsenbeck, SG; Krop, IE; Mao, R; Mayer, IA; Nanda, R; Nuciforo, P; Osborne, CK; Pavlick, AC; Prat, A; Reis-Filho, JS; Rimawi, MF; Schiff, R; Veeraraghavan, J; Wang, T; Weigelt, B; Wolff, AC | 1 |
| Baez-Vallecillo, L; Barcenas, CH; Hess, KR; Moulder, SL; Murthy, RK; Raghavendra, AS; Tripathy, D; Valero, V | 1 |
| Caraglia, M; Desiderio, V; la Noce, M; Liccardo, D; Lombardi, A; Mele, L; Paino, F; Papaccio, F; Papaccio, G; Regad, T; Tirino, V; Wagner, S | 1 |
| de Stanchina, E; Fleisher, M; Kemeny, MM; Li, BT; Morikawa, A; Norton, L; Patil, S; Pentsova, E; Seidman, AD; Tang, K; Van Poznak, C | 1 |
| Cheuk, WY; Cheung, P; Chiu, JW; Kwok, GW; Kwong, A; Leung, R; Lo, J; Suen, D; Tang, V; Wong, H; Wong, TT; Yau, T | 1 |
| Adamo, B; Bermejo, B; Brasó-Maristany, F; Conte, P; Cortés, J; De Angelis, C; Dieci, MV; Fasani, R; Forero, A; Galván, P; Griguolo, G; Guarneri, V; Gutierrez, C; Hilsenbeck, SG; Izquierdo, M; Krop, I; Llombart-Cussac, A; Morales, S; Nuciforo, P; Oliveira, M; Osborne, CK; Paré, L; Parker, JS; Pascual, T; Pavlick, AC; Prat, A; Reis-Filho, JS; Rexer, B; Rimawi, MF; Rodrik-Outmezguine, V; Schiff, R; Veeraraghavan, J; Vidal, M; Wang, T; Wolff, AC | 1 |
| Alvarez, R; Barcenas, CH; Booser, DJ; Brewster, AM; Brown, PH; Davis, DW; Giordano, SH; Ibrahim, NK; Iwase, T; Jackson, SA; Lee, J; Lim, B; Moscow, JA; Moulder, SL; Murthy, RK; Piekarz, R; Shen, Y; Tripathy, D; Ueno, NT; Valero, V; Willey, JS; Wu, J | 1 |
| Chiu, J; Choi, YJ; Cornelio, G; Do, IG; Gong, G; Kim, SB; Kim, TY; Lee, EM; Lee, M; Lee, S; Nathaniel, C; Ng, TY; Oh, HS; Paik, S; Park, KH; Park, S; Ro, J; Sohn, J; Tsang, J; Yap, YS | 1 |
| Exman, P; Pernas, S; Tolaney, SM | 1 |
| Aguirre, E; Antón, A; Bermejo, B; Brunet, J; Ciruelos, E; Cortés, J; Cotes-Sanchís, A; De La Haba, J; García Sáenz, JÁ; Gavilá, J; Guerrero-Zotano, AL; Huerta, M; Lao Romera, J; Llombart-Cussac, A; Muñoz-Couselo, E; Rodríguez Sánchez, CA; Rodríguez-Lescure, Á; Ruiz-Borrego, M; Sánchez Rovira, P; Santaballa, A; Santisteban, M | 1 |
| Baselga, J; Bradbury, I; de Azambuja, E; Dueck, AC; Fumagalli, D; Gelber, RD; Holmes, EM; Korde, L; Moreno-Aspitia, A; Piccart-Gebhart, M; Williams, LS | 1 |
| Stravodimou, A; Voutsadakis, IA | 1 |
| Apolone, G; Baselga, J; Cinieri, S; Daidone, MG; de Azambuja, E; de Braud, FG; De Cecco, L; Di Cosimo, S; Fumagalli, D; Gori, S; Harbeck, N; Huober, J; Izquierdo, M; Peña, L; Piccart, M; Pizzamiglio, S; Putzai, L; Tagliabue, E; Torri, V; Triulzi, T; Verderio, P | 1 |
| Gwak, HS; Han, JM; Moon, JY; Seo, I | 1 |
| Adamchuk, H; Baselga, J; Boyle, F; Ciruelos, E; Dasappa, L; de Azambuja, E; de la Pena, L; Di Cosimo, S; Fumagalli, D; Gelber, RD; Hackman, J; Hickish, T; Holmes, E; Huober, J; Jackisch, C; Jouannaud, C; Lang, I; Lecocq, C; Piccart-Gebhart, M; Sarp, S; Smith, I; Toral Pena, JC; Untch, M; Wildiers, H; Xu, B | 1 |
| Kongkaew, C; Lohitnavy, M; Scholfield, CN; Subongkot, S; Tangamornsuksan, W | 1 |
| Guillen-Ponce, C; Molina-Garrido, MJ; Mora-Rufete, A | 1 |
| Cao, S; Chen, C; Gao, H; Jiang, X; Pan, S; Pang, Z; Xi, Z; Yang, Z; Zhang, Q | 1 |
| Antoniani, B; Botti, C; Ciccarese, M; Cognetti, F; Di Benedetto, A; Ercolani, C; Fabi, A; Ferretti, G; Gori, S; Malaguti, P; Marino, M; Merola, R; Mottolese, M; Nisticò, C; Papaldo, P; Sperduti, I; Vici, P | 1 |
| Ashworth, A; Chong, I; Cunningham, D; Lambros, M; Lord, CJ; Mackay, A; Meijer, T; Reis-Filho, JS; Shiu, KK; Wetterskog, D | 1 |
| Dirix, LY; Dirix, M; Huget, P; Rutten, A | 1 |
| Colon-Otero, G; Dakhil, S; Dueck, AC; Franco, S; Ghanem-Cañete, I; Jenkins, RB; Johnson, D; Kahanic, S; McCullough, AE; Moreno-Aspitia, A; Northfelt, D; Palmieri, FM; Patel, T; Perez, EA; Rodeheffer, R; Tenner, KS | 1 |
| Kümler, I; Larsen, PB; Nielsen, DL | 1 |
| Arpornwirat, W; Chen, G; DeSilvio, ML; Gomez, H; Guan, Z; Jiang, Z; Leung, WL; Lorvidhaya, V; Makhson, A; Newstat, B; Oliva, C; Russo, MW; Shen, Z; Tong, Z; Wang, L; Xu, B; Yang, J | 1 |
| Buss, MC; Castellino, RC; Gayle, SS; Nahta, R | 1 |
| Bean, GR; Chan, PM; Cheng, EH; Chodosh, LA; Dong, Y; Ganesan, YT; Hsieh, JJ; Huang, Y; Liu, H; Takeda, S; Zambetti, GP | 1 |
| Boku, N | 1 |
| Agbor-tarh, D; Azim, HA; Baselga, J; Bradbury, I; Criscitiello, C; de Azambuja, E; Di Cosimo, S; Eidtmann, H; Piccart, M; Rubio, IT | 1 |
| Chang, JC; Forero, A; Goetz, MP; Gutierrez, C; Hilsenbeck, SG; Mayer, IA; Nanda, R; Osborne, CK; Pavlick, AC; Rimawi, MF; Rodriguez, AA; Schiff, R; Wang, T | 1 |
| Aglietta, M; Milani, A; Montemurro, F; Sangiolo, D; Valabrega, G | 1 |
| Chaigneau, L; Demarchi, M; Dobi, E; Merrouche, Y; N'guyen, T; Pivot, X; Romieu, G; Salvat, J; Villanueva, C; Vuillemin, AT | 1 |
| Lind, P; Nearchou, A; Polyzos, NP; Valachis, A | 1 |
| Dewhirst, MW; Geradts, J; Henao, R; Kim, J; Kim, WJ; Kornbluth, S; Kurokawa, M; Liu, L; Lucas, JE; Matsuura, K; Ran, X; Ribar, TJ; Spector, NL; Wang, S; Xia, W | 1 |
| Avery, M; Coombes, RC; Di Leo, A; Frampton, AE; Krell, J; Payne, R; Pestrin, M; Reise, J; Stebbing, J; Woodley, L | 1 |
| Ellis, CE; Fujii, H; Gagnon, RC; Iwata, H; Katsura, K; Masuda, N; Mukai, H; Nakamura, S; Nishimura, Y | 1 |
| Brewster, AM; Esteva, FJ; Florance, AM; Franco, SX; Hagan, MK; Perez, A; Somer, RA; Stein, S; Turner, S; Williams, W | 1 |
| Iyengar, NM; Morris, PG | 1 |
| Chalfant, CE; Garcia-Vargas, A; Park, MA; West, NW | 1 |
| Cameron, D; Krop, I; Piccart, M; Zardavas, D | 1 |
| Belbaraka, R; Elomrani, A; Ismaili, N; Khouchani, M; Tahri, A | 1 |
| Bian, L; Jiang, Z; Wang, T; Zhang, S | 1 |
| Chang, JC; Osborne, CK; Parma, J; Pavlick, A; Rimawi, M; Schiff, R; Trivedi, MV | 1 |
| Balletta, L; Bridges, A; Cheang, MC; Combest, A; Darr, D; Herschkowitz, JI; Jordan, J; Karginova, O; Liu, M; Perou, CM; Prat, A; Roberts, PJ; Rosen, JM; Sharpless, NE; Usary, J; Zamboni, W; Zhao, W | 1 |
| Ariad, S; Geffen, DB; Geva, S; Lazarev, I | 1 |
| Chen, S; Feng, D; Han, T; Jiang, R; Liu, X; Ma, Y; Qiao, H; Wei, Y; Wu, L; Zhang, J; Zhang, S; Zhang, Y; Zhu, X | 1 |
| Albanell, J; Dalmases, A; Rojo, F; Rovira, A | 1 |
| Lou, L; Quan, H; Wang, L; Wang, Q; Xie, C; Zhao, J | 1 |
| Aherne, ST; Clynes, M; Crown, J; Doolan, P; Madden, SF; O'Connor, R; O'Neill, F | 2 |
| Gradishar, WJ | 1 |
| Azria, D; Braccini, AL; Ferrero, JM; Jacot, W; Romieu, G; Thezenas, S | 1 |
| Daschil, N; Datta, S; Doppler, W; Hannesdóttir, L; Koller, JB; Müller-Holzner, E; Parajuli, N; Philipp, S; Sexl, V; Stoitzner, P; Tripp, CH; Tymoszuk, P; Villunger, A; Wasmer, MH; Wiegers, GJ | 1 |
| Ezaki, T; Iguchi, T; Ito, S; Koga, T; Nozoe, E; Nozoe, T; Ohga, T | 1 |
| Piccart, M | 1 |
| Burris, HA; Crown, J; DeSilvio, M; Diéras, V; Espie, M; Kennedy, MJ; Koch, KM; Kothari, D; Lau, MR; Marty, M; Tresca, P | 1 |
| Bessonov, AA; Bozhok, AA; Manikhas, AG; Nikolaev, KS; Semiglazov, VF; Semiglazov, VV; Semiglazova, TIu; Vasil'ev, AG | 1 |
| Gorbunova, VA; Moskvina, EA; Naskhletashvili, DR | 1 |
| Baselga, J; Jin, C; Kharbanda, A; Kharbanda, S; Kufe, D; Panchamoorthy, G; Raina, D; Rajabi, H; Scaltriti, M; Uchida, Y | 1 |
| Aldape, KD; Ding, Z; Guo, H; Huang, S; Huang, WC; Lowery, FJ; Sahin, AA; Steeg, PS; Wang, H; Yu, D; Zhang, C; Zhang, L; Zhang, S | 1 |
| Arteaga, CL; Bialucha, CU; Collins, SD; Defazio-Eli, L; Ettenberg, SA; Garrett, JT; Kurupi, R; Sheng, Q; Sutton, CR; Wallweber, J | 1 |
| Gustafson, DL; Hudachek, SF | 1 |
| Boddapati, S; Gray, JW; Iacovides, DC; Johnson, AB; Korkola, J; Wang, N | 1 |
| Du, JY; Kirouac, DC; Lahdenranta, J; McDonagh, CF; Nielsen, UB; Onsum, MD; Overland, R; Pace, E; Paragas, V; Yarar, D | 1 |
| Awada, A; Bonneterre, J; Germa, C; Geyer, CE; Ito, Y; Kim, SB; Lang, I; Martin, M; Ro, J; Vermette, J; Wang, K | 1 |
| Basaran, G; Benekli, M; Cetin, B; Eralp, Y; Isikdogan, A; Karaca, H; Kucukoner, M; Onur, H; Ozkan, M; Saip, P; Sen, F; Un, O | 1 |
| Barker, HE; Chang, J; Cox, TR; Erler, JT; Martens, JW; Nicolau, MM; Wetterskog, D | 1 |
| Abdulkarim, B; Bhatnagar, P; Graham, K; Lesniak, D; Sabri, S; Suresh, M; Xu, Y | 1 |
| Bachelot, T; Bidard, FC; Campone, M; Cropet, C; Curé, H; Dalenc, F; Dômont, J; Ferrero, JM; Gonçalves, A; Gutierrez, M; Labbe-Devilliers, C; Le Rhun, E; Leheurteur, M; Mahier Aït-Oukhatar, C; Pierga, JY; Romieu, G; Tresca, P | 1 |
| Awada, A; Buttice, A; Cardoso, F; D'Hondt, V; de Azambuja, E; Devriendt, D; Gil, T; Lalami, Y; Lebrun, F; Lemort, M; Moulin, C; Paesmans, M; Piccart-Gebhart, M; Rossari, J; Sotiriou, C; Zardavas, D | 1 |
| Booth, L; Cruickshanks, N; Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Sajithlal, GB; Syed, J; Tavallai, S | 1 |
| Abbruzzi, A; Chen, C; Come, SE; Dang, CT; Hudis, CA; Iyengar, NM; Lehman, R; Lin, N; Morris, PG; Moy, B; Norton, L; Oeffinger, KC; Patil, S; Steingart, R; Winer, EP | 1 |
| Bacus, S; Cheng, Q; Gallagher, RI; Gwin, WR; Liu, L; Lyerly, HK; Osada, T; Petricoin, EF; Spector, NL; Wulfkuhle, JD; Xia, W; Yang, X; Zhao, S | 1 |
| Aura, CM; Azim, HA; Baselga, J; Bavington, M; Cure, H; de Azambuja, E; Di Cosimo, S; Domont, J; Eidtmann, H; Ellis, C; Ferro, A; Gamez, C; Gebhart, G; Ignatiadis, M; Maetens, M; Piccart-Gebhart, M; Rothé, F; Rouas, G; Sotiriou, C; Toral-Peña, JC; Vuylsteke, P | 1 |
| Aglietta, M; Baselga, J; Donadio, M; Galván, P; Montemurro, F; Peraldo-Neia, C; Prat, A; Rossi, V; Sapino, A; Scaltriti, M; Sperinde, J; Valabrega, G | 1 |
| Kümler, I; Nielsen, DL; Tuxen, MK | 1 |
| Aktan, G; Baselga, J; Coccia-Portugal, MA; Cortés, M; Cure, H; de Azambuja, E; Di Cosimo, S; Eidtmann, H; Fauria, K; Flamen, P; Gámez, C; Garcia, C; Gebhart, G; Holmes, E; Kim, SB; Piccart, M; Robles, J; Van Dooren, V; Vuylsteke, P | 1 |
| Johnston, SR | 1 |
| Atkins, JN; Azar, CA; Baez-Diaz, L; Bandos, H; Bear, HD; Brufsky, AM; Costantino, JP; Farrar, WB; Fehrenbacher, L; Geyer, CE; Mamounas, EP; Margolese, RG; Paik, S; Rastogi, P; Robidoux, A; Sarwar, S; Shibata, HR; Swain, SM; Tang, G; Wolmark, N | 1 |
| Gyõrffy, B; Mihály, Z | 1 |
| Benekli, M; Berk, V; Boruban, C; Buyukberber, S; Cetin, B; Coskun, U; Dane, F; Harputluoglu, H; Kaplan, MA; Koca, D; Koral, L; Oksuzoglu, B; Sevinc, A; Turker, I; Ulas, A; Uncu, D; Yilmaz, B | 1 |
| Laoui, D; Van Ginderachter, JA; Van Overmeire, E | 1 |
| Bai, YZ; Chen, L; Kou, DQ; Li, R; Li, XR; Wang, JD; Wang, QS | 1 |
| Candon, D; Crown, J; Healy, J | 1 |
| Barroso-Sousa, R; de Melo Gagliato, D; Mano, MS; Santana, IA; Testa, L | 1 |
| Akça, Z; Büyükçelik, A; Erden, A; Mutlu, H | 1 |
| Bartolotti, M; Brandes, AA; Franceschi, E | 1 |
| Bastida, CC; Falchook, GS; Jiang, Y; Kurzrock, R; Moulder, SL; Wheler, JJ | 1 |
| Mehta, A; Tripathy, D | 1 |
| Bellon, JR; Come, SE; Eichler, AF; Eisenberg, E; Freedman, RA; Gelman, RS; Harris, GJ; Henderson, MA; Ligibel, JA; Lin, NU; Macdonald, SM; Mahadevan, A; Mayer, EL; Moy, B; Ramakrishna, N; Storniolo, AM; Winer, EP; Younger, J | 1 |
| Dering, J; Ellis, C; Finn, RS; Florance, A; Johnston, S; Martin, AM; O'Rourke, L; Press, MF | 1 |
| Bode, AM; D'Alessio, A; De Luca, A; Gallo, M; Maiello, MR; Normanno, N | 1 |
| Chishima, T; Endo, I; Ichikawa, Y; Ishikawa, T; Kita, K; Narui, K; Sasaki, T; Shimada, K; Shimizu, D; Sugae, S; Tanabe, M; Yoneyama, S | 1 |
| Althaus, B; Diéras, V; Fang, L; Guardino, E; Hurvitz, SA; Lalla, D; Miles, D; Sohn, JH; Welslau, M | 1 |
| Bundred, NJ; Clarke, RB; Farnie, G; Johnson, RL; Williams, KE | 1 |
| Agbor-Tarh, D; Aktas, B; Azim, HA; Baselga, J; Bradbury, I; de Azambuja, E; Di Cosimo, S; Dinh, P; Dreosti, L; Eidtmann, H; Greger, JG; Hsieh, RK; Huang, CS; Jackisch, C; Kim, SB; Piccart, M; Smith, I; Vuylsteke, P | 1 |
| Brady, SW; Seok, D; Wang, H; Yu, D; Zhang, J | 1 |
| Fan, Y; Li, HH; Li, Q; Ma, F; Wang, JY; Xu, BH; Yuan, P; Zhang, P | 1 |
| Gamucci, T; Mauri, M; Mentuccia, L; Moscetti, L; Pavese, I; Pizzuti, L; Sperduti, I; Vaccaro, A; Vici, P; Zampa, G | 1 |
| Anderson, T; Blum, JL; Danso, M; Espina, V; Florance, A; Holmes, FA; Krekow, L; Liotta, LA; Mahoney, J; McIntyre, KJ; Nagarwala, YM; O'Shaughnessy, JA; Osborne, CR; Pippen, J | 1 |
| Bailey, ST; Bowman, T; Brown, M; Choi, YJ; Debajit, KB; Foley, KM; Iglehart, JD; Kochupurakkal, B; Maulik, G; Miron, A; Miron, PL; Rodig, SJ; Tian, R | 1 |
| Miller, TW | 1 |
| Agboto, VK; Koumangoye, RB; Nangami, GN; Ochieng, J; Sakwe, AM; Thompson, PD | 1 |
| Calvani, N; Ciccarese, M; Cinieri, S; Fedele, P; Forcignanò, RC; Lorusso, V; Marino, A; Mazzoni, E; Nacci, A; Orlando, L; Rizzo, P; Schiavone, P; Sponziello, F | 1 |
| Andrighetto, S; Chen, B; Dell'orto, P; Dueck, AC; Gelber, RD; Jackisch, C; Jenkins, RB; McCullough, AE; Perez, EA; Piccart-Gebhart, MJ; Reinholz, MM; Russo, L; Untch, M; Viale, G | 1 |
| Brain, E; Briggs, K; Caglevic, C; Desilvio, M; Janni, W; Karaszewska, B; Marini, L; Papadimitriou, C; Pikiel, J; Potemski, P; Salat, C; Sarosiek, T; Staroslawska, E | 1 |
| Du, C; Huang, Y; Li, F; Mahato, RI; Wang, H | 1 |
| Bian, L; Du, G; Guo, YF; Jiang, ZF; Li, W; Song, ST; Wang, T; Wu, SK; Zhang, HQ; Zhang, SH | 1 |
| Eroglu, Z; Somlo, G; Tagawa, T | 1 |
| Tolaney, S | 1 |
| Arteaga, CL; Chanthaphaychith, S; Dahlman, K; Rexer, BN | 1 |
| Alba, E; Albanell, J; Barnadas, A; Burgués, O; Caballero, R; Calvo, L; Cámara, MC; Carrasco, E; de la Haba, J; Lluch, A; Porras, I; Ramos, M; Rojo, F; Sánchez-Rovira, P; Tibau, A | 1 |
| Al-Awar, R; Aman, A; Chung, PE; Deng, T; Egan, SE; Jiang, Z; Joseph, B; Ketela, T; Liu, JC; Moffat, J; Rottapel, R; Schachter, NF; Uehling, D; Zacksenhaus, E | 1 |
| Amiri Kordestani, L; Blumenthal, G; Booth, B; Cortazar, P; Ibrahim, A; Justice, R; Liu, Q; Mehrotra, N; Rahman, A; Schrieber, S; Song, P; Tang, S; Wang, J; Wang, Y; Xu, Q | 1 |
| Arteaga, CL; Bi, X; Guo, M; Mahadevan-Jansen, A; Rexer, B | 1 |
| Basaran, G; Cabuk, D; Dane, F; Korkmaz, T; Seber, S; Telli, F; Teomete, M; Turhal, S; Yumuk, PF | 1 |
| Şendur, MA; Uncu, D; Zengin, N | 1 |
| Beyer, WF; Gooden, D; Liu, L; Soderblom, EJ; Spector, NL; Toone, EJ; Walder, H; Xia, W; Zhao, S | 1 |
| Fu, X; Giuliano, M; Klinowska, T; Morrison, G; Nanda, S; Osborne, CK; Rimawi, MF; Schiff, R; Shea, M; Wang, T | 1 |
| Artioli, F; Bettelli, S; Bisagni, G; Boni, C; Bottini, A; Cagossi, K; Cavanna, L; Conte, P; Ellis, C; Ficarra, G; Frassoldati, A; Generali, DG; Guarneri, V; Holford, C; Maiorana, A; Nuzzo, S; Piacentini, F; Roncaglia, E; Swaby, R; Tagliafico, E | 1 |
| Breslin, S; Corcoran, C; Crown, J; Ghobrial, IM; Gogarty, M; O'Driscoll, L; Rani, S | 1 |
| Kurzrock, R; Parker, BA; Schwab, R; Yan, M | 1 |
| An, Z; Dunne, LW; Fan, X; Huang, Z; Meng, W; Zhang, N; Zhang, Q | 1 |
| Cardinali, B; Crinò, L; Del Mastro, L; Foglietta, J; Gori, S; Inno, A; Lunardi, G | 1 |
| Cañamares-Orbis, I; Cortijo-Cascajares, S; Ferrari-Piquero, JM; García-Muñoz, C; Goyache-Goñi, MP | 1 |
| Brady, SW; Chang, CC; Chang, J; Ellis, K; Esteva, FJ; Landis, MD; Muller, WJ; Priya, P; Sahin, O; Wang, H; Wang, Q; Wong, ST; Yu, D; Zhang, Q; Zhu, R | 1 |
| Cardon, LR; Cox, CJ; Curran, J; Ejlertsen, B; Finkelstein, DM; Goss, PE; McDonnell, SK; Parham, LR; Rappold, E; Schaid, DJ; Spraggs, CF | 1 |
| Awasthi, S; Hamburger, AW | 1 |
| Auerback, G; Chien, AJ; Goga, A; Khanafshar, E; Koch, KM; Melisko, ME; Moasser, MM; Munster, PN; Ordovas, K; Park, JW; Rugo, HS | 1 |
| Cao, KI; Kirova, YM | 1 |
| Inoue, T; Iyoda, T; Uetsuka, Y; Yamamoto, W | 1 |
| Hayashi, M; Hironaka, H; Morita, N; Orita, M | 1 |
| Arima, Y; Hosonaga, M; Kohno, N; Saya, H; Sugihara, E | 1 |
| Nolting, M; Schneider-Merck, T; Trepel, M | 1 |
| Chandarlapaty, S; Crews, JR; Davidson, NE; Esteva, FJ; Giordano, SH; Gonzalez-Angulo, AM; Kirshner, JJ; Krop, I; Levinson, J; Lin, NU; Modi, S; Patt, DA; Perez, EA; Perlmutter, J; Ramakrishna, N; Temin, S; Winer, EP | 1 |
| Altun, A; Altun, GG; Babacan, N; Bahceci, A; Kacan, SB; Kacan, T; Sarac, B; Seker, MM | 1 |
| Fabi, A; Mottolese, M; Segatto, O | 1 |
| Bianco, R; D'Amato, C; D'Amato, V; Damiano, V; De Placido, S; Formisano, L; Iommelli, F; Marciano, R; Nappi, L; Parsons, SJ; Raimondo, L; Rosa, R; Scorziello, A; Troncone, G; Veneziani, B | 1 |
| Gao, HL; He, Q; Ruan, SB; Zhang, L; Zhang, QY; Zhang, S | 1 |
| Boehm, JS; Hahn, WC; Izzo, F; Kim, SY; Luo, L; Moody, SE; Schinzel, AC; Singh, S; Strickland, MR; Thomas, SR; Wang, ZC | 1 |
| Bartholomeusz, C; Hortobagyi, GN; Humphries, J; Lee, J; Mansour, O; Ordentlich, P; Ueno, NT | 1 |
| Balduzzi, S; D'Amico, R; Guarneri, V; Mantarro, S; Moja, L; Pistotti, V; Tagliabue, L | 1 |
| Browne, BC; Clynes, M; Conlon, NT; Crown, J; Dowling, P; Henry, M; McDermott, MS; Meleady, P; O'Brien, NA; O'Donovan, N; Slamon, DJ | 1 |
| Akar, E; Kilickap, S; Mutlu, H; Tural, D | 1 |
| Hao, Y; Huang, H; Lang, K; Menzin, J; Paly, VF; Sasane, M | 1 |
| Balyan, R; Lockman, PR; Morikawa, A; Murphy, CG; Peereboom, DM; Samala, R; Seidman, AD; Simmons, A; Smith, QR; Steeg, PS; Tabar, V; Thorsheim, HR; Weil, RJ | 1 |
| Altundag, K; Arslan, C; Dizdar, O | 2 |
| DeSilvio, M; Ellis, C; Guan, Z; Jiang, Z; Leigh, M; Russo, M; Shen, Z; Tong, Z; Xu, B; Yang, J | 1 |
| Awada, A; Bogaerts, J; Brain, E; Cardoso, F; Fumoleau, P; Hayward, L; Koch, KM; Lokiec, F; Marréaud, S; Rezai, K; Werutsky, G | 1 |
| Bang, YJ; Cha, Y; Han, SW; Han, W; Im, SA; Kim, TY; Noh, DY; Oh, DY; Park, IA; Seol, H | 1 |
| Auten, JJ; Cicci, TA; Corrigan, PA; Lowe, DK | 1 |
| Fasching, PA; Gade, S; Loibl, S; Lübbe, K; Mau, C; Müller, V; Pantel, K; Schem, C; Schwarzenbach, H; Schwedler, K; Steinbach, B; Untch, M; von Minckwitz, G | 1 |
| Brunton, VG; Byron, A; Creedon, H; Hayward, L; Klinowska, T; Main, J | 1 |
| Abdel-Rahman, O; Fouad, M | 1 |
| Joensuu, H | 1 |
| Azim, HA; Barrios, CH; Baselga, J; Boyle, F; de Azambuja, E; Di Cosimo, S; Dreosti, L; Eidtmann, H; Eniu, A; Gelber, RD; Gorbunova, V; Holmes, AP; Holmes, E; Hsieh, RK; Huang, CS; Jackisch, C; Kim, SB; Kuemmel, S; Lang, I; Perez, EA; Piccart-Gebhart, M; Smith, I; Swaby, RF; Tavartkiladze, N; Untch, M; Vuylsteke, P; Xu, B | 1 |
| He, J; Li, YS; Wei, X; Yu, FF; Zhang, TY; Zhang, X; Zhang, XJ | 1 |
| Calvo, I; Estévez, LG; Fernández-Abad, M; García, E; Herrero, M; Hidalgo, M; Lopez Ríos, F; Marcos, M; Márquez, C; Miró, C; Perea, S; Suarez-Gauthier, A | 1 |
| Annunziato, S; Benedicenti, F; Brasca, S; Calabria, A; Gallina, P; Montini, E; Naldini, L; Ranzani, M | 1 |
| Andre, F; Denkert, C; Dohnal, K; Dykgers, A; Eidtmann, H; Fasching, PA; Gade, S; Guo, S; Heinrichs, C; Huober, J; Khandan, F; Lehmann, A; Lindner, JL; Loi, S; Loibl, S; Nekljudova, V; Paepke, S; Pfitzner, B; Rezai, M; Schneeweiss, A; Sinn, P; Sotiriou, C; Untch, M; von Minckwitz, G; Zahm, DM | 1 |
| Dranitsaris, G; Lacouture, ME | 1 |
| Ashrafian, H; Athanasiou, T; Hayashida, T; Jinno, H; Kitagawa, Y; Matsumoto, A; Murata, T; Nagayama, A; Okabayashi, K; Seki, T; Takahashi, M | 1 |
| Halmos, B; Hibshoosh, H; Jin, C; Li, G; Wang, X | 1 |
| Cayre, A; De Wever, O; Doan, VK; Dupouy, S; Forgez, P; Gompel, A; Kouchkar, A; Liu, J; Llorca, FP; Mourra, N; Wu, Z | 1 |
| Akiyama, F; Araki, K; Fukada, I; Horii, R; Ito, Y; Iwase, T; Takahashi, S | 2 |
| Baselga, J; Cortés, J; Garcia-Saenz, JA; Germa, C; Harb, W; Kiger, C; Kim, SB; Martin, M; Moroose, R; Pluard, T; Saura, C; Wang, K; Xu, B | 1 |
| Shawky, H; Tawfik, H | 1 |
| Asztalos, S; Bellis, AD; Bluver, D; Broadbelt, LJ; Dubbury, SJ; Jeruss, JS; Mui, MD; Peñalver Bernabé, B; Saez-Rodriguez, J; Shea, LD; Shin, S; Tonetti, DA; Weiss, MS | 1 |
| Barry, WT; Blackwell, KL; Burstein, HJ; Chew, HK; Cirrincione, CT; Hudis, CA; Lake, DE; Ma, C; Tolaney, SM; Winer, EP | 1 |
| Hao, Y; Huang, H; Lang, K; Lin, I; Menzin, J; Rogerio, JW | 1 |
| Baron-Hay, S; Bauwens, A; Chan, A; Craft, P; de Boer, R; Kotasek, D; Redfern, A; Shannon, C; Townsend, A; Webb, S | 1 |
| Blackwell, K; Diéras, V; Guardino, E; Huober, J; Krop, IE; Lin, NU; Lu, M; Miles, D; Samant, M; Welslau, M | 1 |
| A'Hern, R; Bliss, JM; Bundred, N; Coombes, G; Detre, S; Dowsett, M; Evans, A; Harper-Wynne, C; Haynes, BP; Hills, M; Johnston, SR; Leary, A; Sahoo, R; Smith, I | 1 |
| Cao, S; Jiang, X; Wang, F; Wang, Y; Wei, Y; Xiong, Y; Xu, S; Zhang, Q; Zhang, S; Zou, A | 1 |
| Arold, ST; Bartholomeusz, C; Blachno, KV; Boulbes, DR; Brady, SW; Chang, WC; Chauhan, GB; Deng, N; Esteva, FJ; Hsu, JM; Huang, TH; Hung, MC; Jin, Q; Ladbury, JE; Stone, S; Yu, D | 1 |
| Bańkowski, K; Gniazdowska, E; Koźmiński, P; Królicki, L; Łuniewski, W | 1 |
| Bessadóttir, M; Eccles, S; Gowan, S; Ogmundsdóttir, HM; Ögmundsdóttir, S; Skúladóttir, EÁ | 1 |
| Coussy, F; Cuvier, C; Espié, M; Giacchetti, S; Hocini, H; Teixeira, L | 1 |
| Cao, PR; Huang, W; Kong, YL; Wu, QD; Xu, JH; Ye, M; Zhang, M; Zheng, W | 1 |
| Bodmer, A; Bonnefoi, H; Brain, E; Cameron, D; Chakiba, C; Jacot, W; Jerusalem, G; Matos, E; Messina, CG; Moldovan, C; Petit, T; Quenel-Tueux, N; Saghatchian, M; Slaets, L; Tredan, O; Venat-Bouvet, L; Vuylsteke, P; Zaman, K | 1 |
| Agbor-Tarh, D; Arribas, J; Aura, C; Baselga, J; Bradbury, I; Campbell, C; Chenna, A; Cortes, J; de Azambuja, E; Eidtmann, H; Ellis, C; Harbeck, N; Jimenez, J; Nuciforo, P; Parra, JL; Piccart, M; Prudkin, L; Pusztai, L; Scaltriti, M; Serra, V; Sperinde, J; Winslow, J | 1 |
| Ali, SM; Chmielecki, J; Frampton, GM; Lipson, D; Miller, VA; Morosini, D; Palma, N; Palmer, GA; Ross, JS; Stephens, PJ; Wang, K; Yelensky, R | 1 |
| Haskins, JW; Nguyen, DX; Stern, DF | 1 |
| Abt, MA; Hill, EG; Yeh, ES | 1 |
| Fujisawa, T; Hayashi, N; Honda, Y; Hozumi, Y; Ishida, M; Iwata, H; Kanbayashi, C; Kondo, N; Masuda, N; Matsui, A; Naito, Y; Nakamura, R; Niikura, N; Oshitanai, R; Saji, S; Takashima, S; Tsuneizumi, M; Watanabe, K; Yamauchi, H; Yasojima, H | 1 |
| Carr, A; Cremona, M; Elster, N; Eustace, AJ; Hennessy, BT; Morgan, C; O'Grady, A; Toomey, S | 1 |
| Patil, A; Sherbet, GV | 1 |
| Aleixo, SB; Arantes, H; Caleffi, M; Figueira, AC; Gutierrez, C; Nunes de Matos Neto, J; Osborne, CK; Reiriz, AB; Rimawi, MF; Rozas, AA; Solca, F; Souza, SC; Uttenreuther-Fischer, MM | 1 |
| Guan, X; Nie, W; Shao, J; Song, W; Wang, Y; Zhang, W; Zhu, A | 1 |
| Bai, Y; Cheng, Z; Li, S; Lv, J; Xie, L; Yan, Y; Zhang, J; Zhang, L; Zhang, X; Zhong, W | 1 |
| Dittrich, C; Fridrik, MA; Gampenrieder, SP; Greil, R; Hufnagl, C; Lang, A; Mlineritsch, B; Petru, E; Pircher, M; Ressler, S; Rinnerthaler, G; Thaler, J; Ulmer, H; Weltermann, A | 1 |
| Aura, C; Baselga, J; Bernards, R; Bosma, AJ; de Azambuja, E; de la Peña, L; Díaz-Delgado, MC; Eidtmann, H; Ellis, C; Fumagalli, D; Harbeck, N; Holmes, E; Jimenez, J; Loi, S; Majewski, IJ; Mittempergher, L; Nuciforo, P; Piccart-Gebhart, M; Prudkin, L; Schultz, N; Sotiriou, C | 1 |
| Clurman, BE; Faltermeier, CM; Mendelsohn, L; Porter, PL; Roberts, JM; Zhao, H | 1 |
| Osborne, CK; Rimawi, MF; Schiff, R | 1 |
| Buonanno, A; Canfield, K; Cook, RS; Hu, H; Kurokawa, M; Li, J; Liby, KT; Morrison, MM; Schiff, R; Ung, M; Vullhorst, D; Wells, W; Wilkins, OM; Williams, CR | 1 |
| Karakashev, SV; Reginato, MJ | 1 |
| Bregni, G; de Braud, F; Di Cosimo, S; Galli, G; Gevorgyan, A; Porcu, L; Serpico, D; Tessari, A; Torri, V | 1 |
| Chen, ZT; Xie, QC; Zhang, L; Zhu, B; Zhuo, WL | 1 |
| Allerton, R; Bidoli, P; Chan, S; Chmielowska, E; Ciruelos, E; Dank, M; DeSilvio, M; Fabi, A; Gori, S; Hornyak, L; Karaszewska, B; Manikhas, A; Margolin, S; Nagi, F; Nusch, A; Parikh, R; Pivot, X; Santillana, S; Semiglazov, V; Swaby, RF; Żurawski, B | 1 |
| Marchetti, D; Ngo, JA; Wetzel, MD; Zhang, L | 1 |
| Jiang, Z; Li, L; Pan, Z; Yang, Y; Yue, Z | 1 |
| Ahmed, S; Sami, A; Xiang, J | 1 |
| Bachelot, T; Bernard-Marty, C; Bonneterre, J; Conforti, R; Le Rhun, E; Taillibert, S | 1 |
| Buffa, FM; Harris, AL; Kong, A; Leung, WY; Li, JL; Roxanis, I; Sheldon, H | 1 |
| Brady, SW; Tsai, MH; Yu, D; Zhang, J | 1 |
| Piccart, M; Sonnenblick, A | 1 |
| Bartsch, R; Bergen, ES; Berghoff, AS; Preusser, M; Rudas, M | 1 |
| Kim, EH; Kim, H; Lee, S; Park, Y; Suh, CO | 1 |
| Abdel-Rasoul, M; Friedman, S; Hicks, M; Layman, R; Lustberg, M; Macrae, ER; Mrozek, E; Querry, J; Ramaswamy, B; Shapiro, C; Wesolowski, R | 1 |
| Biganzoli, L; Dambrosio, M; Minelli, M; Molteni, L; Montemurro, F; Mustacchi, G; Pronzato, P; Scaltriti, L | 1 |
| Amonkar, M; Boyle, FM; Buzdar, AU; Ejlertsen, B; Finkelstein, DM; Fumoleau, P; Goss, PE; Gradishar, W; Huang, Y; Kaneko, T; Lindquist, D; Martin, M; Moy, B; O'Shaughnessy, J; Piccart-Gebhart, M; Pritchard, KI; Rappold, E; Smith, IE; Wang-Silvanto, J; Williams, LS | 1 |
| Aparicio, S; Boyle, FM; Chapman, JA; Coleman, RE; Connor, AP; Dent, S; Di Leo, A; Ellard, SL; Gelmon, KA; Huntsman, DG; Kaufman, B; Khasanov, R; Lemieux, J; Manikhas, A; Martin, M; Mukai, H; Nomikos, D; Nusch, A; Parulekar, WR; Pritchard, KI; Rizel, S; Santillana, SL; Schwartzberg, LS; Shepherd, LE; Tjulandin, S; Tonkin, K; Whelan, TJ | 1 |
| Agazie, YM; Ammer, AG; Creighton, CJ; Farrugia, MK; Lin, CC; McLaughlin, SL; Ruppert, JM; Salkeni, MA; Sharma, SB; Stoilov, P; Vanderbilt, DB | 1 |
| Ameels, H; Aura, C; Baselga, J; de la Peña, L; Eidtmann, H; Ellis, C; Holmes, E; Jimenez, J; Martinez, P; Nuciforo, PG; Piccart-Gebhart, MJ; Prudkin, L; Scaltriti, M | 1 |
| Angus, SP; Beltran, AS; Carey, LA; Chen, X; Collins, KA; Duncan, JS; Earp, HS; Gomez, SM; Granger, DA; Graves, LM; Jin, J; Johnson, GL; Kuan, PF; Miller, SM; Nakamura, K; Parker, JS; Reuther, RA; Sciaky, N; Stuhlmiller, TJ; Zawistowski, JS | 1 |
| Abt, MA; Bruce, JS; Ghatnekar, GS; Grek, CL; Rhett, JM; Yeh, ES | 1 |
| Matevossian, A; Resh, MD | 1 |
| Amin, DN; Carmena, JM; Chang, YH; Gray, JW; Korkola, J; Moasser, MM; Tomlin, CJ | 1 |
| Chang, JC; Colon-Otero, G; Dave, B; Patel, TA; Perez, EA; Rodriguez, AA | 1 |
| Bidard, FC; Cottu, P; Escalup, L; Lim, R; Mariani, P; Ng, CK; Norton, L; Pierga, JY; Piscuoglio, S; Reis-Filho, JS; Reyal, F; Sakr, RA; Servois, V; Sigal, B; Vincent-Salomon, A; Wang, L; Weigelt, B | 1 |
| Bolis, M; Fisher, JN; Fratelli, M; Garattini, E; Gianni, M; Goodall, GJ; Kurosaki, M; Lupi, M; Paroni, G; Terao, M; Tsykin, A; Zanetti, A | 1 |
| Aogi, K; Armour, A; Inoue, K; Iwata, H; Kuroi, K; Masuda, N; Nakayama, T; Nishimura, Y; Rai, Y; Sasaki, Y; Shimizu, S | 1 |
| Arpaci, E; Arslan, UY; Artac, M; Bayoglu, IV; Demirci, U; Dogan, M; Guler, T; Isikdogan, A; Koca, D; Kucukoner, M; Kucukzeybek, Y; Oguz, A; Turker, I; Uncu, D; Zengin, N | 1 |
| Bekki, K; Haarmann-Stemmann, T; Ito, T; Li, W; Matsumura, F; Sweeney, C; Vogel, CF; Vogel, H | 1 |
| Briley, LP; Cox, CJ; Dilthey, A; Iqbal, Z; King, KS; Li, L; McVean, G; Nelson, MR; Newcombe, PJ; Parham, LR; Shen, J; Slater, AJ; Spraggs, CF | 1 |
| Chamness, GC; Chang, JC; Contreras, A; De Angelis, C; Fu, X; Giuliano, M; Gray, JW; Gutierrez, C; Heiser, LM; Herrera, S; Hilsenbeck, SG; Hu, H; Lopez-Tarruella, S; Mao, S; Nardone, A; Osborne, CK; Pavlick, AC; Rimawi, MF; Schiff, R; Trivedi, MV; Wang, NJ; Wang, T; Wang, YC | 1 |
| Chen, Z; Dai, C; Fu, L; Huang, Z; Ma, S; To, K; Wang, F; Wu, X; Zhao, H | 1 |
| Chen, WD; Deng, R; Feng, GK; Ji, J; Jiao, L; Kong, PF; Li, X; Li, YT; Li, ZH; Qian, XJ; Wu, RY; Yu, Y; Zhu, XF | 1 |
| Chun, SY; Kim, S; Kwon, YS; Nam, KS | 1 |
| Arribas, J; Aura, C; Boehm, M; Burgues, O; Cortés, J; Deeds, J; Lluch, A; Marangoni, E; Martínez-Barriocanal, Á; Morancho, B; Mosher, R; Navarro Jiménez, A; Nuciforo, P; Peg, V; Rubio, IT; Schlegel, R; Tabernero, J; Vicario, R; Zacarias-Fluck, M; Zhang, J | 1 |
| Agelaki, S; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kallergi, G; Kalykaki, A; Markomanolaki, H; Mavroudis, D; Papadaki, MA | 1 |
| Halstead-Nussloch, G; Irie, HY; Ito, K; Katsyv, I; Olcott, W; Park, SH | 1 |
| Sardesai, SD; Storniolo, AM | 1 |
| Blancafort, A; Brugada, R; Campuzano, Ò; Carrión-Salip, D; Giró-Perafita, A; Gómez-Miragaya, J; González-Suárez, E; Massaguer, A; Oliveras, G; Palafox, M; Palomeras, S; Puig, T; Turrado, C | 1 |
| Al-Foheidi, M; Al-Rehaily, S; Darwish, T; Karim, SM; Mahrous, M; Mansour, M; Mokhtar, M; Rizvi, A; Zekri, J | 1 |
| Moser, A; Piwko, C; Pollex, E; Prady, C; Yunger, S | 1 |
| Herman-Antosiewicz, A; Kaczyńska, A; Świerczyńska, J | 1 |
| Arteaga, CL; Barry, WT; Dees, EC; Falkson, CI; Guo, H; Hobday, TJ; Krop, IE; Lin, NU; Mayer, IA; Najita, JS; Nanda, R; Richardson, AL; Rimawi, MF; Ryabin, N; Van den Abbeele, AD; Winer, EP; Wolff, AC; Yap, JT | 1 |
| Huo, ZJ; Liu, K; Liu, P; Pang, B; Wang, SJ; Wang, ZQ; Zuo, WS | 1 |
| Budani, MC; Capone, E; D'Agostino, D; De Cola, A; De Laurenzi, V; Di Ilio, C; Ferracin, M; Lattanzio, R; Negrini, M; Piantelli, M; Sala, G; Stassi, G; Todaro, M; Turdo, A; Veronese, A; Volpe, S | 1 |
| Aura, C; Baselga, J; Bradbury, I; Campbell, C; de Azambuja, E; Denkert, C; Eidtmann, H; Ellis, CE; Loi, S; Michiels, S; Nucifero, P; Nuciforo, P; Piccart-Gebhart, MJ; Salgado, R; Savas, P; Sotiriou, C | 1 |
| Bandai, Y; Ijichi, M; Kusaka, K; Sakata, H; Shibasaki, M; Tanabe, A; Toda, T | 1 |
| Casanova, C; Dazzi, C; Mazza, V; Verlicchi, A | 1 |
| Di Luca, A; Henry, M; Meleady, P; O'Connor, R | 1 |
| González, V; Hernández-García, S; Pandiella, A; Sanz, E | 1 |
| Bettelli, S; Bicciato, S; Bisagni, G; Cagossi, K; Conte, P; Crescenzo, R; Dieci, MV; Ellis, C; Ficarra, G; Frassoldati, A; Generali, DG; Guarneri, V; Maiorana, A; Musolino, A; Sarti, S; Tagliafico, E | 1 |
| Fouad, TM; Piccart, M; Zardavas, D | 1 |
| Edgerton, SM; He, Z; Huang, J; Liu, B; Lyu, H; Thor, AD | 1 |
| Bianco, R; D'Amato, V; De Placido, S; Formisano, L; Giuliano, M; Raimondo, L; Rosa, R | 1 |
| Cao, L; Guan, X; Shen, Y; Shi, Y; Sun, Z; Zhang, W | 1 |
| Esteva, FJ; Teplinsky, E | 1 |
| Christgen, M; Dorssers, LC; Kreipe, H; Lehmann, U; Looijenga, LH; van Agthoven, T | 1 |
| Harbeck, N | 1 |
| LaBarge, MA; Lakins, J; Lin, CH; Park, C; Pelissier, FA; Weaver, VM; Zhang, H | 1 |
| Alunni-Fabbroni, M; de Gregorio, N; Fehm, T; Friedl, TW; Hartkopf, A; Huober, J; Janni, W; Meier-Stiegen, F; Müller, V; Pantel, K; Rack, B; Schneeweiss, A; Schochter, F; Scholz, C; Schramm, A; Taran, FA; Trapp, E; Wallwiener, D | 1 |
| Choi, JD; Hwang, SG; Jang, CS; Kim, JK; Kim, SY; Kim, YR; Kwon, K; Lee, YS; Myeong, HS; Noh, YH; Park, TH; Ro, YT | 1 |
| Beijnen, JH; Boss, DS; Grob, M; Huitema, AD; Keessen, M; Rehorst, H; Rosing, H; Schellens, JH; Smit, WM; Tibben, MM; van der Noll, R; Wymenga, AN | 1 |
| Chen, S; Ding, L; Lai, X; Qiao, H; Wen, A; Ye, M; Yu, S; Zhang, J; Zhu, X | 1 |
| Bitterman, H; Feldhamer, I; Greenberg-Dotan, S; Hammerman, A; Yerushalmi, R | 1 |
| He, Z; Li, G; Li, J; Lin, Y; Qiu, K; Wu, J; Zhu, J | 1 |
| Brain, E; Briggs, K; Caglevic, C; DeSilvio, M; Janni, W; Karaszewska, B; Mahood, K; Marini, L; Papadimitriou, C; Pikiel, J; Potemski, P; Salat, C; Sarosiek, T; Staroslawska, E | 1 |
| Arribas, J; Aura, C; Burrows, J; Cecchi, F; Cortes, J; Ferreres, JC; Garrido-Castro, A; Hembrough, T; Hoos, W; Jimenez, J; Nuciforo, P; Peg, V; Perez-Garcia, J; Scaltriti, M; Thyparambil, S; Vicario, R; Vilaro, M | 1 |
| Christenson, JL; Denny, EC; Kane, SE | 1 |
| Ding, P; Guo, Q; Jiang, Z; Li, H; Sun, L; Tian, C; Wang, Z; Yuan, Z; Zhang, L; Zhao, Y | 1 |
| Ding, X; Li, Y; Mao, W; Meng, X; Tang, H; Wang, X; Xie, S; Yang, H | 1 |
| Baselga, J; Chen, MF; Comen, EA; D'Andrea, GM; Dang, CT; Drullinsky, PR; Fornier, MN; Gajria, D; Goldfarb, SB; Hudis, CA; Iyengar, NM; Lacouture, ME; Lake, DE; Modi, S; Norton, L; Patil, S; Sugarman, SM; Theodoulou, M; Traina, TA; Troso-Sandoval, TA | 1 |
| Dang, CV; Gao, S; Gurung, B; Hua, X; Jin, G; Katona, BW; Kong, XC; Liao, J; Matkar, S; Muhammad, AB; Sharma, P; Wang, L | 1 |
| Dai, W; He, B; Hu, H; Lin, Z; Wang, J; Wang, X; Zhang, H; Zhang, Q; Zhang, X | 1 |
| Diorio, C; Furrer, D; Jacob, S; Sanschagrin, F | 1 |
| Bonnefoi, H; Grellety, T; Italiano, A; Robert, J; Soubeyran, I | 1 |
| Krop, IE; Lin, NU; Liu, P; Roberts, TM; Spangle, JM; Von, T; Wang, Q; Winer, EP; Zhao, JJ | 1 |
| Bianca, D; Caro, G; Fabbrocini, G; Panariello, L | 1 |
| Amin, DN; Gulizia, N; Moasser, MM; Ruiz-Saenz, A | 1 |
| Anders, CK; Barry, WT; Berry, DA; Carey, LA; Cheang, MC; Cirrincione, CT; Harris, LN; Henry, NL; Hoadley, KA; Hudis, CA; Iglesia, M; Krop, IE; Ollila, DW; Perou, CM; Pitcher, BN; Singh, B; Weckstein, DJ; Winer, EP | 1 |
| Ali, HR; Bentley, D; Caldas, C; Chin, SF; Contente-Cuomo, T; Dawson, SJ; Farahani, H; Gale, D; Grant, J; Humphray, S; Kingsbury, Z; Marass, F; Murtaza, M; Pogrebniak, K; Provenzano, E; Rosenfeld, N; Rueda, OM; Shah, P; Shah, SP; Shumansky, K; Tsui, DWY; Wallis, M | 1 |
| Pang, X; Wan, X; Zhang, Q; Zhang, Z; Zheng, X | 1 |
| Avisar, E; Bacus, S; Beitsch, P; Blackwell, K; Cartee, L; Gittelman, M; Glenn, K; Harris, J; Kimbrough, CL; Koch, KM; Robertson, FC; Smith, DA; Spector, NL | 1 |
| Goel, S; Winer, EP | 1 |
| Afonso, N; Alves, C; Andrade, S; Batel-Marques, F; Cardoso, F; Costa, L; Mendes, D; Passos-Coelho, JL | 1 |
| Eisenstein, M | 1 |
| Coarfa, C; Edwards, DP; Hilsenbeck, SG; Holdman, XB; Huang, S; Mo, Q; Pond, A; Rajapakshe, K; Rosen, JM; Welte, T; Zhang, X | 1 |
| Choi, J; Kim, A; Kim, C; Kim, J; Lee, J | 1 |
| Bachelot, T; Barriere, J; Bono, P; Ciruelos, E; Cortés, J; Dieras, V; Espié, M; Hurvitz, S; Joensuu, H; Kellokumpu-Lehtinen, PL; Kim, SB; Le Rhun, E; Nabholtz, JM; Ould-Kaci, M; Piacentini, F; Ro, J; Roux, F; Schneeweiss, A; Sohn, JH; Taguchi, J | 1 |
| Armour, A; Baselga, J; Boyle, F; de Azambuja, E; Di Cosimo, S; Diéras, V; Dinh, P; Dolci, S; Dueck, AC; Eidtmann, H; Gelber, RD; Goldhirsch, A; Gomez, H; Harbeck, N; Hillman, DW; Holmes, AP; Holmes, E; Huang, CS; Im, YH; Jackisch, C; Lang, I; McCullough, AE; McFadden, E; Perez, EA; Piccart-Gebhart, M; Pritchard, KI; Smith, I; Suter, T; Tjulandin, S; Tonghua, L; Untch, M; Viale, G; Wolff, AC; Xu, B; Zujewski, JA | 1 |
| Bregni, G; de Braud, F; Di Cosimo, S; Zanardi, E | 1 |
| Edgerton, SM; He, Z; Liu, B; Lyu, H; Thor, AD; Wu, X; Yang, XH | 1 |
| Biernat, W; Czartoryska-Arłukowicz, B; Dębska-Szmich, S; Demlova, R; Duchnowska, R; Foszczyńska-Kłoda, M; Hajac, Ł; Jassem, J; Karczmarek-Borowska, B; Korski, K; Kowalczyk, A; Lang, I; Merdalska, M; Myśliwiec, P; Niwińska, A; Orlikowska, M; Radecka, B; Studziński, M; Wysocki, PJ; Żawrocki, A; Ziółkowska, B; Zuziak, D | 1 |
| Barrios, CH; Bines, J; Blajman, C; Capó, A; Fanelli, M; Fein, L; Gómez, HL; Ismael, G; Lerzo, G; Mano, M; Martínez-Mesa, J; Neciosup, S; Nerón, Y; Pinczowski, H; Sampaio, C; Santi, PX; Tosello, C; Varela, MS; Werutsky, G; Zarba, JJ | 1 |
| Dang, C; Friedman, MD; Lacouture, M | 1 |
| Bian, L; Du, G; Guo, Y; Jiang, Z; Song, S; Wang, T; Xu, X; Zhang, S; Zhuo, J | 1 |
| Grunt, TW; Gschwantler-Kaulich, D; Kölbl, H; Muhr, D; Singer, CF; Wagner, R | 1 |
| Le, QA | 1 |
| Cameron, D; Davies, L; de Souza, P; Di Leo, A; Ellis, C; Gebski, VJ; Geyer, C; Johnston, S; Lee, CK; Loi, S; Lord, SJ; Marschner, I; Press, MF; Simes, J | 1 |
| Boyle, F; Buzdar, AU; Ejlertsen, B; Finkelstein, DM; Fumoleau, P; Goss, PE; Gradishar, W; Horick, N; Lindquist, D; Martin, M; Moy, B; O'Shaughnessy, J; Piccart-Gebhart, M; Pritchard, KI; Rappold, E; Smith, IE; Strasser-Weippl, K | 1 |
| Beauchemin, C; Lachaine, J; Letarte, N; Mathurin, K; Yelle, L | 1 |
| Griggs, JJ; Hayes, DF; Henry, NL; Kidwell, KM; Merajver, SD; Murthy, P; Schott, AF; Smerage, JD; Van Poznak, CH; Wicha, MS | 1 |
| Balla, J; Brunton, VG; Byron, A; Canel, M; Creedon, H; Fraser, C; Gómez-Cuadrado, L; Klinowska, T; Le Bihan, T; MacLeod, KG; Serrels, B; Sims, AH; Tarnauskaitė, Ž; Tracey, N; Unciti-Broceta, A | 1 |
| Bartsch, R; Brodowicz, T; Knittelfelder, R; Kuhar, CG; Lang, I; Melichar, B; Petruzelka, L; Singer, CF; Thallinger, C; Zielinski, C | 1 |
| Harvey, R; Simpson, E; Squires, H; Stevens, J; Stevenson, M | 1 |
| Castro, DJ; Gray, JW; Gu, S; Hu, Z; Morry, J; Ngamcherdtrakul, W; Reda, MM; Yantasee, W | 1 |
| Chen, B; Hu, JL; Jing, T; Yu, Y; Zhang, XP; Zheng, YB | 1 |
| Barinoff, J; Buyse, M; Cameron, D; Cobleigh, M; Di Leo, A; Gasparini, G; Grun, D; Johnston, S; Kaufman, B; Marguet, S; Marty, M; Michiels, S; Nekljudova, V; Paluch-Shimon, S; Penault-Llorca, F; Piccart, M; Pugliano, L; Slamon, D; Vogel, C; von Minckwitz, G | 1 |
| de la Cruz Merino, L; Marcos Rodríguez, JA; Romero Carreño, E; Santana Martínez, S | 1 |
| Chen, W; Li, W; Liu, C; Wang, H; Wei, Q; Zhai, L; Zhang, J | 1 |
| Abt, MA; Phelps-Polirer, K; Smith, D; Yeh, ES | 1 |
| Kumar, PV; Prabaharan, S; Ravind, R | 1 |
| Agbor-Tarh, D; Azim, HA; Boyle, F; Bradbury, I; Campbell, C; de Azambuja, E; Dueck, AC; Gomez, H; Huang, Y; Jackisch, C; Lang, I; Perez, EA; Piccart, M; Pritchard, KI; Smith, I; Sonnenblick, A; Untch, M; Wolff, AC; Xu, B | 1 |
| Ajgal, Z; Alexandre, J; Arrondeau, J; Goldwasser, F; Huillard, O; Hulin, A; Lavaud, P; Rousseau, B | 1 |
| Arya, N; Bang, YJ; Beyer, J; Botbyl, J; Briley, LP; Cartee, L; Chu, Q; Chung, HC; Dar, MM; Koch, KM; Smith, DA; White, JH | 1 |
| Clavarezza, M; D'Amico, M; DeCensi, A; Gennari, A; Paleari, L; Provinciali, N; Puntoni, M | 1 |
| Herman-Antosiewicz, A; Kaczyńska, A | 1 |
| Allemand, DH; Charreau, EH; Cidlowski, JA; Cordo Russo, RI; Cortese, E; De Martino, M; Elizalde, PV; Guzmán, P; Huang, TH; Izzo, F; Mercogliano, MF; Oakley, RH; Pereyra, MG; Proietti, CJ; Rivas, MA; Roa, JC; Schillaci, R; Venturutti, L; Yankilevich, P | 1 |
| Baselga, J; Bernards, R; Bria, E; Conte, P; Denkert, C; Guarneri, V; Holmes, E; Loi, S; Loibl, S; Majewski, I; Nekljudova, V; Piccart, M; Schem, C; Sotiriou, C; Untch, M; von Minckwitz, G | 1 |
| Barni, S; Bisagni, G; Bogina, G; Duranti, S; Fabi, A; Fiorio, E; Foglietta, J; Gori, S; Inno, A; Leonardi, V; Lunardi, G; Marchetti, F; Montemurro, F; Pavese, I; Pellegrino, A; Rossi, V; Santini, D; Saracchini, S; Turazza, M; Vici, P; Zambelli, A | 1 |
| López-Tarruella, S; Martin, M | 1 |
| Conklin, DS; Khan, F; Kokabee, L; Sevinsky, CJ; Sun, Y; Wang, X; Wong, J | 1 |
| Li, G; Yang, B; Yang, N; Yang, YS; Zhu, HL | 1 |
| Adamo, B; Cheang, MC; Ellis, C; Gagnon, R; Galván, P; Johnston, S; Muñoz, M; Nuciforo, P; Paré, L; Prat, A; Press, MF; Viladot, M | 1 |
| Feng, J; Ha, Q; Han, D; Han, X; Hua, W; Li, D; Li, J; Li, X; Liao, F; Liu, C | 1 |
| Davoodzadeh, H; Ebadi, A; Rahmani, H; Shahriary, A; Sheikhi, MA | 1 |
| Bao, J; Li, J; Wang, H; Wu, C | 1 |
| Ambroggi, M; Ardizzoni, A; Bisagni, G; Boggiani, D; Cagossi, K; Conte, PF; Dieci, MV; Generali, DG; Gianni, L; Guarneri, V; Musolino, A; Naldi, N; Piacentini, F; Rimanti, A; Sarti, S; Sgargi, P; Zanoni, D | 1 |
| Hurvitz, S; Zhang, B | 1 |
| Bégin, LR; Bourque, G; Caron, M; Deblois, G; Giguère, V; Gravel, SP; Labbé, DP; Muller, WJ; Park, M; Savage, P; Smith, HW; St-Pierre, J; Tam, IS; Tremblay, ML | 1 |
| Chen, S; Chen, X; Dou, K; Qiao, H; Wei, L; Zhang, J; Zhang, R | 1 |
| Chen, MC; Huang, CC; Huang, PH; Lee, YT; Lin, H; Wang, HY; Yue, CH | 1 |
| Gonzalez-Martin, A; Kim, SB; Krop, IE; Lysbet de Haas, S; Smitt, M; Wildiers, H; Yu, R | 1 |
| Amici, A; Andreani, C; Bartolacci, C; Belletti, B; Elexpuru Zabaleta, M; Galeazzi, R; Gambini, V; Garulli, C; Hysi, A; Iezzi, M; Kalogris, C; Marchini, C; Orlando, F; Pietrella, L; Provinciali, M; Tilio, M; Wang, J | 1 |
| Bisagni, G; Conte, P; Dieci, MV; Ficarra, G; Generali, DG; Guarneri, V; Paré, L; Piacentini, F; Prat, A; Tagliafico, E | 1 |
| Ahn, JH; Ahn, SH; Gong, G; Jung, KH; Kang, MJ; Kim, HH; Kim, JE; Kim, SB; Lee, HJ; Moon, DH; Park, JH; Shin, HJ; Son, BH | 1 |
| Gonçalves, A | 1 |
| Bae, YH; Kang, JH; Le, QA | 1 |
| Chang, TY; Chen, PS; Hsu, HP; Huang, MT; Kuo, KT; Lai, HH; Li, JN; Lyu, YJ; Su, CM; Su, JL | 1 |
| Blohmer, JU; Darb-Esfahani, S; Denkert, C; Dietel, M; Endris, V; Jackisch, C; Klare, P; Kümmel, S; Loi, S; Loibl, S; Möbs, M; Nekljudova, V; Reimer, T; Salat, C; Schem, C; Schmitt, W; Sinn, B; Sinn, P; Stenzinger, A; Tesch, H; Untch, M; von Minckwitz, G; Weichert, W | 1 |
| Liu, P; Xu, B; Zhang, C | 1 |
| Bonizzi, G; Pruneri, G; Vingiani, A | 1 |
| Chen, TM; Chen, YJ; Chien, PH; Huang, WC; Hung, CM; Lin, YM; Pan, HL; Wei, CT | 1 |
| Azadi, S; Habibi-Anbouhi, M; Moradi, L; Omidvar, R; Tafazzoli-Shadpour, M | 1 |
| Cho, BJ; Choi, EJ; Kim, DH; Kim, IA; Park, JM; Yu, T | 1 |
| Chiba, Y; Haratani, K; Hayashi, H; Kawakami, H; Nakagawa, K; Nonagase, Y; Takahama, T; Takeda, M; Takegawa, N; Tamura, T; Tanizaki, J; Tsurutani, J; Ueda, H; Watanabe, S; Yonesaka, K; Yoshida, T | 1 |
| Li, D; Marchenko, ND | 1 |
| Akhand, SS; Brown, WS; Wendt, MK | 1 |
| Guo, WW; Huang, Q; Jiang, G; Tian, Y; Xin, Y; Zhang, LZ; Zhang, P | 1 |
| Alexander, PB; Chen, R; Ding, Y; Gong, C; Jasper, JS; Markowitz, GJ; McDonnell, DP; Song, E; Wang, XF; Xu, X; Yang, P; Yuan, L | 1 |
| Chan, EC; Chan, JC; Lim, P; Ong, PS; Teng, PX | 1 |
| Yamamoto, C; Yamamoto, D; Yamamoto, M | 1 |
| Breslin, S; Lowry, MC; O'Driscoll, L | 1 |
| Asano, H; Cui, X; Kanzaki, H; Kitamura, Y; Miyoshi, S; Murali, R; Namba, K; Sato, H; Sendo, T; Shien, K; Soh, J; Suzawa, K; Takeda, T; Tomida, S; Torigoe, H; Toyooka, S; Tsukuda, K; Watanabe, M; Yamamoto, H; Yoshioka, T | 1 |
| Harbeck, N; Wuerstlein, R | 1 |
| Armour, A; Baselga, J; Chia, S; Eidtmann, H; Harbeck, N; Hatzis, C; Holmes, E; Jiang, T; Loi, S; Nuciforo, P; Peña, L; Piccart-Gebhart, M; Pusztai, L; Rimm, DL; Rosa, DD; Rossari, J; Shi, W; Sotiriou, C; Ueno, T; Wardley, A | 1 |
| Ahluwalia, MS; Angelov, L; Barnett, GH; Chao, ST; Kotecha, R; Miller, JA; Mohammadi, AM; Murphy, ES; Peereboom, DM; Suh, JH; Vogelbaum, MA | 1 |
| Gao, B; Guo, L; Hao, S; Hu, C; Jiang, Y; Luo, D; Tian, W; Yan, J; Zhang, G; Zhang, S; Zhang, X; Zhao, J | 1 |
| Berkers, CR; Kuster, B; Lemeer, S; Ruprecht, B; Wu, W; Zaal, EA; Zecha, J | 1 |
| Bermejo, B; Cortés, J; de la Peña, L; Galván, P; Llombart-Cussac, A; López, R; Martínez, N; Morales, S; Muñoz, M; Nuciforo, P; Oliveira, M; Paré, L; Peláez, A; Pernas, S; Prat, A; Vidal, M | 1 |
| Buskens, E; de Bock, GH; Greuter, MJW; Koleva-Kolarova, RG; Oktora, MP; Reyners, AKL; Robijn, AL | 1 |
| Gao, L; Gao, X; Li, N; Liu, PJ; Tie, XJ; Xu, ZQ; Zhang, Y | 1 |
| Banna, G; Berardi, R; Bisagni, G; Cagossi, K; Cavanna, L; Conte, P; Dieci, MV; Ficarra, G; Frassoldati, A; Generali, D; Goubar, A; Griguolo, G; Guarneri, V; Michelotti, A; Piacentini, F; Puglisi, F | 1 |
| Nahleh, ZA | 1 |
| Elstner, E; Emde, A; Eucker, J; Kühnl, A; Liu, H; Planas-Silva, MD; Possinger, K; Rosche, M; Schulz, CO; Zang, C | 1 |
| Cameron, DA; Stein, S | 1 |
| Benusiglio, PR | 1 |
| Conte, P; Frassoldati, A; Giovannelli, S; Guarneri, V; Jovic, G; Oliva, C; Piacentini, F | 1 |
| Huober, J; Spirig, C; Thürlimann, B | 1 |
| Ena, L; Ena, P; Fadda, GM; Farris, A; Santeufemia, DA | 1 |
| Arya, N; Chu, QS; Cianfrocca, ME; Fleming, RA; Gale, M; Goldstein, LJ; Koch, KM; Loftiss, J; Murray, N; Pandite, L; Paul, E; Rowinsky, EK | 1 |
| Bartholomeusz, C; Bornmann, WG; Esteva, FJ; Hortobagyi, GN; Pal, A; Ueno, NT; Yamasaki, F; Zhang, D | 1 |
| Benowitz, S | 1 |
| Bronder, JL; Feigenbaum, L; Gril, B; Herring, JM; Liewehr, DJ; Merino, MJ; Palmieri, D; Rubin, SD; Steeg, PS; Steinberg, SM; Vega-Valle, E | 1 |
| Paoletti, P | 1 |
| Azim, H; Azim, HA | 1 |
| Amonkar, MM; Cameron, D; Geyer, C; Sherrill, B; Stein, S; Walker, M | 1 |
| Paul, B; Thompson, J; Trovato, JA | 1 |
| Spector, N | 1 |
| Perez, EA | 1 |
| Toi, M | 1 |
| Halterman, PA | 1 |
| Harris, P; Hartwell, D; Loveman, E; Takeda, A; Welch, K | 1 |
| Belkacémi, Y; Kuten, A | 1 |
| Cohen, MH; Ibrahim, A; Johnson, J; Justice, R; Ko, CW; Pazdur, R; Ryan, Q; Sridhara, R | 1 |
| Glantz, M; Melisko, ME; Rugo, HS | 1 |
| Camara, O; Egbe, A; Hammer, U; Hoeffken, K; Jörke, C; Pachmann, K; Rabenstein, C; Runnebaum, IB | 1 |
| Benz, CC; Neve, RM; Park, JW; Szollosi, J | 1 |
| Aglietta, M; Botti, G; Bottini, A; Clavarezza, M; Danese, S; dei Tos, AP; del Curto, B; Di Bonito, M; Di Palma, S; Donadio, M; Durando, A; Jacomuzzi, ME; Kulka, J; Montemurro, F; Redana, S; Sanna, G; Sapino, A; Valabrega, G; Viale, G | 1 |
| Ma, CD; Shen, KW; Shen, ZZ | 1 |
| Arbushites, MC; Aziz, Z; Bines, J; Dering, J; Di Leo, A; Finn, RS; Gomez, HL; Guerrera, SF; Koehler, M; Oliva, C; Press, MF; Stein, SH; Williams, LS; Zvirbule, Z | 1 |
| Chen, FL; Spector, NL; Xia, W | 1 |
| de Azambuja, E; Dinh, P; Piccart-Gebhart, M; Snoj, N; Tomasello, G | 1 |
| Arbushites, M; Cameron, D; Danenberg, K; Di Leo, A; Finn, RS; Gagnon, R; Gasparyan, A; Geyer, CE; Guzman, R; Koehler, MT; Ma, Y; Martin, AM; Oliva, C; Press, MF; Santiago, A; Stein, S; Villalobos, IE; Williams, L | 1 |
| Adjei, AA; Erlichman, C; Felten, SJ; Flatten, KS; Friedman, R; Gálvez-Peralta, M; Gilmer, TM; Jewell, RC; Kaufmann, SH; Koch, KM; Mandrekar, S; Molina, JR; Mullin, RJ; Reid, JM; Rubin, SD | 1 |
| Anania, FA; Knight, BB; Merlin, D; O'Regan, RM; Saxena, NK; Sharma, D; Taliaferro-Smith, L | 1 |
| Castellino, S; Chism, JP; Demby, VE; John-Williams, LS; Olson, KL; Otto, V; Polli, JW; Woodard, SM; Yeager, RL | 1 |
| Arribas, J; Baselga, J; Guzman, M; Jimenez, J; Landolfi, S; Parra, JL; Pedersen, K; Ramon y Cajal, S; Scaltriti, M; Smith, DJ; Verma, C | 1 |
| Ciccarese, M; Lorusso, V | 1 |
| Belyayeva, Y; Gkouvi, A; Gregoriou, S; Katsambas, A; Larios, G; Rigopoulos, D | 1 |
| Carrasco-Pancorbo, A; Fernandez-Gutierrez, A; Garcia-Villalba, R; Menendez, JA; Oliveras-Ferraros, C; Segura-Carretero, A; Vazquez-Martin, A | 1 |
| Azambuja, E; Cardoso, F; Dolci, S; Ignatiadis, M; Meirsman, L; Piccart-Gebhart, MJ; Sotiriou, C; Straehle, C; Vantongelen, K | 1 |
| Fricker, J | 1 |
| Hay, JW; Le, QA | 1 |
| Brown, PH; Gilmer, TM; Hill, JL; Hilsenbeck, SG; Kim, HT; Li, Y; Osborne, CK; Sexton, KR; Shen, Q; Strecker, TE; Wang, C; Zhang, Y | 1 |
| Amonkar, MM; Cameron, D; Cella, D; Geyer, CE; Segreti, A; Stein, S; Walker, M; Zhou, X | 1 |
| Arbushites, MC; Blackwell, KL; Burstein, HJ; Forster, JK; Maltzman, JD; Pegram, MD; Rubin, SD; Schwartzberg, LS; Stein, SH; Tan-Chiu, E | 1 |
| Blum, JL; Brufsky, A; Christodoulou, C; Ciruelos, E; Dharan, B; Diéras, V; Gori, S; Greil, R; Lin, NU; Liu, MC; Loibl, S; Lossignol, D; Oliva, C; Paoletti, P; Paul, D; Roché, H; Roychowdhury, D; Rubin, SD; Stemmler, HJ; Steplewski, K; Wardley, A; Winer, EP; Yardley, D; Zembryki, D | 1 |
| Ali-Osman, F; Bigner, D; Buolamwini, J; Friedman, H; Haystead, T; Okamura, T; Singh, S | 1 |
| Amir, E; Freedman, O; Seruga, B; Tannock, I | 1 |
| Casalini, P; Croce, CM; Di Leva, G; Iorio, MV; Ménard, S; Merlo, A; Piovan, C; Tagliabue, E; Triulzi, T | 1 |
| Pikó, B | 2 |
| Rowan, K | 1 |
| Ross, JS | 2 |
| Hortobagyi, GN; Pusztai, L; Ravdin, PM; Ross, JS; Slodkowska, EA; Symmans, WF | 1 |
| McArthur, H | 1 |
| Jaén, P; Muñoz-Zato, E; Pérez, B; Truchuelo, M; Vano-Galvan, S | 1 |
| Awada, A; Bachelot, T; Blackwell, K; DeSilvio, M; Johnston, S; Kaufman, B; Salazar, V; Spector, N; Trudeau, M; Westlund, R; Zaks, T | 1 |
| Elzawawy, A | 1 |
| Bedard, PL; de Azambuja, E; Piccart-Gebhart, M; Suter, T | 1 |
| Holmes, D | 1 |
| Abad, M; Esparís-Ogando, A; Montero, JC; Ocaña, A; Ortiz-Ruiz, MJ; Pandiella, A | 1 |
| Cameron, DA; Hall, PS; Hanby, A | 1 |
| Castañeda, CA; Gomez, HL | 1 |
| Belvin, M; Eastham-Anderson, J; Friedman, LS; Gunter, B; Haverty, PM; Hoeflich, KP; Lee-Hoeflich, ST; Lewin-Koh, N; Murray, LJ; Sliwkowski, MX; Truong, T; Yao, E; Zhou, W | 1 |
| Coombes, RC; Filipovic, A; Francis, RE; Gojis, O; Guest, SK; Hartman, J; Krol, J; Lam, EW; McGovern, UB; Myatt, SS; Palmieri, C; Peck, B; Peston, D; Shousha, S; Sicinski, P; Wang, J; Yu, Q | 1 |
| del Barco, S; Martín-Castillo, B; Menéndez, JA; Oliveras-Ferraros, C; Vázquez-Martín, A | 1 |
| Jo Chien, A; Rugo, HS | 1 |
| Oestreicher, N | 1 |
| Carpenter, G; Liao, HJ | 1 |
| Arbushites, M; Dering, J; Di Leo, A; Finn, RS; Koehler, M; Oliva, C; Press, MF; Williams, LS | 1 |
| Cathomas, R; von Moos, R | 1 |
| Azim, H; Azim, HA; Escudier, B | 1 |
| Azim, HA | 2 |
| Bravo Marques, JM | 1 |
| Annan, R; Gilmer, TM; Greger, J; Greshock, J; Halsey, W; Liu, L; Liu, Y; Martin, AM; Sathe, GM; Shi, H | 1 |
| Amir, E; Ocaña, A | 1 |
| Collins, D; Hill, AD; Young, L | 1 |
| Amadori, D; Brigliadori, G; Carloni, S; Fabbri, F; Tesei, A; Ulivi, P; Vannini, I; Zoli, W | 1 |
| Baselga, J; Cortes, J | 1 |
| Dieras, V; Florance, A; Gomez, HL; Johnston, S; Kennedy, MJ; Lichinitser, M; Maltzman, J; Manikhas, A; O'Rourke, L; Oliva, C; Pegram, M; Pippen, J; Pivot, X; Press, MF; Romieu, G; Sadeghi, S; Stein, S | 1 |
| Beard, C; Kasparian, E; Lin, NU; Morganstern, DE | 1 |
| Frampton, JE | 1 |
| Capri, G; Chang, J; Chen, SC; Conte, P; Cwiertka, K; De Placido, S; Jerusalem, G; Jiang, Z; Johnston, S; Kaufman, B; Link, J; Oliva, C; Parikh, R; Preston, A; Ro, J; Rosenlund, J; Schütte, J; Selzer, M; Zembryki, D | 1 |
| Allen, KE; Aogi, K; Arai, T; Ellis, CE; Fujiwara, Y; Gagnon, RC; Ito, Y; Iwata, H; Katsura, K; Nakamura, S; Rai, Y; Sasaki, Y; Taguchi, T; Takashima, S; Toi, M; Tokuda, Y; Wakamatsu, T; Watanabe, J | 1 |
| Clegg, A; Jones, J; Picot, J; Takeda, A; von Keyserlingk, C | 1 |
| Camp, JT; Kimple, RJ; Sambade, MJ; Sartor, CI; Shields, JM | 1 |
| Amalfitano, A; Barry, WT; Chen, W; Clay, TM; Devi, GR; Hartman, Z; Hobeika, AC; Jiang, H; Lei, G; Lyerly, HK; Morse, MA; Osada, T; Peplinski, S; Ren, XR; Spector, N; Wei, J; Xia, W | 1 |
| Arbushites, M; Di Leo, A; Finn, RS; Gagnon, R; Koehler, M; Press, MF | 1 |
| Berton-Rigaud, D; Bourbouloux, E; Campone, M; Frenel, JS; Sadot-Lebouvier, S; Zanetti, A | 1 |
| Guarneri, V | 1 |
| Wicha, MS | 1 |
| Schwartz, J | 1 |
| D'Alessio, A; De Luca, A; Gallo, M; Lamura, L; Maiello, MR; Napolitano, M; Normanno, N; Rachiglio, AM | 1 |
| Bedard, PL; de Azambuja, E; Devriendt, D; Lossignol, D; Piccart-Gebhart, MJ; Tomasello, G | 1 |
| Esteva, FJ; Hortobagyi, GN; Hung, MC; Yu, D | 1 |
| Gutteridge, E; Robertson, JF | 1 |
| Cancello, G; Colleoni, M; Montagna, E; Rizzo, S; Scarano, E; Torrisi, R | 1 |
| Ansaldi, F; Bagnasco, L; Ballestrero, A; Cea, M; Cirmena, G; Garuti, A; Grillo, V; Icardi, G; Moran, E; Nencioni, A; Parodi, S; Patrone, F; Rocco, I; Soncini, D; Zoppoli, G | 1 |
| Amonkar, MM; Aziz, Z; Bines, J; Di Leo, A; Gomez, HL; Sherrill, B; Wu, Y; Zvirbule, Z | 1 |
| Amir, E; Clemons, M; Freedman, O; Ocaña, A; Seruga, B | 1 |
| Iwata, K; Yamashita, T | 1 |
| Kolesar, JM; Tevaarwerk, AJ | 1 |
| Baselga, J; Bischoff, J; Blackwell, KL; Burstein, HJ; Casey, M; Ellis, C; Koehler, M; O'Shaughnessy, J; Rugo, H; Sledge, G; Storniolo, AM; Vukelja, S | 1 |
| Bacus, S; Chen, FL; Husain, I; Koch, KM; Liu, L; Liu, Z; Moseley, MA; Spector, NL; Thompson, JW; Xia, W; Zhao, S | 1 |
| Ballestrero, A; Cea, M; Garuti, A; Moran, E; Nencioni, A; Passalacqua, M; Patrone, F; Pistoia, V; Raffaghello, L; Soncini, D; Zoppoli, G | 1 |
| Brandes, AA; Degli Esposti, R; Franceschi, E; Tosoni, A | 1 |
| Arbushites, M; Di Leo, A; Downey, L; Guzman, R; Koehler, M; Livingston, RB; Press, MF; Santiago, A; Villalobos, I; Williams, L | 1 |
| Florance, A; Franco, SX; Johnston, S; Maltzman, J; O'Rourke, L; Schwartzberg, LS; Schwarzberg, LS | 1 |
| Ferraz, MB; Puga, ME; Riera, R; Soárez, PC | 1 |
| Arnould, L; Coudert, B; Favier, L; Fumoleau, P; Guiu, S | 1 |
| Detre, S; Dowsett, M; Drury, S; Johnston, SR; Leary, AF; Lykkesfeldt, AE; Martin, LA; Pancholi, S | 1 |
| Arteaga, CL; Mayer, IA | 1 |
| Ashley, S; Bhatti, R; Camburn, T; Chan, S; Davidson, N; Johnston, SR; Miles, D; Nouras, H; Shehata, M; Sutherland, S; Wardley, A | 1 |
| Barok, M; Hemmilä, P; Ilvesaro, J; Isola, J; Köninki, K; Pitkänen, J; Staff, S; Tanner, M | 1 |
| Flores, LM; Hemler, ME; Krop, IE; Li, Q; Xu, F; Yang, XH; Zhou, P | 1 |
| Abujamra, AL; Cornelio, DB; Roesler, R; Schwartsmann, G | 1 |
| Balsari, A; Campiglio, M; Pupa, SM; Tagliabue, E | 1 |
| Amonkar, MM; Bachelot, T; Johnston, S; Kaufman, B; Salazar, V; Sherrill, B; Viens, P; Wu, Y | 1 |
| Chow, LW; Ong, EY; Tse, LA; Yip, AY | 1 |
| Byrne, AT; Crown, J; Gallagher, WM; McGee, S; O'Connor, AE; O'Donovan, N | 1 |
| Cheng, Y; Hait, WN; Li, H; Niu, T; Ren, X; Yang, J | 1 |
| Vitry, AI | 1 |
| Deng, X; Dewan, MZ; Kuroi, K; Saji, S; Takada, M; Terunuma, H; Toi, M; Yamamoto, N | 1 |
| Mukai, H | 1 |
| Amadori, D; Brigliadori, G; Carloni, S; Fabbri, F; Silvestrini, R; Ulivi, P; Zoli, W | 1 |
| Dickler, MN | 1 |
| Angelini, PD; Arribas, J; Aura, C; Baselga, J; Cameron, D; Chandarlapaty, S; Ellis, C; Gagnon, R; Geyer, C; Gomez, H; Guzman, M; Jimenez, J; Koehler, M; Parra, JL; Prudkin, L; Rosen, N; Sánchez, G; Scaltriti, M | 1 |
| Camp, JT; Kimple, RJ; Livasy, CA; Peters, E; Sambade, MJ; Sartor, CI; Shields, JM | 1 |
| Abbruzzi, A; Chen, C; Come, S; Dang, C; Hudis, C; Lin, N; Morris, P; Moy, B; Norton, L; Patil, S; Steingart, R; Sugarman, S; Winer, E | 1 |
| Fornier, M; Murphy, CG | 1 |
| Rastogi, P | 1 |
| Bilici, A; Gumus, M; Kefeli, AU; Kefeli, U; Seker, M; Ustaalioglu, BB; Yildirim, ME | 1 |
| Arboleda, J; Browne, BC; Chow, L; Crown, J; Duffy, MJ; Ginther, C; O'Brien, NA; O'Donovan, N; Slamon, DJ; Wang, Y | 1 |
| Cristofanilli, M | 1 |
| Boussen, H; Cristofanilli, M; DeSilvio, M; Salazar, V; Spector, N; Zaks, T | 1 |
| Chan, A; Gril, B; Kim, SB; Kurebayashi, J; Liu, L; Lu, YS; Moon, H; Vogel, C | 1 |
| Pownall, M | 1 |
| Abrahámová, J; Bacanu, F; Brincat, S; Brize, A; Cesas, A; Cufer, T; Dank, M; Duchnowska, R; Eniu, A; Jassem, J; Kahán, Z; Matos, E; Padrik, P; Plāte, S; Pokker, H; Purkalne, G; Steger, GG; Timcheva, C; Tzekova, V; Vyzula, R; Zielinski, CC | 1 |
| Balbi, A; Ballestrero, A; Castagnino, N; Montagna, R; Moran, E; Nencioni, A; Parodi, S; Pesenti, R; Soncini, D; Tortolina, L | 1 |
| Bono, P; Joensuu, H | 1 |
| Curran, MP | 1 |
| Blohmer, JU; Costa, SD; Eidtmann, H; Fasching, PA; Fehm, T; Gerber, B; Hanusch, C; Hilfrich, J; Kreienberg, R; Loibl, S; Nekljudova, V; Solbach, C; Strumberg, D; Untch, M; von Minckwitz, G | 1 |
| Cufí, S; Del Barco, S; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A | 1 |
| André, F; Bachelot, T; Campone, M; Juin, P | 1 |
| Crown, J; Duffy, MJ; O'Donovan, N | 1 |
| Luo, J; Ma, C; Niu, X; Shao, Z; Shen, K | 1 |
| Cognetti, F; Crinò, L; Fabi, A; Foglietta, J; Giannarelli, D; Gori, S; Metro, G; Mottolese, M; Papaldo, P; Russillo, M; Stocchi, L; Vidiri, A | 1 |
| Junttila, TT; Li, G; Parsons, K; Phillips, GL; Sliwkowski, MX | 1 |
| Kaklamani, V; Moreira, C | 1 |
| Cameron, D; Casey, M; Geyer, CE; Imwalle, B; Newstat, B; Oliva, C | 1 |
| Burandt, E; Sauter, G | 1 |
| Amonkar, MM; Johnston, S; Maltzman, J; O'Rourke, L; Sherif, B; Sherrill, B | 2 |
| Moulder, SL | 1 |
| Awada, A; Azim, HA; Metzger Filho, O; Saini, KS | 1 |
| Mukohara, T | 1 |
| Arai, H; Nishimura, Y; Yamaki, M | 1 |
| Fusi, A; Keilholz, U; Liu, Z; Schmittel, A; Schneider, A; Tinhofer, I | 1 |
| Bareford, MD; Dent, P; Eulitt, P; Hossein, H; Martin, AP; Mitchell, C; Nephew, KP; Yacoub, A; Yang, C | 1 |
| Baas, J; Bloemendal, HJ; Boven, E; de Graaf, H; Hop, WC; Kroep, JR; Linn, SC; Mandjes, IA; Nortier, JW; Schröder, CP; Smit, WM; van den Bosch, J; Vermeulen, GJ | 1 |
| Egerton, N | 1 |
| Bang, YJ; Cha, Y; Ham, HS; Han, SW; Im, SA; Im, YH; Kim, HP; Kim, TY; Lee, KS; Oh, DY; Park, IH; Park, JW; Rhee, J; Ro, J | 1 |
| Emde, A; Köstler, WJ; Yarden, Y | 1 |
| Brunner, C; Hubalek, M; Marth, C; Matthä, K | 1 |
| Keane, MP; Kelly, E; McDonnell, TJ; Mhurchu, EN; Sukor, S; Tryfonopoulos, D | 1 |
| Singer, CF | 1 |
| Baek, JM; Boulbes, D; Esteva, FJ; Gomez-Cabello, D; Hawke, DH; Hortobagyi, GN; Hung, MC; Jin, Q; Lee, MH; Wang, YN; Yeung, SC; Yuan, LX | 1 |
| Aono, T; Iwase, K; Nakamura, Y; Nomura, M; Tanaka, Y | 1 |
| Abbey, R; DeSilvio, M; Dobrovolskaya, N; Jagiello-Gruszfeld, A; Manikhas, A; Pienkowski, T; Ridderheim, M; Tjulandin, S | 1 |
| Bailey, TA; Band, H; Band, V; Clubb, RJ; Duan, L; Natarajan, A; Nyong, AM; Ortega-Cava, C; Raja, SM; Reddi, AL; Williams, SH; Zhao, X | 1 |
| Gelmon, KA; MacFarlane, RJ | 1 |
| Dobbins, TA; Drew, AK; Harris, CA; Pearson, S; Ward, RL | 1 |
| Barbieri, E; Conte, P; Dieci, MV; Guarneri, V; Piacentini, F | 1 |
| Chiuri, VE; De Laurentiis, M; Giampaglia, M; Lorusso, V; Silvestris, N; Tinelli, A | 1 |
| Arteaga, C; Chakrabarty, A; Chamness, GC; Chang, JC; Dave, B; Gutierrez, MC; Hilsenbeck, SG; Huang, J; Migliaccio, I; Narasanna, A; Osborne, CK; Rimawi, M; Schiff, R; Wong, H; Wu, MF | 1 |
| Arpino, G; Gutierrez, C; Hilsenbeck, SG; Huang, C; Massarweh, S; Migliaccio, I; Osborne, CK; Rimawi, MF; Schiff, R; Soliz, R; Wang, YC; Ward, R; Wiechmann, LS; Wu, MF | 1 |
| Catalano, O; De Giuli, L; Della Porta, MG; Eleuteri, E; Riccardi, A; Tondini, C; Zambelli, A | 1 |
| Aglietta, M; Capellero, S; Cavalloni, G; Gammaitoni, L; Giordano, S; Migliardi, G; Milani, A; Moggio, A; Montemurro, F; Pecchioni, C; Peraldo-Neia, C; Petrelli, A; Sapino, A; Valabrega, G; Zaccarello, G | 1 |
| de Weger, RA; Moelans, CB; van Diest, PJ | 1 |
| Baselga, J; Chandarlapaty, S; Grbovic-Huezo, O; Majumder, PK; Rodrik-Outmezguine, V; Rosen, N; Sawai, A; Scaltriti, M; Serra, V | 1 |
| Ito, Y | 2 |
| Bing, N; Briley, LP; Budde, LR; Cardon, LR; Cox, CJ; King, KS; Mooser, VE; Preston, AJ; Spraggs, CF; Stein, SH; Whittaker, JC | 1 |
| Abramson, V; Arteaga, CL | 1 |
| Bouchalova, K; Cizkova, M; Cwiertka, K; Friedecky, D; Hajduch, M; Trojanec, R | 1 |
| Morioka, T; Niikura, N; Okamura, T; Saito, Y; Suzuki, Y; Terada, M; Terao, M; Tokuda, Y; Tsuda, B | 1 |
| Arteaga, CL; Balko, JM; Bates, M; Chakrabarty, A; Dua, R; Ghosh, R; González-Angulo, AM; Kostler, WJ; Leitzel, K; Lipton, A; Liu, S; Mills, GB; Mukherjee, A; Narasanna, A; Penuel, E; Pidaparthi, S; Sperinde, J; Wang, SE; Winslow, J | 1 |
| Katano, M; Morisaki, T; Nakafusa, Y; Nakashima, Y; Onishi, H; Yokohata, K | 1 |
| Brachtel, E; Chiba, N; Edelman, EJ; Hayashida, T; Maheswaran, S; Moriyama, H; Ramaswamy, S; Shimada, T; Tajima, K; Takahashi, F; Takahashi, M | 1 |
| Addeo, R; Caraglia, M | 1 |
| Bethke, K; Cianfrocca, M; Gordon, J; Gradishar, W; Hansen, N; Jeruss, JS; Jovanovic, B; Kaklamani, VG; Khan, SA; Lacouture, M; Meservey, C; Parimi, V; Rosen, S; Scholtens, D; Siziopikou, K; Uthe, R; Von Roenn, J; Wayne, J | 1 |
| Abbruzzi, A; Chen, C; Come, S; Dang, CT; Dickler, M; Fleisher, M; Hudis, CA; Lehman, R; Lin, N; McArthur, HL; Morris, PG; Moy, B; Norton, L; Patil, S; Steingart, R; Sugarman, S; Winer, E | 1 |
| Arao, T; Azuma, K; Fujisaka, Y; Kaneda, H; Kurata, T; Nakagawa, K; Nishio, K; Okamoto, I; Sakai, K; Satoh, T; Takeda, M; Tsurutani, J; Watatani, M | 1 |
| Arteaga, CL; Chakrabarty, A; Chang, J; Cook, RS; Dave, B; Garrett, JT; Granja-Ingram, ND; Manning, HC; McKinely, E; Olivares, MG; Pao, W; Rinehart, C; Sánchez, V | 1 |
| Barco, SD; Brunet, J; Cufí, S; Lopez-Bonet, E; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Sauri-Nadal, T; Torres-Garcia, VZ; Vazquez-Martin, A | 1 |
| Amonkar, MM; Baselga, J; Blackwell, KL; Burstein, HJ; Ellis, C; O'Shaughnessy, J; Sherrill, BH; Wu, Y | 1 |
| Twombly, R | 1 |
| Ali, SM; Carney, W; Gagnon, R; Leitzel, K; Lipton, A; Maltzman, J; Martin, AM; Platek, G; Steplewski, K; Westlund, R | 1 |
| Dao-Pick, T; DeFazio-Eli, L; Goodman, L; Parry, G; Strommen, K; Winslow, J | 1 |
| Ho, PC; Lo, YH; Wang, SC; Zhao, H | 1 |
| Fumita, S; Nakagawa, K; Nishio, K; Okamoto, I; Okamoto, W; Tanizaki, J | 1 |
| Callahan, R; Hurvitz, S | 1 |
| Barok, M; Isola, J; Köninki, K; Tanner, M | 1 |
| Berille, J; Bonneterre, J; Brain, E; Dieras, V; Isambert, N; Lokiec, F; Rezai, K; Roche, H; Urien, S | 1 |
| Hatake, K; Ito, Y; Iwase, T | 1 |
| Chi, HD; Chua, D; Jiang, ZF; Liu, DG; Luo, RC; Martin, AM; Newstat, B; Preston, A; Shao, ZM; Wang, L; Wang, XJ; Xu, BH; Yeo, W; Yu, SY | 1 |
| Burstein, HJ; DiPiro, PJ; Krop, IE; Lin, NU; Najita, JS; Olson, EM; Winer, EP | 1 |
| Brasseur, L; Cvitkovic, F; Gutierrez, M; Le Scodan, R; Lyazidi, S | 1 |
| Chang, Y; Chen, S; Feng, J; Li, X; Wang, Z; Wen, A | 1 |
| Borštnar, S; Cwiertka, K; Das Gupta, A; Greil, R; Koza, I; Linn, M; Marcou, Y; Petráková, K; Pikiel, J; Steger, GG; Wojtukiewicz, MZ | 1 |
| Berton-Rigaud, D; Bourbouloux, E; Campone, M; Frenel, JS; Sophie, S; Zanetti, A | 1 |
| Korman, DB | 1 |
| Almendro, V; Ametller, E; Casas, I; Fernández-Nogueira, P; García-Recio, S; Gascón, P; Mayordomo, C; Pastor-Arroyo, EM; Vinyals, L | 1 |
| Antonelli, A; Borsari, V; Carpi, A; Fallahi, P; Ferrari, P; Fini, M; Miccoli, P; Nicolini, A | 1 |
| Chefrour, M; Ciccolini, J; Denden, A; Fischel, JL; Formento, P; Giacometti, S; Iliadis, A; Milano, G; Renée, N | 1 |
| Kawaguchi, H; Koga, C; Nakamura, Y; Nishimura, S; Ohno, S; Tanaka, K; Yamaguchi, H; Yoshiyama, T | 1 |
| Kalofonos, H; Koutras, A; Labropoulou-Karatza, C; Makatsoris, T; Onyenadum, A; Peroukides, S; Tsamandas, A | 1 |
| Cognetti, F; Di Benedetto, A; Fabi, A; Ferretti, G; Metro, G; Mottolese, M; Papaldo, P; Russillo, M | 1 |
| Bacus, SS; Blackwell, KL; Clay, TM; Hartman, ZC; He, J; Liu, L; Liu, Z; Lyerly, HK; Mao, Y; Osada, T; Petricoin, EF; Spector, NL; Wulfkuhle, JD; Xia, W; Yang, XY; Zhao, S; Zong, R | 1 |
| Amala, K; Bhujanga Rao, AK; Gondi, CS; Gorantla, B; Jogi, KV; Junnarkar, A; Myneni, PC; Naidu, MU; Rao, JS; Venkat Ramana, G | 1 |
| Guo, H; Hu, X; Jia, Z; Shao, Z; Sun, S; Wang, B; Wang, L; Wang, Z; Zhang, J; Zhang, Q | 1 |
| Okamura, T; Saito, Y; Suzuki, Y; Tokuda, Y | 1 |
| Bonanni, B; Decensi, A; Dotti, MC; Galimberti, V; Guerrieri-Gonzaga, A; Johansson, H; Lazzeroni, M; Luini, A; Macis, D; Pala, O; Pruneri, G; Puntoni, M; Serrano, D; Veronesi, P; Viale, G | 1 |
| Adams, A; Dolan, R; Graham, TR; Liu, T; Lobo, C; O'Regan, RM; Sun, SY; Taliaferro-Smith, LD; Tighiouart, M; Yacoub, R; Yang, L | 1 |
| Alvarez, RH; Cristofanilli, M; De Giorgi, U; De Laurentiis, M; De Placido, S; Giordano, A; Giuliano, M; Handy, BC; Hess, KR; Hortobagyi, GN; Jackson, S; Mego, M; Reuben, JM; Ueno, NT; Valero, V | 1 |
| Amonkar, MM; Browning, D; Cameron, D; Delea, TE; Karnon, J; Sofrygin, O; Tappenden, P; Walker, MD | 1 |
| Campone, M; Eierman, W; Greil, R; Kaufman, B; Lane, SR; Lin, NU; Rubin, SD; Steplewski, K; Winer, EP; Zembryki, D | 1 |
| Davidson, NE | 1 |
| Danko, J; Horton, K; Kostyal, D; Lanning, C; Shay, T; Welt, RS; Welt, S | 1 |
| Chew, HK; Christensen, S; Davies, AM; Gandour-Edwards, R; Gitlitz, B; Linden, H; Mack, PC; Solis, LJ; Somlo, G; Yang, X | 1 |
| Breindl, S; Brockhoff, G; Buchholz, S; Diermeier-Daucher, S; Ortmann, O | 1 |
| Pandiella, A; Sánchez-Martín, M | 1 |
| Albain, KS; Clementz, AG; Meeke, K; Miele, L; Osipo, C; Pandya, K; Roberts, J; Rogowski, A | 1 |
| Brosens, JJ; Chan, KY; Chen, J; Cheung, YN; Feltes, A; Gomes, AR; Ho, KK; Karadedou, CT; Khoo, US; Lam, EW; Petkovic, M; Tsang, JW; Wong, SY; Zwolinska, AK | 1 |
| Cortes, J; Roché, H | 1 |
| Bissell, MJ; Hilsenbeck, SG; Huang, C; Osborne, CK; Park, CC; Rimawi, MF; Schiff, R; Shou, J; Wang, YC; Ward, R | 1 |
| Chen, C; D'Andrea, G; Drullinsky, P; Feigin, K; Gajria, D; Gonzalez, J; Hudis, CA; Lake, D; Norton, L; Patil, S; Theodoulou, M; Traina, TA | 1 |
| Bao, Y; Chang, CJ; Hortobagyi, GN; Hsu, JL; Hung, MC; Lang, JY; Meric-Bernstam, F; Wang, Q; Woodward, WA; Xie, X; Yamaguchi, H; Yu, D | 1 |
| Albini, A; Anzà, C; Baravelli, M; Bucci, EO; Cammarota, R; Cesana, E; Donatelli, F; Noonan, DM | 1 |
| Jehn, C; Kunc, K; Lüftner, D; Possinger, K; Seidel, J | 1 |
| Bignon, YJ; Cayre, A; El Guerrab, A; Nemlin, CC; Penault-Llorca, F; Rossignol, F; Vigier, F; Zegrour, R | 1 |
| Benhaim, L; Bohanes, PO; El-Khoueiry, A; El-Khoueiry, R; Gerger, A; Labonte, MJ; Ladner, RD; Lenz, HJ; Ning, Y; Wilson, PM; Yang, D; Zhang, W | 1 |
| Abair, T; O'Shaughnessy, J | 1 |
| Jung, SY; Kang, HS; Kim, SW; Ko, K; Kwon, Y; Lee, KS; Lee, S; Nam, BH; Park, IH; Ro, J; Shin, KH | 1 |
| Castellino, S; Gril, B; Hua, E; Lockman, J; Lockman, PR; Mittapalli, RK; Palmieri, D; Polli, JW; Rubin, SD; Rudraraju, V; Samala, R; Smith, QR; Steeg, PS; Taskar, KS; Thorsheim, HR | 1 |
| Awada, A; Bozovic-Spasojevic, I; Saliba, W | 1 |
| Constantinidou, A; Smith, I | 1 |
| Azim, HA; de Azambuja, E; Loi, S; Metzger-Filho, O; Piccart, M; Saini, KS; Sotiriou, C | 1 |
| DeMichele, A; Hirsh, RL | 1 |
| Bisagni, G; Clavarezza, M; Cognetti, F; Crivellari, D; Fabi, A; Ferzi, A; Foglietta, J; Gamucci, T; Gori, S; Metro, G; Montemurro, F; Silva, RR; Spazzapan, S; Stocchi, L; Torrisi, E | 1 |
| Bianchini, G; Gianni, L | 1 |
| de Azambuja, E; Metzger-Filho, O | 1 |
| A'Hern, R; Anderson, H; Bliss, J; Dowsett, M; Dunbier, A; Evans, A; Ghazoui, Z; Iskender, A; Johnson, L; Pinhel, I; Robertson, J; Robison, L; Salter, J; Skene, T; Smith, I; Wilcox, M | 1 |
| Arnold, SL; Gayle, SS; Nahta, R; O'Regan, RM | 1 |
| Bartosch, N; Duyster, J; Engh, RA; Kancha, RK; Peschel, C; von Bubnoff, N | 1 |
| Aoki, Y; Fujii, T; Hada, K; Ishii, N; Kondoh, O; Mio, T; Miura, T; Nakanishi, Y; Nakano, K; Ono, N; Saitoh, R; Sakata, K; Sato, S; Suda, A; Tachibana, Y; Tsukuda, T; Yamazaki, T | 1 |
| Bassano, C; Centritto, F; Flora, M; Fratelli, M; Garattini, E; Gardini, G; Guarnaccia, V; Paroni, G; Terao, M; Ubezio, P; Zanetti, A | 1 |
| Bode, AM; D'Alessio, A; De Luca, A; Dong, Z; Ericson, ME; Grubbs, C; Li, J; Lubet, RA; Normanno, N; Zhu, F | 1 |
| Botero, MF; Chamness, GC; Fu, X; Gillihan, R; Guo, J; Healy, NA; Hilsenbeck, SG; Morrison, G; Osborne, CK; Phillips, GL; Rimawi, MF; Schiff, R; Wang, YC; Ward, RM | 1 |
| Arteaga, CL; Gianni, L; Osborne, CK; Perez, EA; Puglisi, F; Sliwkowski, MX | 1 |
| Armstrong, A; Bagust, A; Blundell, M; Boland, A; Davis, H; Dickson, R; Dundar, Y; Fleeman, N; Moonan, M; Oyee, J; Thorp, N | 1 |
| Baergen, RN; Boeck, M; Christos, P; Chuang, E; Cigler, T; Cobham, MV; Donovan, D; Jain, S; Lam, C; Lane, ME; Mittal, V; Moore, A; O'Loughlin, J; Rafii, S; Schneider, S; Swistel, A; Vahdat, LT; Ward, MM; Wiener, N | 1 |
| Arbushites, MC; Chien, AJ; Dickler, MN; Franco, SX; Glencer, A; Hudis, C; Lahiri, S; Nulsen, B; Park, JW; Rugo, HS; Scott, J; Stopeck, AT | 1 |
| Ishiba, T; Kuwayama, T; Nakagawa, T; Oda, G; Sato, T; Sugihara, K; Sugimoto, H | 1 |
| Chudenko, VA; Dashian, GA; Filatova, LV; Gershanovich, ML; Latipova, DKh; Luk'ianchikova, VS; Paltuev, RM; Semiglazov, VV; Semiglazova, TIu | 1 |
| Afonso, N; de Mello, RA; de Vasconcelos, A; Pereira, D; Pousa, I; Ribeiro, RA; Rodrigues, H | 1 |
| Bonneterre, J; Brain, E; Cottura, E; Dalenc, F; Diéras, V; Fumoleau, P; Isambert, N; Jimenez, M; Lokiec, F; Mahier-Aït Oukhatar, C; Mefti-Lacheraf, F; Rezai, K; Tresca, P; Vanlemmens, L | 1 |
| Chia, SK | 1 |
| Bischoff, J; Blohmer, JU; Eidtmann, H; Fasching, PA; Gerber, B; Hanusch, C; Hilfrich, J; Huober, J; Jackisch, C; Kaufmann, M; Kreienberg, R; Kühn, T; Loibl, S; Nekljudova, V; Rezai, M; Strumberg, D; Tesch, H; Untch, M; von Minckwitz, G | 1 |
| Carli, P; Crivellari, D; Di Lauro, V; Dolcetti, R; Lamaj, E; Miolo, G; Quitadamo, D; Spada, A; Spazzapan, S; Turchet, E; Veronesi, A | 1 |
| Aktan, G; Aura, C; Baselga, J; Bradbury, I; Chang, TW; Coccia-Portugal, M; de Azambuja, E; Di Cosimo, S; Dinh, P; Domont, J; Eidtmann, H; Fauria, K; Gelber, RD; Goldhirsch, A; Gómez, H; Horváth, Z; Kunz, G; Lerzo, G; Palacova, M; Piccart-Gebhart, M; Probachai, V; Pusztai, L; Semiglazov, V; Sohn, JH; Tseng, LM; Untch, M; Van Dooren, V | 1 |
| Awada, A; Bozovic-Spasojevic, I; Chow, L | 1 |
| Evens, A; Osborne, CK | 1 |
| Chan, A; Chan, EC; Chanthawong, S; Ho, HK; Saetaew, M; Teo, YL; Yap, YS | 1 |
| Loibl, S; Untch, M; Von Minckwitz, G | 1 |
| Aura, C; Baselga, J; Calvo, MT; García-García, C; Grueso, J; Guzmán, M; Ibrahim, YH; Jessen, K; Liu, Y; Pérez, J; Rommel, C; Scaltriti, M; Serra, V; Tabernero, J | 1 |
| Jelovac, D; Wolff, AC | 1 |
| Battelli, N; Bessi, S; Biganzoli, L; Buyse, M; Coombes, CR; Di Leo, A; Di Marsico, R; Gianni, L; Gori, S; Masci, G; Minisini, AM; Pestrin, M; Puglisi, F; Ravaioli, A; Stebbing, J; Tondini, C | 1 |
| Beijnen, JH; Guchelaar, HJ; Opdam, FL; Schellens, JH | 1 |
| Artioli, F; Bagnalasta, M; Bisagni, G; Boni, C; Bottini, A; Cagossi, K; Cavanna, L; Conte, P; D'Amico, R; Frassoldati, A; Generali, DG; Giardina, G; Guarneri, V; Marini, L; Musolino, A; Orlando, L; Piacentini, F; Ravaioli, A; Sarti, S; Serra, P; Untch, M | 1 |
| André, F; Bachelot, T; Campone, M; Frenel, JS; Juin, P | 1 |
| Giuliano, M; Schiff, R; Trivedi, MV | 1 |
| Han, J; Kil, WH; Kim, S; Lee, JE; Nam, SJ; Shin, I | 1 |
| Batra, SK; Chen, AC; Creighton, CJ; Gutierrez, MC; Huang, C; Lopez-Tarruella, S; Massarweh, S; Migliaccio, I; Osborne, CK; Rimawi, M; Schiff, R; Wang, YC | 1 |
| Amler, L; Girish, S; Guardino, E; Krop, IE; LoRusso, P; Lu, M; Miller, KD; Modi, S; Rodriguez, G; Rugo, HS; Winer, EP; Yardley, D; Zheng, M | 1 |
| D'Alessio, G; De Lorenzo, C; Fedele, C; Malara, AE; Riccio, G | 1 |
| Arpino, G; De Angelis, C; Minisini, AM; Puglisi, F | 1 |
| Arbushites, MC; Bernini, P; Bertini, I; Biganzoli, L; Cappadona, S; Claudino, WM; Di Leo, A; Luchinat, C; Nepi, S; Oakman, C; Tenori, L | 1 |
| Aktan, G; Baselga, J; Bischoff, J; Blackwell, KL; Burstein, HJ; Ellis, C; Florance, A; O'Shaughnessy, J; Rugo, HS; Sledge, G; Storniolo, AM; Vukelja, S | 1 |
| Dixon, JM; Symmans, WF; Verrill, M; Wilson, V | 1 |
| Criscitiello, C; de Azambuja, E; de Castro, G; Diaz, M; La Gerche, A; Metzger-Filho, O; Piccart-Gebhart, MJ; Saini, KS | 1 |
| Altundag, K; Dogan, E; Ozer, N; Ozisik, Y; Petekkaya, I; Yorgun, H | 1 |
| Amonkar, MM; Diaz, JR; Forbes, CA; Kleijnen, J; Lykopoulos, K; Rea, DW; Riemsma, R | 1 |
| Amir, E; Bouganim, N; Clemons, M; Fralick, M; Hilton, JF | 1 |
| Anderson, L; Britten, CD; Christensen, JG; Cohen, DJ; Conklin, D; Desai, AJ; Finn, RS; Ginther, C; Kalous, O; O'Brien, NA; Slamon, DJ; Taylor, I | 1 |
| Burton, L; Chan, E; Fridlyand, J; Koeppen, H; Li, J; Lin, E; Merchant, M; Moffat, J; Neve, R; Peng, J; Penuel, E; Ribas, A; Settleman, J; Sosman, J; Sutherlin, DP; Wang, Y; Wilson, TR; Yan, Y | 1 |
| Kato, Y; Kawamura, H; Makino, T; Nishina, M; Yokoyama, E | 1 |
| Alici, S; Arslan, UY; Bilici, M; Boruban, C; Buyukberber, S; Dayan, A; Demir, L; Durnalı, AG; Elkiran, ET; Geredeli, C; Gumusay, O; Inal, A; Isikdogan, A; Kaplan, MA; Koca, D; Kocer, M; Kucukoner, M; Mert, AG; Ozkan, M; Suner, A; Tarhan, MO; Unal, OU; Urakci, Z; Yaman, S; Yildiz, R | 1 |
| Chung, JS; Im, YH; Kim, S; Kim, TY; Moon, H; Park, S; Rha, SY; Ro, J; Santillana, S | 1 |
| Bang, YJ; Bates, M; Cha, Y; Haddad, M; Han, SW; Huang, W; Im, SA; Kim, TY; Lee, KS; Lie, Y; Oh, DY; Paquet, A; Park, IH; Ro, J; Sherwood, T; Weidler, J | 1 |
| Komurov, K; Moss, TJ; Muller, M; Nagrath, D; Ram, PT; Seviour, EG; Tseng, JT; Yang, L | 1 |
| Lind, P; Mauri, D; Nearchou, A; Valachis, A | 1 |
| Bissell, MJ; Furuta, S; Kenny, PA; Lee, SY; Lenburg, ME; Meier, R; Xu, R | 1 |
| Lim, E; Lin, NU | 1 |
| Dorssers, LC; Foekens, JA; Godinho, MF; Look, MP; Petricoin, EF; Sieuwerts, AM; Sleijfer, S; van Agthoven, T; Wulfkuhle, JD | 1 |
| Bischoff, J; Eidtmann, H; Fasching, PA; Fehm, T; Hauschild, M; Huober, J; Issa-Nummer, Y; Karn, T; Khandan, F; Liedtke, C; Loibl, S; Mau, C; Meinhold-Heerlein, I; Müller, V; Rack, B; Schem, C; Schmatloch, S; Untch, M; von Minckwitz, G; Witzel, I; Zu Eulenburg, C | 1 |
| Cornelio, GH; Devi, BC; Khorprasert, C; Kim, SB; Kim, TY; Kobayashi, M; Landis, SH; Lee, SC; Moon, H; Park, YH; Ro, J; Sohn, JH; Sutandyo, N; Wong, DW; Yap, YS; Yeoh, EM | 1 |
| Benjamin, L; Buthion, V; Farah, B; Iskedjian, M; Rioufol, C; Vidal-Trécan, G | 1 |
| Cardoso, F; Sousa, B | 1 |
| Booth, L; Cruickshanks, N; Dent, P; Grant, S; Hamed, H; Tang, Y | 1 |
| Bartlett, J; Bogaerts, J; Bonnefoi, H; Cameron, D; Debled, M; Fiche, M; Fournier, M; Koch, KM; Marreaud, S; Nobahar, M; Pierga, JY; Zaman, K; Zimmer, A | 1 |
| Brouwers, AH; de Vries, EG; Lub-de Hooge, MN; Oude Munnink, TH; Schröder, CP; Timmer-Bosscha, H; Vedelaar, SR | 1 |
| Carey, LA; Chiu, WM; Dees, EC; Halle, JS; Horton, JK; Ivanova, A; Kimple, RJ; Lawrence, JA; Livasy, CA; Ollila, DW; Sartor, CI; Shields, JM | 1 |
| Fujiwara, Y; Ito, Y; Iwata, H; Katsura, K; Narabayashi, M; Saji, S; Sasaki, Y; Usami, S | 1 |
| Bozovic-Spasojevic, I; de Azambuja, E; Zardavas, D | 1 |
| Baselga, J; Blackwell, K; Diéras, V; Fang, L; Gianni, L; Guardino, E; Krop, IE; Lu, MW; Miles, D; Oh, DY; Olsen, S; Pegram, M; Verma, S; Welslau, M | 1 |
| Lin, NU; Vaz-Luis, I; Winer, EP | 1 |
| Adam, J; Doss, S; Robertson, J | 1 |
| Bell, R; Khasraw, M | 1 |
| Ager, E; Chung, E; Duyverman, AM; Eichler, AF; Engelman, JA; Farrar, CT; Fukumura, D; Goel, S; Hiddingh, L; Huang, Y; Incio, J; Jain, RK; Kamoun, W; Kodack, DP; Lussiez, A; Mahmood, S; Snuderl, M; Song, Y; Tannous, BA; Yamashita, H | 1 |
| Cooper, T; Nowsheen, S; Stanley, JA; Yang, ES | 1 |
| Hoe, N; Iorns, E; Jegg, AM; Landgraf, R; Liu, X; Pegram, MD; Singh, S; Ward, TM; Zhou, J | 1 |
| Barrick, B; Fraga, G; Matthys, B | 1 |
| Bachelot, T; Campone, M; Cropet, C; Curé, H; Dalenc, F; Diéras, V; Domont, J; Ferrero, JM; Gonçalves, A; Gutierrez, M; Jimenez, M; Labbe-Devilliers, C; Le Rhun, E; Leheurteur, M; Pierga, JY; Romieu, G | 1 |
| Bartsch, R; Preusser, M | 1 |
| Belliere, A; Chevrier, R; Chollet, P; Dillies, AF; Durando, X; Kwiatkowski, F; Mahammedi, H; Mouret-Reynier, MA; Thivat, E; Van Praagh, I | 1 |
| Chiba, A; Inaba, M; Inari, H; Ino, H; Kojima, I; Kuroda, K; Matsuo, A; Matsuura, H; Mukaibashi, T; Shimizu, S; Suganuma, N; Yamanaka, T; Yoshida, A | 1 |
| Fujita, Y; Goto, M; Hamaoka, A; Imai, A; Mizuta, N; Morita, M; Nakatsukasa, K; Sakaguchi, K; Shouji, M; Taguchi, T; Umeda, Y | 1 |
| Cheng, T; Ge, Z; Li, R; Qiao, K; Zhang, L; Zhang, X | 1 |
| Benekli, M; Berk, V; Boruban, C; Buyukberber, S; Cetin, B; Coskun, U; Dane, F; Harputluoglu, H; Isıkdogan, A; Kaplan, MA; Koca, D; Koral, L; Oksuzoglu, B; Sevinc, A; Turker, I; Ulas, A; Uncu, D; Yilmaz, B | 1 |
| Aronson, AB; Bose, R; Ding, L; Ellis, MJ; Goel, N; Kavuri, SM; Koboldt, DC; Li, S; Ma, CX; Mardis, ER; Monsey, J; Searleman, AC; Shen, D; Shen, W | 1 |
| Bosserman, L; DeSilvio, ML; Hagan, MK; Hart, L; Mahoney, JM; Nagarwala, Y; Richards, P; Salleh, MN; Waterhouse, DM; Yardley, DA | 1 |
| Arteaga, CL; Cook, RS; Garrett, JT; Kuba, MG; Sutton, CR | 1 |
| Guo, Q; Ma, C; Song, X; Wang, X; Wei, L; Zuo, W | 1 |
| Aboagye, EO; Contractor, KB; Coombes, RC; El-Bahrawy, M; Elsheikh, SE; Hadjiminas, DJ; Horimoto, Y; Lam, EW; Mansi, JL; Marconell, MH; Miller, ML; Palmieri, C; Reise, JA; Shaw, JA; Shousha, S; Stebbing, J; Tat, T; Walker, RA | 1 |
| Lønning, PE | 1 |
| Aktan, G; Boyle, F; Buzdar, AU; Chavarri-Guerra, Y; Ejlertsen, B; Finkelstein, DM; Fumoleau, P; Goss, PE; Gradishar, W; Kaufmann, M; Lindquist, D; Martin, M; Moy, B; O'Shaughnessy, J; Piccart-Gebhart, M; Pritchard, KI; Rappold, E; Smith, IE; Williams, LS | 1 |
| Amano, S; Enomoto, K; Fujisaki, S; Hara, Y; Hirano, T; Maeda, T; Nagashima, S; Sakurai, K; Suzuki, S; Tomita, R | 1 |
| Nieder, C | 1 |
| Basavalingaiah, A; Madhusudhan, N; Revannasiddaiah, S; Susheela, SP | 1 |
| Bachelot, T; Campone, M; Cropet, C; Diéras, V; Jimenez, M | 1 |
| Durante, M; Gómez, H; Goodman, V; Johnston, SR; Pandite, L; Richie, M; Slamon, D; Stemmer, SM | 1 |
| Cho, N; Hayashi, M; Yomo, S | 1 |
| Damodaran, S; Olson, EM | 1 |
| Bachelot, T; Bonneterre, J; Gilabert, M; Gonçalves, A; Heudel, P; Labidi-Gally, I; Le Rhun, E; Pierga, JY | 1 |
| Corominas-Faja, B; Cufí, S; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Urruticoechea, A; Vazquez-Martin, A | 1 |
| Brünner, N; Deng, X; Fogh, L; Jensen, V; Lademann, U; Schrohl, AS; Stenvang, J; Yang, H | 1 |
| Akman, T; Alici, S; Arslan, UY; Boruban, C; Coskun, U; Dayan, A; Demir, L; Durnalı, AG; Elkiran, ET; Geredeli, C; Gumusay, O; Inal, A; Inanc, M; Isikdogan, A; Kaplan, MA; Koca, D; Kocer, M; Kucukoner, M; Oksuzoglu, B; Ozdemir, NY; Sener, N; Suner, A; Tarhan, MO; Urakci, Z; Yildiz, R | 1 |
| Inoue, K | 1 |
| Chen, WS; Chen, YJ; Hsia, TC; Hsu, SC; Huang, CY; Huang, TC; Huang, WC; Hung, MC; Tsai, SL; Tu, CY; Wei, YL; Yeh, MH; Yen, CJ; Yu, MC; Yu, YL | 1 |
| Aktan, G; Baselga, J; Bines, J; Boyle, F; Bradbury, I; de Azambuja, E; Dooren, VV; Jackisch, C; Lang, I; Metzger-Filho, O; Perez, EA; Piccart-Gebhart, M; Pritchard, KI; Saini, KS; Simon, SD; Smith, I; Untch, M; Wolff, AC; Xu, B | 1 |
| Selam, M | 1 |
| Hochberg, FH; Kirsch, DG | 1 |
| Ho, P; Liu, LH; Spector, NL; Xia, W | 1 |
| Earp, HS; Kim, YS; McCall, W; Peletier, A; Sartor, CI; Zhou, H | 1 |
| Burris, HA | 1 |
| Blackwell, K; Chen, S; Chu, I; Slingerland, J | 1 |
| Baudson, NM; Gerard, CM; Liu, L; Ory, TL; Spector, NL; Xia, W | 1 |
| Berger, M; Finn, R; Gilmer, TM; Keith, BR; Konecny, GE; Mullin, RJ; Pegram, MD; Podratz, KC; Rahmeh, M; Rusnak, DW; Slamon, DJ; Spehar, G; Untch, M; Venkatesan, N; Yang, G | 1 |
| Bacus, S; Bisi, J; Carrick, K; Dush, M; Graham, KM; Hardwicke, MA; Liao, Q; Liu, L; Spector, NL; Strum, J; Treece, AL; Westlund, RE; Xia, W; Zhao, S | 1 |
| Brose, MS; Flaherty, KT | 1 |
| Bacus, S; Harris, J; Hegde, P; Hill, J; Husain, I; Liu, L; Lyass, L; Paulazzo, G; Spector, NL; Strum, J; Trusk, P; Xia, W | 1 |
| Saito, Y; Suzuki, Y; Tokuda, Y | 1 |
| Budman, DR; Calabro, A; Diasio, R; Soong, R; Tai, J | 1 |
| Boggess, KA; Dees, EC; Dorflinger, LJ; Graham, M; Harris, J; Humes, E; Kelly, H; O'Neil, BH; Spector, NL | 1 |
| Albanell, J | 1 |
| Berger, M; Cameron, D; Campone, M; Chan, A; Chan, S; Crown, J; Davidson, N; Forster, J; Geyer, CE; Jagiello-Gruszfeld, A; Kaufman, B; Lindquist, D; Oliva, C; Pienkowski, T; Romieu, CG; Rubin, SD; Skarlos, D; Stein, S | 1 |
| Muss, HB | 1 |
| Berger, M; Lipton, A; Planas-Silva, MD; Viallet, J; Witkoski, A; Witters, LM | 1 |
| Aglietta, M; Montemurro, F; Valabrega, G | 1 |
| Bacus, S; Husain, I; Liu, L; Pry, K; Saini, S; Spector, NL; Spohn, J; Stein, SH; Westlund, R; Xia, W | 1 |
| Du, Y; Esteva, FJ; Nahta, R; Yuan, LX | 1 |
| Tuma, RS | 1 |
| Goss, PE; Moy, B | 2 |
| Bartsch, R; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Sonpavde, G | 1 |
| Healy, B | 1 |
| Burstein, HJ; Lin, NU; Mayer, EL | 1 |
| Anido, J; Arribas, J; Baselga, J; Cortes, J; Di Cosimo, S; Guzman, M; Matias-Guiu, X; Ocaña, A; Ramon y Cajal, S; Rojo, F; Scaltriti, M | 1 |
| Hatake, K; Ito, Y; Sugihara, T; Takahashi, S; Tokudome, N | 1 |
| Alligood, K; Bertiaux, M; Gagnon, R; Gilmer, TM; Hegde, PS; Rusnak, D; Strum, J | 1 |
| Awada, A; Cardoso, F; de Azambuja, E; Dinh, P; Gil, T; Piccart-Gebhart, M; Widakowich, C | 1 |
| Engel, RH; Kaklamani, VG | 1 |
| Bilancia, D; Dinota, A; Germano, D; Manzione, L; Romano, R; Rosati, G | 1 |
| Goss, P; Kar, S; Kirkpatrick, P; Moy, B | 1 |
| Amar, S; Moreno-Aspitia, A; Perez, EA | 1 |
| Cameron, D | 1 |
| Hatake, K | 1 |
| Chan, S; Dhadda, AS; Mukherjee, A; Shehata, M | 1 |
| Boughey, JC; Brandt, KR; Degnim, AC; Dy, GK; Goetz, MP; Ingle, JN; Perez, EA; Pruthi, S; Reynolds, CA; Schomberg, PJ | 1 |
| Becze, E | 1 |
| Andersson, M; Nielsen, DL | 1 |
| Dhillon, S; Wagstaff, AJ | 1 |
| Abraham, J; Higa, GM | 1 |
| Pal, SK; Pegram, M | 1 |
| Berveiller, P; Goffinet, F; Goldwasser, F; Mir, O; Pons, G; Ropert, S; Treluyer, JM | 1 |
| Eniu, A | 1 |
| Peckham, C | 1 |
| Campone, M; Coudert, B; Favier, L; Ferrant, E; Fumoleau, P; Mayer, F | 1 |
| Geyer, CE; Harkins, B | 1 |
| Frankel, C | 1 |
| Cameron, D; Campone, M; Casey, M; Chan, A; Chan, S; Crown, J; Davidson, N; Geyer, CE; Gorbounova, V; Jagiello-Gruszfeld, A; Kaufman, B; Lindquist, D; Newstat, B; Oliva, C; Paoletti, P; Pienkowski, T; Press, M; Raats, JI; Romieu, CG; Roychowdhury, D; Rubin, S; Skarlos, D; Stein, S; Viens, P | 1 |
| Ben Ahmed, S; Blackwell, K; Boussen, H; Citrin, DL; DeSilvio, ML; Harris, J; Johnston, S; Kaufman, B; Lombardi, DP; LoRusso, P; Salazar, V; Spector, NL; Trudeau, M; Westlund, RE; Zaks, TZ | 1 |
| Doyle, DM; Miller, KD | 1 |
| Blackwell, KL; Burstein, HJ; Forster, J; Franco, S; Rubin, S; Salazar, VM; Stein, S; Storniolo, AM | 1 |
| Brunet, J; Colomer, R; Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A | 1 |
| Heinemann, V; Rack, B; Salat, C; Schindlbeck, C; Sommer, H; Walther, J | 1 |
| Sledge, GW | 1 |
| Blumenfeld, M; Farrar, W; Landon, MB; Pant, S; Shapiro, CL | 1 |
| Geyer, CE; Greenberg, L; Ulhoa-Cintra, A | 1 |
| Cardoso, F; de Azambuja, E; Dolci, S; Meirsman, L; Piccart-Gebhart, M; Straehle, C; Vantongelen, K | 1 |
| Mukesh, M; Murray, P | 1 |
| Kopper, L | 1 |
| Dean-Colomb, W; Esteva, FJ | 1 |
| Bullitt, E; Burstein, HJ; Carey, LA; Come, SE; Crawford, A; Ewend, M; Gelman, R; Harris, GJ; Henson, JW; Hochberg, F; Kasparian, E; Kirsch, DG; Li, X; Lin, NU; Liu, MC; Van den Abbeele, AD; Winer, EP; Younger, J | 1 |
| Chamness, GC; Chang, JC; Gutierrez, C; Hilsenbeck, SG; Huang, J; Lewis, MT; Li, X; Osborne, CK; Pavlick, A; Rosen, J; Wong, H; Wu, MF; Zhang, X | 1 |
| Ang, PC; Arbushites, MC; Aziz, Z; Berger, MS; Casey, MA; Chavez, MA; Chow, LW; Doval, DC; Franco, SX; Gomez, HL; Nag, S; Ng, C; Sledge, GW; Stein, SH | 1 |
| Seruga, B; Tannock, IF | 1 |
| Krop, IE; Winer, EP | 1 |
| Amar, S; Perez, EA; Roy, V | 1 |
| Nanda, R | 1 |
| Schmidt, C | 1 |
| Ito, Y; Miura, H | 1 |
| Hirte, HW; Hotte, SJ | 1 |
| Arya, N; Burris, HA; Fleming, RA; Ho, PT; Jones, SF; Koch, KM; Lebowitz, PF; Loftiss, J; Overmoyer, B; Pandite, L; Paul, E; Peacock, NW; Pegram, MD; Silverman, P; Storniolo, AM | 1 |
| Conte, PF; Frassoldati, A; Giovannelli, S; Guarneri, V; Jovic, G; Oliva, C; Piacentini, F | 1 |
229 review(s) available for lapatinib and Breast Cancer
| Article | Year |
|---|---|
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cranial Irradiation; Disease Progression; Female; Humans; Lapatinib; Life Expectancy; Magnetic Resonance Imaging; Metastasectomy; Middle Aged; Oxazoles; Pyridines; Quinazolines; Quinolines; Radiosurgery; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab | 2021 |
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Breast Neoplasms; Clinical Trials as Topic; Female; Genes, erbB-2; Humans; Lapatinib; Neoadjuvant Therapy; Quinolines; Receptor, ErbB-2; Trastuzumab | 2021 |
Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Hormones; Humans; Lapatinib; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab | 2022 |
Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast Neoplasms; Female; Humans; Incidence; Lapatinib; Maytansine; Neoplasms, Second Primary; Receptor, ErbB-2; Trastuzumab | 2022 |
Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis.
Topics: Afatinib; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Protein Kinase Inhibitors | 2022 |
Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhoea: A Review.
Topics: Antineoplastic Agents; Breast Neoplasms; Diarrhea; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Receptor, ErbB-2 | 2022 |
Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Hormones; Humans; Lapatinib; Receptor, ErbB-2 | 2022 |
Therapeutic landscape of advanced HER2-positive breast cancer in 2022.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Immunoconjugates; Lapatinib; Maytansine; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Receptor, ErbB-2; Taxoids; Trastuzumab | 2022 |
Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2023 |
Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Stroke Volume; Trastuzumab; Ventricular Function, Left | 2022 |
Pyrotinib versus lapatinib therapy for HER2 positive metastatic breast cancer patients after first-line treatment failure: A meta-analysis and systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Lapatinib; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Failure | 2023 |
[Targeting HER2 in colorectal cancer].
Topics: Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorectal Neoplasms; Female; Humans; Lapatinib; Prognosis; Receptor, ErbB-2; Trastuzumab | 2023 |
[Targeted systemic treatments and locoregional radiotherapy for breast cancer: Can we expect a benefit from the potentiation of local treatment?]
Topics: Breast Neoplasms; Female; Humans; Lapatinib; Prognosis; Prospective Studies; Receptor, ErbB-2; Trastuzumab | 2023 |
Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer.
Topics: Ado-Trastuzumab Emtansine; Breast Neoplasms; Female; Humans; Lapatinib; Receptor, ErbB-2; Trastuzumab | 2023 |
Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Humans; Lapatinib; Receptor, ErbB-2; Trastuzumab | 2020 |
Mechanisms and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs: Insights from in vitro, in vivo, and clinical studies in breast cancer patients.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; Female; Heart; Humans; Lapatinib; Molecular Targeted Therapy; Myocytes, Cardiac; Receptor, ErbB-2; Trastuzumab | 2020 |
Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Disease Management; Drug Monitoring; Everolimus; Female; Humans; Immunoconjugates; Incidence; Lapatinib; Lung Diseases, Interstitial; Neoplasm Metastasis; Paclitaxel; Pneumonia; Receptor, ErbB-2; Trastuzumab | 2020 |
Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Breast Neoplasms; Clinical Trials, Phase I as Topic; Female; Humans; Injections, Spinal; Lapatinib; Meningeal Carcinomatosis; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab | 2020 |
Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast; Breast Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Immunoconjugates; Lapatinib; Mastectomy; Maytansine; Medical Oncology; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxazoles; Practice Guidelines as Topic; Pyridines; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab | 2020 |
Recent Advances on Epidermal Growth Factor Receptor as a Molecular Target for Breast Cancer Therapeutics.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinolines; Trastuzumab | 2021 |
Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Lymphocytes, Tumor-Infiltrating; Neoadjuvant Therapy; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab | 2017 |
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Oncogene Addiction; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Trastuzumab; Tumor Microenvironment | 2017 |
Recent advances in HER2 positive breast cancer epigenetics: Susceptibility and therapeutic strategies.
Topics: Animals; Antineoplastic Agents, Immunological; Breast; Breast Neoplasms; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2017 |
The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Analysis; Time Factors; Treatment Outcome | 2017 |
Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; ErbB Receptors; Female; Heart; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Ventricular Dysfunction, Left | 2017 |
The updated network meta-analysis of neoadjuvant therapy for HER2-positive breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Bayes Theorem; Breast Neoplasms; Female; Humans; Lapatinib; Neoadjuvant Therapy; Network Meta-Analysis; Odds Ratio; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2018 |
Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Disease Progression; Disease-Free Survival; Female; Humans; Lapatinib; Maytansine; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Survival Analysis; Time Factors; Trastuzumab; Treatment Outcome | 2018 |
A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2018 |
Lapatinib nano-delivery systems: a promising future for breast cancer treatment.
Topics: Antineoplastic Agents; Biological Availability; Breast Neoplasms; Drug Delivery Systems; Female; Humans; Lapatinib; Liposomes; Nanoparticles; Solubility | 2018 |
HER2-positive breast cancer: Current and new therapeutic strategies.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Humans; Lapatinib; Maytansine; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2018 |
Treatment of advanced HER2-positive breast cancer: 2018 and beyond.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Immunotherapy; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2018 |
Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer.
Topics: Afatinib; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Quinolines; Receptor, ErbB-2 | 2018 |
Optimal treatment of early stage HER2-positive breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Lapatinib; Maytansine; Progression-Free Survival; Quinolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2018 |
Dual HER2-Targeting in the Adjuvant Setting: Where We Have Been and Where We Are Going.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Lapatinib; Mastectomy; Molecular Targeted Therapy; Neoplasm Metastasis; Protein Kinase Inhibitors; Receptor, ErbB-2; Trastuzumab | 2018 |
A Systematic Review and Meta-analysis of the Combination of Vinorelbine and Lapatinib in Patients With Her2-positive Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Humans; Lapatinib; Receptor, ErbB-2; Survival Analysis; Treatment Outcome; Vinorelbine | 2019 |
HLA-DRB1*07:01 and lapatinib-induced hepatotoxicity: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Case-Control Studies; Chemical and Drug Induced Liver Injury; Female; HLA-DRB1 Chains; Humans; Lapatinib | 2020 |
Targeted anti-HER2 cancer therapy in elderly women diagnosed with breast cancer.
Topics: Aged; Aging; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2014 |
Trastuzumab emtansine in breast cancer.
Topics: Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Immunoconjugates; Lapatinib; Maytansine; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2013 |
A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2013 |
HER2-positive gastric cancer.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Prognosis; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2014 |
Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.
Topics: Antibodies, Monoclonal, Humanized; Antigen-Presenting Cells; Antineoplastic Agents; Breast Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Combined Modality Therapy; Female; Humans; Immunotherapy, Active; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2013 |
Cardiac toxicity in breast cancer patients treated with dual HER2 blockade.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Heart Diseases; Humans; Lapatinib; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab | 2013 |
Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer .
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoadjuvant Therapy; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab; Treatment Outcome | 2013 |
[Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer].
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gene Amplification; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Neovascularization, Pathologic; Prognosis; Quinazolines; Receptor, ErbB-2; Taxoids; TOR Serine-Threonine Kinases; Trastuzumab | 2013 |
[The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Medical Oncology; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Research Design; Signal Transduction; Translational Research, Biomedical; Trastuzumab | 2013 |
Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Maytansine; Neoadjuvant Therapy; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
A systematic review of dual targeting in HER2-positive breast cancer.
Topics: Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Everolimus; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Neoadjuvant Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Quinolines; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Treatment Outcome; Up-Regulation | 2014 |
[HER2-positive breast cancer: available targeted agents and biomarkers for therapy response].
Topics: Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Everolimus; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Quinolines; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab | 2013 |
Biological therapies in breast cancer: common toxicities and management strategies.
Topics: Ado-Trastuzumab Emtansine; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biological Therapy; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Everolimus; Humans; Immunosuppressive Agents; Lapatinib; Maytansine; Quinazolines; Sirolimus; Trastuzumab | 2013 |
Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Chemoradiotherapy; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2013 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2014 |
Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2014 |
New HER2-positive targeting agents in clinical practice.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lapatinib; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2014 |
[Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Dacarbazine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Receptor, ErbB-2; Temozolomide; Thalidomide; Topoisomerase I Inhibitors; Topotecan; Trastuzumab; Vinblastine; Vinorelbine | 2014 |
[Clinical evaluation of lapatinib therapy in metastatic breast cancer using the Bayes meta-analysis].
Topics: Antineoplastic Agents; Bayes Theorem; Breast Neoplasms; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Treatment Outcome | 2014 |
Lapatinib.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Topics: Ado-Trastuzumab Emtansine; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Comorbidity; Docetaxel; Drug Administration Schedule; Evidence-Based Medicine; Female; Health Status Disparities; Healthcare Disparities; Humans; Lapatinib; Letrozole; Maytansine; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Societies, Medical; Taxoids; Trastuzumab; Treatment Outcome; Triazoles; United States | 2014 |
Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2014 |
Trastuzumab-containing regimens for metastatic breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Bridged-Ring Compounds; Disease-Free Survival; Female; Humans; Lapatinib; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
P95 HER2 fragments and breast cancer outcome.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Lapatinib; Prognosis; Quinazolines; Receptor, ErbB-2; Survival; Trastuzumab | 2014 |
Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Breast; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2014 |
Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Immunoconjugates; Lapatinib; Maytansine; Molecular Targeted Therapy; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2014 |
Risk of selected gastrointestinal toxicities in breast cancer patients treated with regimens containing lapatinib; a pooled analysis of randomized controlled studies.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Monitoring; Female; Gastrointestinal Diseases; Humans; Lapatinib; Quinazolines; Randomized Controlled Trials as Topic; Risk | 2014 |
Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2014 |
Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Biomarkers, Tumor; Breast Neoplasms; Comparative Effectiveness Research; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Odds Ratio; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2014 |
[New targeted therapies in breast cancer].
Topics: Ado-Trastuzumab Emtansine; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Drug Delivery Systems; Female; Humans; Lapatinib; Maytansine; Neoadjuvant Therapy; Neoplasm Metastasis; Neovascularization, Pathologic; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Receptor, ErbB-2; TOR Serine-Threonine Kinases; Trastuzumab | 2014 |
Therapeutic approach to the management of HER2-positive breast cancer metastatic to the brain.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Disease Management; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neural Stem Cells; Protein Kinase Inhibitors; Quinazolines; Radiotherapy; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2015 |
Targeting HER2 for the treatment of breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Female; Humans; Lapatinib; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab; Triazoles | 2015 |
[Efficacy of lapatinib versus trastuzumab in neoadjuvant therapy of HER-2 positive breast cancer: a meta-analysis].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; China; Humans; Lapatinib; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2014 |
HER2-directed therapy: current treatment options for HER2-positive breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Small Molecule Libraries; Trastuzumab | 2015 |
[Systemic treatment of brain metastases from breast cancer].
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Female; Genes, erbB-2; Humans; Lapatinib; Medicine; Molecular Targeted Therapy; Patient Care Team; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2015 |
Adjuvant systemic therapy in breast cancer: quo vadis?
Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Mastectomy; Paclitaxel; Patient Selection; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Tamoxifen; Trastuzumab; Triple Negative Breast Neoplasms | 2015 |
Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Lymph Nodes; Molecular Targeted Therapy; Neoadjuvant Therapy; Publication Bias; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2015 |
HER2-positive metastatic breast cancer: a changing scenario.
Topics: Ado-Trastuzumab Emtansine; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Breast; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Maytansine; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2015 |
Dual HER2 blockade: preclinical and clinical data.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Gefitinib; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2014 |
Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
Mechanisms of lapatinib resistance in HER2-driven breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene Amplification; Humans; Lapatinib; Mutation; Phosphotransferases; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen | 2015 |
Analysis of different HER-2 mutations in breast cancer progression and drug resistance.
Topics: Antineoplastic Agents; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mutation; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?
Topics: Antibodies, Monoclonal, Humanized; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Drug Delivery Systems; Female; Humans; Immunoconjugates; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
Identification of novel therapeutic target genes in acquired lapatinib-resistant breast cancer by integrative meta-analysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Lapatinib; Oligonucleotide Array Sequence Analysis; Protein Interaction Maps; Quinazolines | 2016 |
Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with breast cancer treated with HER2 blockade.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Lapatinib; Middle Aged; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Risk Factors; Trastuzumab | 2015 |
Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Lapatinib; Molecular Probe Techniques; Nucleic Acid Amplification Techniques; Prognosis; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer--a systematic review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab | 2015 |
Better Together: Targeted Combination Therapies in Breast Cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2015 |
Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Decision Support Techniques; Disease-Free Survival; Female; Humans; Lapatinib; Maytansine; Neoplasm Metastasis; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Rate; Taxoids; Trastuzumab | 2016 |
Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoadjuvant Therapy; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2016 |
Emerging Therapeutic Options for HER2-Positive Breast Cancer.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cancer Vaccines; Female; Humans; Immunotherapy; Lapatinib; Maytansine; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2016 |
Applications of cardiotoxicity in breast cancer: a meta-analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotoxicity; Female; Humans; Lapatinib; Odds Ratio; Quinazolines; Risk; Trastuzumab; Ventricular Function, Left | 2017 |
Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Drug Discovery; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoadjuvant Therapy; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2016 |
[Not Available].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Neoadjuvant Therapy; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triple Negative Breast Neoplasms | 2016 |
Biomarkers for the identification of recurrence in human epidermal growth factor receptor 2-positive breast cancer patients.
Topics: Animals; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2016 |
Effects of lapatinib or trastuzumab, alone and in combination, in human epidermal growth factor receptor 2-positive breast cancer: a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Odds Ratio; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2016 |
Neoadjuvant Therapy for HER2-positive Breast Cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Breast Neoplasms; Bridged-Ring Compounds; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2017 |
Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Exanthema; Female; Humans; Lapatinib; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Risk Factors; Trastuzumab; Treatment Outcome; Withholding Treatment | 2017 |
Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Everolimus; Female; Humans; Lapatinib; Life Expectancy; Molecular Targeted Therapy; Neoplasm Metastasis; Piperazines; Pyridines; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Trastuzumab | 2017 |
Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2017 |
Molecularly targeted therapy in breast cancer: the new generation.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Design; Female; Humans; Indoles; Lapatinib; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptors, Estrogen; Sunitinib | 2008 |
Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Tamoxifen; Time Factors; Trastuzumab | 2008 |
Targeting Her-2/neu in breast cancer: as easy as this!
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2008 |
Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Food-Drug Interactions; Humans; Lapatinib; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2008 |
Treatment of metastatic ErbB2-positive breast cancer: options after progression on trastuzumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2008 |
Cardiac toxicity of ErbB2-targeted therapies: what do we know?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Heart; Heart Failure; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2008 |
Novel targeting therapy concept for breast cancer treatment.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Gene Targeting; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Taxoids; Trastuzumab | 2008 |
Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Epothilones; Female; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines | 2008 |
Time to full publication of studies of anti-cancer medicines for breast cancer and the potential for publication bias: a short systematic review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Consensus Development Conferences as Topic; Databases, Bibliographic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lapatinib; Paclitaxel; Publication Bias; Publishing; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Technology Assessment, Biomedical; Time; Trastuzumab | 2008 |
New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer.
Topics: Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2009 |
Unraveling the biologic and clinical complexities of HER2.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2008 |
[Advances in research on treatment of breast cancer with lapatinib].
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Cell Proliferation; ErbB Receptors; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2008 |
Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Humans; Lapatinib; Models, Biological; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2008 |
Jumping higher: is it still possible? The ALTTO trial challenge.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Trastuzumab | 2008 |
Acute paronychia caused by lapatinib therapy.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Paronychia; Quinazolines | 2009 |
Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cytological Techniques; Drug Resistance, Neoplasm; Female; Gene Amplification; Gene Expression; Genes, erbB-2; Genetic Techniques; Guidelines as Topic; Humans; Lapatinib; Prognosis; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2009 |
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Everolimus; Evidence-Based Medicine; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization; Lapatinib; Neoplasm Staging; Polymerase Chain Reaction; Practice Guidelines as Topic; Prognosis; Pyrazoles; Pyrimidines; Quinazolines; Receptor, ErbB-2; RNA, Messenger; Sirolimus; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome; Up-Regulation | 2009 |
An overview of HER-targeted therapy with lapatinib in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2 | 2009 |
Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?
Topics: Adjuvants, Immunologic; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Heart Failure; Humans; Lapatinib; Oxidative Stress; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Rate; Trastuzumab; Ventricular Outflow Obstruction | 2009 |
mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Metformin; Models, Biological; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Receptor, ErbB-2; TOR Serine-Threonine Kinases | 2009 |
Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2009 |
Costs of adjuvant breast cancer treatments.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Health Care Costs; Humans; Lapatinib; Quinazolines; Tamoxifen; Trastuzumab | 2009 |
Trastuzumab versus lapatinib: the cardiac side of the story.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Heart Diseases; Humans; Lapatinib; Quinazolines; Trastuzumab | 2009 |
Review article optimizing the use of her-2/neu targeting agents in breast cancer : a developing nation perspective.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2007 |
Treatment of brain metastases in patients with HER2+ breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Incidence; Lapatinib; Prognosis; Quinazolines; Receptor, ErbB-2; Time Factors; Trastuzumab | 2009 |
Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions.
Topics: Afatinib; Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Forecasting; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Morpholines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Quinolines; Trastuzumab; Up-Regulation | 2009 |
Lapatinib: a competitor or companion to trastuzumab?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Interactions; Female; Humans; Lapatinib; Quinazolines; Trastuzumab | 2009 |
Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Gene Expression; Humans; Lapatinib; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab | 2009 |
Lapatinib for the treatment of HER2-overexpressing breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2 | 2009 |
Lapatinib in metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Trastuzumab | 2009 |
Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Humans; Lapatinib; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2009 |
Current combination chemotherapy regimens for metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Breast Neoplasms; Capecitabine; Cytotoxins; Deoxycytidine; Diarrhea; Drug Delivery Systems; Epothilones; Female; Fluorouracil; Humans; Lapatinib; Quinazolines; Signal Transduction; Skin Diseases; Trastuzumab | 2009 |
Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carcinoma; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2010 |
Molecular predictors of response to trastuzumab and lapatinib in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2010 |
[Lapatinib treatment-option in trastuzumab-resistant breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Clinical Trials as Topic; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Eruptions; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis; Trastuzumab; Treatment Outcome | 2009 |
Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer.
Topics: Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Lapatinib; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2010 |
Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
Topics: Breast Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2009 |
Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Female; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Trastuzumab | 2010 |
Lapatinib for treatment of advanced or metastasized breast cancer: systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Randomized Controlled Trials as Topic | 2009 |
[Management of metastatic HER2-positive breast cancer: present and future].
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Bevacizumab; Brain Neoplasms; Breast Neoplasms; Disease Progression; Female; Heart; Humans; Lactams, Macrocyclic; Lapatinib; Letrozole; Neoplasm Proteins; Nitriles; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2010 |
Does lapatinib work against HER2-negative breast cancers?
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Quinazolines; Receptor Cross-Talk; Receptor, ErbB-2; Receptors, Estrogen | 2010 |
HER2 as a target for breast cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cancer Vaccines; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2010 |
Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: a systematic review.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Survival Analysis | 2010 |
Systemic treatment in breast-cancer patients with brain metastasis.
Topics: Animals; Anticonvulsants; Antineoplastic Agents; Biological Products; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Glucocorticoids; Humans; Lapatinib; Quinazolines | 2010 |
Targeted therapy in breast cancer: current status and future directions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Forecasting; Genes, BRCA1; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Trastuzumab; Treatment Failure | 2010 |
HER2-positive breast cancer: beyond trastuzumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2010 |
Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation, Preclinical; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2010 |
[Novel targeted drug therapies in breast cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bevacizumab; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Tamoxifen; Trastuzumab | 2010 |
Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Triazoles | 2010 |
Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2011 |
Use of molecular markers for predicting therapy response in cancer patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Breast Neoplasms; Cytochrome P-450 CYP2D6; ErbB Receptors; Female; Genotype; Humans; Lapatinib; Mutation; Precision Medicine; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Trastuzumab | 2011 |
Lapatinib and breast cancer: current indications and outlook for the future.
Topics: Animals; Breast Neoplasms; Clinical Trials as Topic; Female; Forecasting; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2010 |
Prevention and management of major side effects of targeted agents in breast cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast; Breast Neoplasms; Cardiovascular Diseases; Female; Gastrointestinal Diseases; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Skin Diseases; Trastuzumab | 2012 |
Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Receptors, IgG; Signal Transduction; Trastuzumab | 2011 |
[Pharmacological profiles and clinical effects of lapatinib tosilate (Tykerb)].
Topics: Antineoplastic Agents; Breast Neoplasms; Gene Expression; Humans; Lapatinib; Quinazolines; Receptor Cross-Talk; Signal Transduction; Tumor Cells, Cultured | 2010 |
Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Marrow; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Interactions; Epothilones; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lymphatic Metastasis; Peripheral Nervous System Diseases; Quinazolines; Treatment Failure; Treatment Outcome; Tubulin Modulators | 2010 |
Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antinematodal Agents; Breast; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab; Up-Regulation | 2012 |
Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Division; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Phosphatidylinositol 3-Kinase; Prognosis; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2010 |
[Principles and method of action of targeted therapies].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab; Vascular Endothelial Growth Factor A | 2010 |
Lapatinib for breast cancer: a review of the current literature.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2011 |
The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.
Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Letrozole; Neoplasm Metastasis; Nitriles; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Triazoles | 2011 |
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Neoadjuvant Therapy; Prognosis; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2010 |
Lapatinib in breast cancer: clinical experiences and future perspectives.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Forecasting; Humans; Lapatinib; Lymphatic Metastasis; Neoadjuvant Therapy; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2010 |
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers; Breast Neoplasms; Cardiotoxins; Cardiovascular Diseases; Female; Heart Failure; Humans; Indoles; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk Assessment; Sorafenib; Sunitinib; Trastuzumab | 2011 |
New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2011 |
Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment.
Topics: Antineoplastic Agents; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Female; Genes, erbB-2; Humans; Lapatinib; Phosphatidylinositol 3-Kinases; Predictive Value of Tests; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Treatment Outcome | 2010 |
Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.
Topics: Angiogenesis Modulating Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2011 |
Eradication of breast cancer cells in patients with distant metastasis: the finishing touches?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Design; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Neoplastic Cells, Circulating; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2012 |
[Leptomeningeal meningitis related to breast cancer overexpressing HER2: is there a place for a more specific treatment?].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barrier; Breast Neoplasms; Disease Models, Animal; Female; Humans; Lapatinib; Meningeal Carcinomatosis; Meningeal Neoplasms; Primates; Quinazolines; Rats; Receptor, ErbB-2; Trastuzumab | 2011 |
[Her2 positive breast cancer: practices].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Female; Genes, erbB-2; Heart; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2011 |
Cancer stem cells: perspectives of new therapeutical approaches for breast cancer.
Topics: Aldehyde Dehydrogenase 1 Family; Antigens, Neoplasm; Antineoplastic Agents; ATP-Binding Cassette Transporters; Breast Neoplasms; Dendritic Cells; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; HSP90 Heat-Shock Proteins; Humans; Immunotherapy; Integrin alpha6; Isoenzymes; Lapatinib; Membrane Proteins; Models, Biological; Mucin-1; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2; Retinal Dehydrogenase; Signal Transduction | 2011 |
[Tykerb for breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Lapatinib; Quinazolines; Trastuzumab | 2011 |
Docetaxel combined with targeted therapies in metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Indoles; Lapatinib; Pyrroles; Quinazolines; Sunitinib; Taxoids; Trastuzumab | 2012 |
Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Early Detection of Cancer; Evidence-Based Medicine; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Risk Assessment; Survival Analysis; Treatment Outcome | 2011 |
Beyond trastuzumab: new treatment options for HER2-positive breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Belgium; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Prognosis; Protein Kinase Inhibitors; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Risk Assessment; Survival Analysis; Trastuzumab | 2011 |
Treatment of HER2-positive breast cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cancer Vaccines; Disease Progression; Female; Gene Amplification; Genes, erbB-2; Heat-Shock Proteins; Humans; Lapatinib; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, IGF Type 1; Trastuzumab | 2011 |
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.
Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Lapatinib; Letrozole; Nitriles; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2011 |
[Novel target therapies used in breast cancer management].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Humans; Lapatinib; Molecular Targeted Therapy; Mutation; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Quinolines; RANK Ligand; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab | 2011 |
Insight into p95HER2 in breast cancer: molecular mechanisms and targeted therapies.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Immunoconjugates; Lapatinib; Patents as Topic; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2012 |
Target therapy in elderly breast cancer patients.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab | 2012 |
What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer?
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lapatinib; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2012 |
The adjuvant treatment of HER2-positive breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cardiotoxins; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Genes, erbB-2; Heart; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2012 |
Lapatinib for advanced or metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines | 2012 |
[Tumor resistance to HER2 inhibitors: the drug sedimentation concept].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2012 |
Overcoming treatment resistance in HER2-positive breast cancer: potential strategies.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Phosphatidylinositol 3-Kinase; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Trastuzumab | 2012 |
[Progress of molecularly targeted therapy for breast cancer].
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Denosumab; Drug Design; Drug Therapy, Combination; Everolimus; Humans; Lapatinib; Letrozole; Maytansine; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2012 |
Targeted therapies in breast cancer: are heart and vessels also being targeted?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Female; Heart Failure; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Trastuzumab; Ventricular Dysfunction, Left | 2012 |
Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease Progression; Female; Humans; Lapatinib; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Cytoplasmic and Nuclear; Triazoles | 2012 |
Dual blockade of HER2 - twice as good or twice as toxic?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab | 2012 |
Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Female; Humans; Lapatinib; Neoadjuvant Therapy; Preoperative Period; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2012 |
New insights and emerging therapies for breast cancer brain metastases.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Paclitaxel; Peptides; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Radiotherapy; Receptor, ErbB-2; Trastuzumab | 2012 |
Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer.
Topics: Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasms, Hormone-Dependent; Quinazolines; Quinolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2012 |
Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?
Topics: Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Lapatinib; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Receptors, Estrogen; Treatment Outcome | 2013 |
Primary systemic therapy in HER2-amplified breast cancer: a clinical review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Celecoxib; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Lapatinib; Mastectomy, Segmental; Paclitaxel; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sulfonamides; Taxoids; Trastuzumab | 2012 |
[Systemic treatment of brain metastases from breast cancer: cytotoxic chemotherapy and targeted therapies].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase I as Topic; Drugs, Investigational; ErbB Receptors; Humans; Lapatinib; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2 | 2004 |
Her-2 targeted therapy: beyond breast cancer and trastuzumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Female; Humans; Lapatinib; Morpholines; Neoplasms; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2006 |
[Molecular-targeted agents in breast cancer].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Drug Delivery Systems; Female; Humans; Indoles; Lapatinib; Middle Aged; Paclitaxel; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sunitinib; Taxoids; Trastuzumab | 2006 |
Dual/pan-HER tyrosine kinase inhibitors: focus in breast cancer.
Topics: Animals; Breast Neoplasms; ErbB Receptors; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2006 |
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Lapatinib; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2007 |
HER-2-positive breast cancer: hope beyond trastuzumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; ErbB Receptors; Female; HSP90 Heat-Shock Proteins; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2007 |
Novel approaches to advanced breast cancer: bevacizumab and lapatinib.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lapatinib; Quinazolines; Vascular Endothelial Growth Factor A | 2007 |
Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?
Topics: Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2007 |
Molecular targeted therapies in breast cancer: where are we now?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; ErbB Receptors; Female; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Receptors, Estrogen; Tamoxifen; Trastuzumab | 2007 |
HER2-positive breast cancer: current and future treatment strategies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2007 |
Lapatinib in breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Randomized Controlled Trials as Topic | 2007 |
Issues and controversies in the treatment of HER2 positive metastatic breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Hormones; Humans; Lapatinib; Medical Oncology; Models, Biological; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2008 |
Lapatinib-associated toxicity and practical management recommendations.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Lapatinib; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2 | 2007 |
[Breast cancer and Her-2].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Drug Design; Drug Therapy, Combination; ErbB Receptors; Female; Gene Targeting; Humans; Lapatinib; Protease Inhibitors; Pyrazines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2007 |
Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Humans; Lapatinib; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic | 2007 |
A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Brachytherapy; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Combined Modality Therapy; Cytochrome P-450 CYP2D6; Genes, erbB-2; Humans; Lapatinib; Male; Mastectomy; Pharmacogenetics; Quinazolines; Radiation Dosage; Tamoxifen; Trastuzumab; Treatment Outcome | 2007 |
Targeted therapies in breast cancer: challenging questions from oncology nurses.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Delivery Systems; Drug Monitoring; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Nurse's Role; Oncology Nursing; Quinazolines; Trastuzumab; Vascular Endothelial Growth Factor A | 2007 |
Lapatinib (Tykerb) for advanced breast cancer.
Topics: Breast Neoplasms; Drug Therapy, Combination; Drugs, Investigational; Female; Humans; Lapatinib; Quinazolines | 2007 |
[Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Trastuzumab | 2007 |
Lapatinib.
Topics: Antineoplastic Agents; Breast Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2007 |
Lapatinib in the treatment of breast cancer.
Topics: Biomarkers; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Genes, erbB-2; Humans; Lapatinib; Quinazolines | 2007 |
HER2 targeted therapy in breast cancer...beyond Herceptin.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2007 |
Emerging therapeutic options for breast cancer chemotherapy during pregnancy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Lapatinib; Oligohydramnios; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2008 |
Integrating biological agents into systemic therapy of breast cancer: trastuzumab, lapatinib, bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Genetic Testing; Heart Diseases; Humans; Lapatinib; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
[Targeting ErbB receptors in breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2007 |
Overcoming treatment challenges in advanced breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2007 |
Choosing the appropriate breast cancer therapy for today's breast cancer patient.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Mastectomy; Patient Care Planning; Quinazolines; Radiotherapy, Adjuvant; Receptor, ErbB-2; Trastuzumab | 2007 |
[Metastatic breast cancer--new methods of treatment].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Histocytochemistry; Humans; Lapatinib; Neoplasm Metastasis; Osteonecrosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Risk Factors; Signal Transduction; Time Factors; Trastuzumab | 2008 |
The emerging role of lapatinib in HER2-positive breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; ErbB Receptors; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2008 |
[The new generation of breast cancer clinical trials: the right drug for the right target].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; International Cooperation; Lapatinib; Microarray Analysis; Multicenter Studies as Topic; Organizational Objectives; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab | 2008 |
Lapatinib: a sword with two edges.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Neoplasms; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2008 |
Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Dioxoles; Diphtheria Toxin; Drug Resistance, Neoplasm; Drugs, Investigational; Epothilones; Female; Furans; Gemcitabine; Glutamates; Guanine; Humans; Interleukin-2; Ketones; Lapatinib; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Quinazolines; Recombinant Fusion Proteins; Tetrahydroisoquinolines; Trabectedin; Vinblastine; Vinorelbine | 2008 |
Treatment of metastatic breast cancer: looking towards the future.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Lapatinib; Medical Oncology; Neoplasm Metastasis; Paclitaxel; Quinazolines; Taxoids; Trastuzumab; Treatment Outcome | 2009 |
Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Genes, erbB-2; Humans; Lapatinib; Neoplasm Staging; Quinazolines; Trastuzumab; Treatment Outcome | 2007 |
[Combined chemotherapy with molecular-targeted agent for breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Humans; Lapatinib; Quinazolines; Trastuzumab | 2008 |
199 trial(s) available for lapatinib and Breast Cancer
| Article | Year |
|---|---|
Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Lapatinib; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Trastuzumab; United Kingdom | 2022 |
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Gene Expression Profiling; Humans; Immunoglobulin G; Lapatinib; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Transcriptome; Trastuzumab; Treatment Outcome | 2023 |
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Male; Neoadjuvant Therapy; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2023 |
Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Female; Gene Expression Profiling; Humans; Lapatinib; Neoadjuvant Therapy; Proportional Hazards Models; Receptor, ErbB-2; ROC Curve; Transcriptome; Trastuzumab; Treatment Outcome | 2019 |
Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Metastasis; Progression-Free Survival; Pyrrolidines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2019 |
A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Treatment Outcome; Tumor Burden | 2019 |
Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Follow-Up Studies; Humans; Lapatinib; Lymphocytes; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoadjuvant Therapy; Prognosis; Receptor, ErbB-2; Trastuzumab | 2020 |
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Lapatinib; Letrozole; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab; Treatment Outcome; Young Adult | 2020 |
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade.
Topics: Adult; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Lapatinib; Neoadjuvant Therapy; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2020 |
Administration of Lapatinib with Food Increases Its Plasma Concentration in Chinese Patients with Metastatic Breast Cancer: A Prospective Phase II Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; China; Female; Humans; Lapatinib; Prospective Studies; Quinazolines; Receptor, ErbB-2 | 2020 |
NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Chemotherapy, Adjuvant; DNA Damage; Epithelial-Mesenchymal Transition; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Prognosis; Receptor, ErbB-2; Trastuzumab | 2020 |
N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Trastuzumab | 2020 |
Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with Trastu
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Central Nervous System Neoplasms; Female; Humans; Lapatinib; Middle Aged; Prognosis; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Trastuzumab | 2020 |
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Fulvestrant; Humans; Lapatinib; Middle Aged; Postmenopause; Progression-Free Survival; Receptor, ErbB-2; Trastuzumab | 2021 |
Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Neoadjuvant Therapy; Receptor, ErbB-2; Trastuzumab | 2021 |
Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859].
Topics: Aged; Biomarkers, Tumor; Breast; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; DNA-Binding Proteins; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Letrozole; Middle Aged; Mutation; Neoplasm Proteins; Progression-Free Survival; Receptor, ErbB-2; Tumor Suppressor Protein p53 | 2020 |
Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial.
Topics: Antineoplastic Agents, Immunological; Breast Neoplasms; Databases, Factual; Disease-Free Survival; Drug Administration Schedule; Fasting; Female; Humans; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2020 |
Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Transcriptome; Trastuzumab; Young Adult | 2020 |
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Killer Cells, Natural; Lapatinib; MCF-7 Cells; Middle Aged; Neoadjuvant Therapy; Protein Kinase Inhibitors; Receptor, ErbB-2; RNA-Seq; Trastuzumab; Young Adult | 2021 |
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Tumor Microenvironment | 2020 |
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.
Topics: Acrylamides; Adult; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Prognosis; Receptor, ErbB-2; Survival Rate | 2021 |
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Humans; Lapatinib; Quality of Life; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2021 |
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Survival Analysis; Trastuzumab | 2021 |
Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Doxorubicin; Female; Humans; Lapatinib; Liposomes; Maximum Tolerated Dose; Middle Aged; Polyethylene Glycols; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Analysis; Treatment Outcome | 2017 |
Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.
Topics: Antineoplastic Agents; Breast Neoplasms; Diabetes Mellitus; Disease-Free Survival; Female; Humans; Hypoglycemic Agents; Insulin; Lapatinib; Metformin; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2017 |
Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.
Topics: Antineoplastic Agents; Axilla; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lapatinib; Lymph Nodes; Lymphatic Irradiation; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Trastuzumab; Tumor Burden | 2017 |
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Combined Chemotherapy Protocols; Axl Receptor Tyrosine Kinase; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Vascular Endothelial Growth Factor Receptor-1 | 2017 |
Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab).
Topics: Adult; Aged; Antigens, Neoplasm; Breast Neoplasms; Carbonic Anhydrase IX; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Analysis; Tissue Inhibitor of Metalloproteinase-1; Trastuzumab; Treatment Outcome; Young Adult | 2017 |
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Breast Neoplasms; Breast Neoplasms, Male; Bridged-Ring Compounds; Capecitabine; Diarrhea; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Lapatinib; Male; Maytansine; Middle Aged; Quinazolines; Receptor, ErbB-2; Response Evaluation Criteria in Solid Tumors; Retreatment; Survival Rate; Taxoids; Thrombocytopenia; Trastuzumab; Vomiting; Young Adult | 2017 |
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Bridged-Ring Compounds; Chemotherapy-Induced Febrile Neutropenia; Diarrhea; Early Termination of Clinical Trials; Female; Hemorrhage; Humans; Lapatinib; Male; Maytansine; Middle Aged; Neoplasm Metastasis; Neutropenia; Practice Patterns, Physicians'; Quinazolines; Receptor, ErbB-2; Retreatment; Survival Rate; Taxoids; Thrombocytopenia; Trastuzumab | 2017 |
Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; Female; Follow-Up Studies; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2017 |
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Class I Phosphatidylinositol 3-Kinases; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Genotype; Humans; Lapatinib; Middle Aged; Mutation; Neoadjuvant Therapy; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Signal Transduction; Taxoids; Trastuzumab | 2017 |
Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Female; Genetic Predisposition to Disease; Genotype; HLA-DRB1 Chains; Humans; Lapatinib; Liver; Neoplasm Staging; Risk Factors; Taxoids; Trastuzumab | 2018 |
PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Aminopyridines; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug Dosage Calculations; Drug Resistance, Neoplasm; Female; France; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2017 |
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Mutation; Neoadjuvant Therapy; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2018 |
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Postmenopause; Receptor, ErbB-2; Trastuzumab | 2018 |
Improved progression-free survival in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Progression-Free Survival; Quality Improvement; Receptor, ErbB-2; Trastuzumab; United Kingdom | 2018 |
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).
Topics: Aged; Biomarkers; Breast Neoplasms; Cardiotoxicity; Cardiovascular Abnormalities; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lapatinib; Middle Aged; Natriuretic Peptide, Brain; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Troponin T | 2018 |
A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Demography; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Vinblastine; Vinorelbine | 2018 |
Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre,
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2018 |
Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Survival Analysis; Trastuzumab; Treatment Outcome | 2018 |
A Pharmacometric Analysis of Patient-Reported Outcomes in Breast Cancer Patients Through Item Response Theory.
Topics: Ado-Trastuzumab Emtansine; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Lapatinib; Longitudinal Studies; Maytansine; Models, Biological; Patient Reported Outcome Measures; Trastuzumab; Treatment Outcome; Young Adult | 2018 |
A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Mutation; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2018 |
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Premenopause; Prognosis; Receptor, ErbB-2; Survival Rate; Trastuzumab | 2019 |
Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial.
Topics: Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Receptor, ErbB-2; Receptors, Antigen, T-Cell; Trastuzumab | 2018 |
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Neoadjuvant Therapy; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Receptor, ErbB-2; Trastuzumab | 2019 |
A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Follow-Up Studies; Furans; Humans; Ketones; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Trastuzumab | 2019 |
Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Central Nervous System Neoplasms; Drug Administration Schedule; Humans; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Receptor, ErbB-2; Treatment Outcome | 2019 |
A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Breast Neoplasms, Male; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Lapatinib; Male; Middle Aged; Neoplasm Metastasis; Pyridines; Receptor, ErbB-2; Survival Rate; Trastuzumab | 2019 |
Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Proportional Hazards Models; Receptor, ErbB-2; Trastuzumab | 2019 |
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Female; Humans; Lapatinib; Mastectomy; Neoadjuvant Therapy; Paclitaxel; Progression-Free Survival; Protein Kinase Inhibitors; Receptor, ErbB-2; Risk Assessment; Risk Factors; Time Factors; Trastuzumab | 2019 |
RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Staging; Paclitaxel; Quinazolines; Receptor, ErbB-2; Stroke Volume; Trastuzumab; Treatment Outcome; Ventricular Function, Left | 2013 |
Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Odds Ratio; Paclitaxel; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Up-Regulation | 2013 |
Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Decision Making; Female; Humans; Lapatinib; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab; Treatment Outcome; Young Adult | 2013 |
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Lapatinib; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab; Treatment Outcome; Triazoles; Up-Regulation | 2013 |
Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer-Study BES 06.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cohort Studies; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Letrozole; Middle Aged; Neoplasm Grading; Nitriles; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Triazoles | 2013 |
The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study.
Topics: Adult; Aged; Breast Neoplasms; ErbB Receptors; Gene Amplification; Humans; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Quinazolines; Receptor, ErbB-2 | 2013 |
Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Diarrhea; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Stomatitis; Treatment Outcome | 2015 |
An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Liver Neoplasms; Lung Neoplasms; Middle Aged; Prospective Studies; Quinazolines; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer.
Topics: Acneiform Eruptions; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Drug Eruptions; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2013 |
Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Polyethylene Glycols; Quinazolines; Receptor, ErbB-2; Recombinant Proteins; Taxoids; Trastuzumab; Young Adult | 2013 |
[HER2-positive breast cancer: standard and double targeted therapy].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2013 |
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Nausea; Quinazolines; Quinolines; Receptor, ErbB-2; Treatment Outcome; Vomiting | 2013 |
Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: a multicentric Turkish Oncology Group (TOG) trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Humans; Intention to Treat Analysis; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Time Factors; Turkey; Vinblastine; Vinorelbine | 2013 |
Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2013 |
Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Dacarbazine; Disease-Free Survival; Female; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Temozolomide; Treatment Outcome | 2013 |
Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Heart Failure; Humans; Lapatinib; Middle Aged; Paclitaxel; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2013 |
Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Paclitaxel; Quinazolines; Receptor, ErbB-2; Trastuzumab; Young Adult | 2013 |
Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Prognosis; Prospective Studies; Quinazolines; Receptor, ErbB-2; Transcriptome; Trastuzumab; Treatment Outcome | 2014 |
18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lapatinib; Neoadjuvant Therapy; Positron-Emission Tomography; Quinazolines; Receptor, ErbB-2; Time Factors; Tomography, X-Ray Computed; Trastuzumab; Treatment Outcome | 2013 |
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Chi-Square Distribution; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Intention to Treat Analysis; Lapatinib; Logistic Models; Mastectomy; Molecular Targeted Therapy; Neoadjuvant Therapy; Odds Ratio; Paclitaxel; Protein Kinase Inhibitors; Puerto Rico; Quinazolines; Receptor, ErbB-2; Time Factors; Trastuzumab; Treatment Outcome; United States | 2013 |
Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Trastuzumab; Treatment Outcome | 2013 |
A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Quality of Life; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2013 |
Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Health Status; Humans; Lapatinib; Maytansine; Medication Adherence; Middle Aged; Quality of Life; Quinazolines; Receptor, ErbB-2; Self Report; Surveys and Questionnaires; Time Factors; Trastuzumab; Treatment Outcome | 2014 |
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Diarrhea; Drug Administration Schedule; Drug Eruptions; Female; Humans; Incidence; Lapatinib; Logistic Models; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2; Time Factors; Trastuzumab | 2013 |
Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Biomarkers, Pharmacological; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Administration Schedule; Female; Forkhead Box Protein O1; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphorylation; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Signal Transduction; STAT5 Transcription Factor; Trastuzumab | 2013 |
Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.
Topics: Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Breast Neoplasms; Early Detection of Cancer; Estrogen Receptor alpha; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Italy; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2014 |
A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Vinblastine; Vinorelbine | 2014 |
Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Maytansine; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Survival Rate; Trastuzumab; Treatment Outcome | 2014 |
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Double-Blind Method; Female; Humans; Ki-67 Antigen; Lapatinib; Letrozole; Middle Aged; Mutation; Neoadjuvant Therapy; Nitriles; Phosphatidylinositol 3-Kinases; Phosphorylation; Postmenopause; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2014 |
Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Female; Genetic Predisposition to Disease; Genotype; HLA-DRB1 Chains; Humans; Lapatinib; Middle Aged; Prospective Studies; Quinazolines; Reproducibility of Results; Risk Factors | 2014 |
Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2 | 2014 |
A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome | 2014 |
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Survival Analysis; Trastuzumab; Treatment Outcome | 2014 |
Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ.
Topics: Adult; Aged; Apoptosis; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cell Proliferation; ErbB Receptors; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Lapatinib; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Prognosis; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2014 |
Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Exanthema; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Models, Biological; Quinazolines; Risk Factors; ROC Curve; Skin Neoplasms | 2014 |
Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Capecitabine; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Neoplasm Metastasis; Paresthesia; Quinazolines; Quinolines; Receptor, ErbB-2; Syndrome; Trastuzumab; Treatment Outcome | 2014 |
All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer--a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Prospective Studies; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2014 |
Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Estradiol; Female; Fulvestrant; Hormones; Humans; Lapatinib; Middle Aged; Postmenopause; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2014 |
Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Radiography; Response Evaluation Criteria in Solid Tumors; Vinblastine; Vinorelbine | 2014 |
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Central Nervous System Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Lapatinib; Maytansine; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Young Adult | 2015 |
Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039).
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Proliferation; Chemotherapy, Adjuvant; Double-Blind Method; Female; Humans; Lapatinib; Middle Aged; Preoperative Period; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Treatment Outcome | 2015 |
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2015 |
A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Polyethylene Glycols; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2015 |
PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Odds Ratio; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2015 |
Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Quality of Life; Quinazolines; Receptor, ErbB-2; Surveys and Questionnaires | 2015 |
Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Drug Eruptions; Female; Follow-Up Studies; Humans; International Cooperation; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Staging; Patient Selection; Quality of Life; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2015 |
Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromosomes, Human, Pair 10; Female; Follow-Up Studies; Gene Deletion; Humans; Immunoenzyme Techniques; Lapatinib; Neoadjuvant Therapy; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Prospective Studies; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Remission Induction; Trastuzumab | 2015 |
Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer.
Topics: Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Diarrhea; Female; Hemoglobins; Humans; Japan; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinazolines; Receptor, ErbB-2; Survival Rate | 2015 |
Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01.
Topics: Alanine Transaminase; Alleles; Antineoplastic Agents; Breast Neoplasms; Case-Control Studies; Chemical and Drug Induced Liver Injury; ErbB Receptors; Female; Genome-Wide Association Study; HLA-DRB1 Chains; Humans; Hyperbilirubinemia; INDEL Mutation; Lapatinib; Polymorphism, Single Nucleotide; Quinazolines; Risk | 2016 |
Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cell Count; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression; Humans; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Postmenopause; Premenopause; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Analysis; Treatment Outcome | 2015 |
Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography I
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Female; Fluorodeoxyglucose F18; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2015 |
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Remission Induction; Retrospective Studies; Risk Factors; Time Factors; Trastuzumab; Treatment Outcome; Young Adult | 2015 |
Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Lapatinib; Mutation; Neoadjuvant Therapy; Phosphatidylinositol 3-Kinases; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplastic Cells, Circulating; Phenotype; Quality of Life; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2016 |
Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Fatigue; Female; Gemcitabine; Humans; Lapatinib; Middle Aged; Quinazolines | 2015 |
Final overall survival analysis of a phase II trial evaluating vinorelbine and lapatinib in women with ErbB2 overexpressing metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lapatinib; Lymphatic Metastasis; Middle Aged; Quinazolines; Receptor, ErbB-2; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Dose-Response Relationship, Drug; Feasibility Studies; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pilot Projects; Prognosis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab | 2016 |
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Estrogen Receptor alpha; Female; Gene Expression; Humans; Immunoglobulin G; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Trastuzumab; Treatment Outcome; Tumor Microenvironment; Tumor Suppressor Protein p53; Young Adult | 2016 |
Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor.
Topics: Administration, Oral; Adult; Animals; Antineoplastic Agents; Area Under Curve; Breast Neoplasms; Cell Line, Tumor; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Dosage Calculations; ErbB Receptors; Female; Half-Life; Humans; Immunohistochemistry; Lapatinib; Mice; Mice, SCID; Phosphorylation; Quinazolines; ROC Curve; Tandem Mass Spectrometry; Transplantation, Heterologous | 2015 |
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 tr
Topics: Adult; Afatinib; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Canada; Disease Progression; Disease-Free Survival; Europe; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Republic of Korea; Risk Factors; Time Factors; Trastuzumab; Treatment Outcome; United States; Vinblastine; Vinorelbine | 2015 |
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Staging; Patient Selection; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2016 |
A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine; Young Adult | 2016 |
Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Eruptions; Female; Humans; Lapatinib; Middle Aged; Paclitaxel; Quinazolines; Trastuzumab | 2016 |
Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Patient Selection; Precision Medicine; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Time Factors; Treatment Outcome | 2016 |
Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trial.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Therapy, Combination; Female; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Vinblastine; Vinorelbine | 2016 |
Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Eruptions; Exanthema; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Survival Rate; Time Factors; Trastuzumab; Treatment Outcome | 2016 |
Effect of lapatinib on oral digoxin absorption in patients.
Topics: Administration, Oral; Adult; Alberta; Antineoplastic Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; Cardiotonic Agents; Cross-Over Studies; Digoxin; Drug Interactions; Female; Gastrointestinal Absorption; Half-Life; Humans; Lapatinib; Metabolic Clearance Rate; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Seoul | 2015 |
Ongoing Clinical Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Lapatinib; Lymphatic Metastasis; Middle Aged; Neoplastic Cells, Circulating; Peptide Fragments; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Young Adult | 2016 |
Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Maytansine; Phosphatidylinositol 3-Kinases; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2016 |
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.
Topics: Adult; Aged; Biopsy, Large-Core Needle; Breast Neoplasms; Female; Humans; Lapatinib; Lymphocytes, Tumor-Infiltrating; Microarray Analysis; Middle Aged; Neoadjuvant Therapy; Prognosis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab | 2016 |
Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after ne
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers, Tumor; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Lapatinib; Letrozole; Lymphocyte Count; Lymphocytes, Tumor-Infiltrating; Mastectomy; Middle Aged; Neoadjuvant Therapy; Nitriles; Positron-Emission Tomography; Postmenopause; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Triazoles | 2016 |
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; DNA, Neoplasm; Exome Sequencing; Female; Humans; Lapatinib; Molecular Targeted Therapy; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; rhoA GTP-Binding Protein; Trastuzumab | 2017 |
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Remission Induction; Survival Rate; Trastuzumab | 2017 |
Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial).
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Research Design; Trastuzumab | 2008 |
A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Female; Humans; Lapatinib; Letrozole; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Nitriles; Ovarian Neoplasms; Quinazolines; Triazoles | 2008 |
Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Recurrence; Survival Analysis | 2008 |
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Approval; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; United States; United States Food and Drug Administration; Young Adult | 2008 |
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Placebos; Quinazolines; Receptor, ErbB-2; Retrospective Studies | 2008 |
Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Female; Humans; In Vitro Techniques; Lapatinib; Male; Maximum Tolerated Dose; Mice; Middle Aged; Neoplasms; Quinazolines; Topotecan; Xenograft Model Antitumor Assays | 2008 |
Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quality of Life; Quinazolines; Receptor, ErbB-2; Surveys and Questionnaires | 2009 |
Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Female; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Failure; Treatment Outcome | 2009 |
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2009 |
Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Recurrence; Skin Diseases; Treatment Outcome | 2009 |
Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Female; Gene Amplification; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lapatinib; Paclitaxel; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2009 |
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Letrozole; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Survival Analysis; Treatment Outcome; Triazoles | 2009 |
An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Lapatinib; Lymphatic Metastasis; Middle Aged; Quinazolines; Receptor, ErbB-2; Safety; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Female; Humans; Japan; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Young Adult | 2009 |
Lapatinib for the treatment of HER2-overexpressing breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2 | 2009 |
Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Genes, erbB-2; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Probability; Prognosis; Proportional Hazards Models; Quinazolines; Survival Analysis; Treatment Outcome | 2009 |
Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Health Status; Humans; Lapatinib; Neoplasm Metastasis; Paclitaxel; Quality of Life; Quinazolines; Receptor, ErbB-2 | 2010 |
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quality of Life; Quinazolines; Receptor, ErbB-2; Stroke Volume; Trastuzumab; Ventricular Function, Left | 2010 |
Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Synergism; Female; Humans; Lapatinib; Letrozole; Middle Aged; Nitriles; Placebos; Postmenopause; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Triazoles | 2010 |
Impact of lapatinib monotherapy on QOL and pain symptoms in patients with HER2+ relapsed or refractory inflammatory breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cohort Studies; Female; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Pain; Quality of Life; Quinazolines | 2010 |
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diarrhea; Dose-Response Relationship, Drug; Doxorubicin; Feasibility Studies; Female; Filgrastim; Follow-Up Studies; Gene Amplification; Granulocyte Colony-Stimulating Factor; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pilot Projects; Polyethylene Glycols; Quinazolines; Receptor, ErbB-2; Recombinant Proteins; Survival Rate; Trastuzumab; Treatment Outcome | 2010 |
Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Inflammation; Lapatinib; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines | 2010 |
Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cross-Over Studies; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Liver; Middle Aged; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Ventricular Function, Left | 2010 |
Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Lapatinib; Letrozole; Nitriles; Quality of Life; Quinazolines; Receptor, ErbB-2; Triazoles | 2010 |
A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lapatinib; Latvia; Middle Aged; Paclitaxel; Poland; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Romania; Russia; Up-Regulation | 2010 |
Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Diarrhea; Female; Heart Function Tests; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pilot Projects; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2012 |
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Breast Neoplasms; C-Reactive Protein; Carcinoma; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Lapatinib; Middle Aged; Quinazolines; Stroke Volume; Trastuzumab; Troponin I | 2011 |
Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Neoplasm Metastasis; Quality of Life; Quinazolines; Receptor, ErbB-2; Surveys and Questionnaires; Trastuzumab; Treatment Outcome | 2011 |
Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Capecitabine; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; Diarrhea; Disease Progression; Disease-Free Survival; Exanthema; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Lapatinib; Middle Aged; Mutation; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Quinazolines; Receptor, ErbB-2; Remission Induction | 2011 |
Combination therapy of lapatinib and Capecitabine for ErbB2-positive metastatic or locally advanced breast cancer: results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Europe; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Treatment Outcome | 2011 |
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Enzyme Activation; Exons; Female; Fluorouracil; Follow-Up Studies; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Mutation; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Quinazolines; Taxoids; Trastuzumab; Treatment Outcome | 2011 |
Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; ErbB Receptors; Female; Humans; Hyperplasia; Immunohistochemistry; In Situ Hybridization, Fluorescence; Ki-67 Antigen; Lapatinib; Middle Aged; Placebos; Prevalence; Quinazolines; Receptor, ErbB-2; Time Factors | 2011 |
Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab.
Topics: Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Confidence Intervals; Cost-Benefit Analysis; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lapatinib; Models, Economic; Probability; Quality-Adjusted Life Years; Quinazolines; State Medicine; Trastuzumab; United Kingdom; Women's Health | 2012 |
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Topotecan | 2011 |
Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Lung Neoplasms; Male; Middle Aged; Prostatic Neoplasms; PTEN Phosphohydrolase; Quinazolines; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2012 |
Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Lapatinib; Letrozole; Nitriles; Quinazolines; Receptor, ErbB-2; Survival Rate; Triazoles | 2011 |
A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2 | 2012 |
Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Cell Count; Cohort Studies; Dasatinib; Female; Hemangioblasts; Hematopoietic Stem Cells; Humans; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pyrimidines; Quinazolines; Thiazoles; Trastuzumab; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Female; Gene Expression; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2012 |
Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab; Vinblastine; Vinorelbine | 2012 |
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.
Topics: Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Young Adult | 2012 |
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lapatinib; Liver; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2012 |
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Female; Humans; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2012 |
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2 | 2012 |
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Immunotoxins; Lapatinib; Male; Maytansine; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2012 |
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cross-Over Studies; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Staging; Odds Ratio; Prognosis; Proportional Hazards Models; Quality of Life; Quinazolines; Receptor, ErbB-2; Risk Factors; Trastuzumab; Treatment Outcome | 2012 |
Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Survival Analysis; Treatment Outcome | 2012 |
Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Survival Rate; Trastuzumab | 2012 |
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Humans; Lapatinib; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Predictive Value of Tests; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Translational Research, Biomedical; Trastuzumab; Treatment Outcome | 2012 |
An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Taxoids | 2013 |
Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Cohort Studies; ErbB Receptors; Female; Humans; Immunohistochemistry; Lapatinib; Maximum Tolerated Dose; Middle Aged; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2012 |
A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Asian People; Brain Neoplasms; Breast Neoplasms; Cranial Irradiation; Drug Administration Schedule; Female; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2013 |
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Lapatinib; Maytansine; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Survival Rate; Trastuzumab; Young Adult | 2012 |
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Central Nervous System; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2 | 2013 |
Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Nausea; Paclitaxel; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2013 |
An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study).
Topics: Adult; Aged; Biopsy; Breast Neoplasms; Cell Proliferation; ErbB Receptors; Female; Forkhead Box Protein M1; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Lapatinib; Middle Aged; Oncogene Protein v-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Estrogen | 2013 |
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lapatinib; Lymph Nodes; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Female; Humans; Indazoles; Lapatinib; Middle Aged; Neoplasm Staging; Pyrimidines; Quinazolines; Receptor, ErbB-2; Sulfonamides; Treatment Outcome | 2013 |
Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Socie
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Trastuzumab; Treatment Outcome | 2014 |
Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; International Cooperation; Lapatinib; Multicenter Studies as Topic; Quinazolines; Randomized Controlled Trials as Topic; Time Factors; Trastuzumab | 2013 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Heart Diseases; Humans; Lapatinib; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Analysis | 2006 |
Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2007 |
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines; Trastuzumab | 2008 |
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cohort Studies; Female; Humans; Immunoenzyme Techniques; Inflammation; Lapatinib; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Sensitivity and Specificity; Skin Neoplasms | 2008 |
A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Quinazolines | 2008 |
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2008 |
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2008 |
Dual-agent molecular targeting of the ErbB2 receptor: killing one bird with two stones.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Female; Humans; Lapatinib; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Analysis; Trastuzumab; Treatment Outcome | 2008 |
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Quinazolines; Receptor, ErbB-2; Risk Assessment; Survival Analysis; Trastuzumab; Treatment Outcome | 2008 |
Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB).
Topics: Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Female; Genes, erbB-2; Humans; Lapatinib; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Quinazolines; Treatment Outcome; Triazoles | 2008 |
616 other study(ies) available for lapatinib and Breast Cancer
| Article | Year |
|---|---|
Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dogs; Epidermal Growth Factor; ErbB Receptors; Ether-A-Go-Go Potassium Channels; Female; Hepatocytes; Humans; Indazoles; Keratinocytes; Lapatinib; Male; Metabolic Clearance Rate; Mice; Mice, Nude; Mice, SCID; Microsomes; Molecular Structure; Neoplasms, Experimental; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Wistar; Receptor, ErbB-2; Survival Rate; Xenograft Model Antitumor Assays | 2008 |
Discovery of novel small-molecule inhibitors of human epidermal growth factor receptor-2: combined ligand and target-based approach.
Topics: Amino Acid Sequence; Aniline Compounds; Antineoplastic Agents; Binding Sites; Breast Neoplasms; Catalytic Domain; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Humans; Ligands; Models, Molecular; Molecular Sequence Data; Piperazines; Pyrimidines; Quantitative Structure-Activity Relationship; Quinazolines; Quinolines; Receptor, ErbB-2; Small Molecule Libraries | 2008 |
Synthesis and biological evaluation of pyrimidine-based dual inhibitors of human epidermal growth factor receptor 1 (HER-1) and HER-2 tyrosine kinases.
Topics: Acrylamides; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Mice; Mice, Inbred ICR; Models, Molecular; Mutation; Oxazoles; Pyrimidines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, ErbB-2; Stomach Neoplasms; Structure-Activity Relationship | 2012 |
Identification of quinones as HER2 inhibitors for the treatment of trastuzumab resistant breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; High-Throughput Screening Assays; Humans; Models, Molecular; Molecular Structure; Quinones; Receptor, ErbB-2; Structure-Activity Relationship; Trastuzumab | 2014 |
Design and synthesis of piperidine derivatives as novel human heat shock protein 70 inhibitors for the treatment of drug-resistant tumors.
Topics: Binding Sites; Breast Neoplasms; Cell Line, Tumor; Computer Simulation; Drug Design; Drug Resistance, Neoplasm; Female; HSP70 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Models, Molecular; Piperidines | 2015 |
Design and molecular modeling of novel P38α MAPK inhibitors targeting breast cancer, synthesized from oxygen heterocyclic natural compounds.
Topics: Antineoplastic Agents; Apoptosis; Biological Products; Breast Neoplasms; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Heterocyclic Compounds; Humans; MCF-7 Cells; Mitogen-Activated Protein Kinase 14; Models, Molecular; Molecular Structure; Oxygen; Protein Kinase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured | 2019 |
Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Breast Neoplasms; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; MCF-7 Cells; Molecular Docking Simulation; Protein Kinase Inhibitors; Quantitative Structure-Activity Relationship; Thiazoles | 2020 |
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2 | 2021 |
A pH-sensitive T7 peptide-decorated liposome system for HER2 inhibitor extracellular delivery: an application for the efficient suppression of HER2+ breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Cells, Cultured; Collagen Type IV; Drug Screening Assays, Antitumor; Female; Humans; Lapatinib; Liposomes; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Optical Imaging; Peptide Fragments; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Receptor, ErbB-2 | 2021 |
Human induced pluripotent stem cell-derived platelets loaded with lapatinib effectively target HER2+ breast cancer metastasis to the brain.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Drug Carriers; Humans; Induced Pluripotent Stem Cells; Lapatinib; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2 | 2021 |
Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Progression-Free Survival; Receptor, ErbB-2; Retrospective Studies | 2021 |
HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway.
Topics: Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; MAP Kinase Signaling System; Mutation; Oxazoles; Protein Kinase Inhibitors; Pyridines; Quinazolines; Quinolines; Receptor, ErbB-2; Tumor Escape | 2021 |
The efficacy of lapatinib in patients with metastatic HER2 positive breast cancer who received prior therapy with monoclonal antibodies and antibody-drug conjugate: a single institutional experience.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Hormones; Humans; Immunoconjugates; Ki-67 Antigen; Lapatinib; Neoplasm Recurrence, Local; Receptor, ErbB-2; Trastuzumab | 2022 |
LASP-1 interacts with ErbB2 in ovarian cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Adult; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cohort Studies; Cytoskeletal Proteins; Female; HEK293 Cells; Humans; Lapatinib; LIM Domain Proteins; Middle Aged; Ovarian Neoplasms; Phosphorylation; Plasmids; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transfection | 2022 |
The efficacy of pyrotinib-based therapy in lapatinib-resistant metastatic HER2-positive breast cancer.
Topics: Acrylamides; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib | 2022 |
Dual targeting micelles loaded with paclitaxel and lapatinib for combinational therapy of brain metastases from breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Blood-Brain Barrier; Brain; Brain Neoplasms; Breast Neoplasms; Disease Models, Animal; Drug Delivery Systems; Female; Humans; Injections, Intravenous; Lapatinib; Mice; Micelles; Paclitaxel; Peptides; Tumor Cells, Cultured | 2022 |
INHBA is a mediator of aggressive tumor behavior in HER2+ basal breast cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Neoplasm Invasiveness; Receptor, ErbB-2 | 2022 |
Glyceollins Trigger Anti-Proliferative Effects in Hormone-Dependent Aromatase-Inhibitor-Resistant Breast Cancer Cells through the Induction of Apoptosis.
Topics: Apoptosis; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estrogens; Female; Humans; Lapatinib; Letrozole; Neoplasm Recurrence, Local; Nitriles; Pterocarpans; Triazoles | 2022 |
Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort.
Topics: Ado-Trastuzumab Emtansine; Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Lapatinib; Receptor, ErbB-2; Retrospective Studies; Taxoids; Trastuzumab | 2022 |
Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancer.
Topics: Ado-Trastuzumab Emtansine; Breast Neoplasms; Female; Humans; Lapatinib; Patient Reported Outcome Measures; Trastuzumab | 2022 |
Mechanistic Modeling of Central Nervous System Pharmacokinetics and Target Engagement of HER2 Tyrosine Kinase Inhibitors to Inform Treatment of Breast Cancer Brain Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Central Nervous System; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2022 |
Flow Cytometry Analysis to Detect Lapatinib-Induced Modulation of Constitutive and IFN-γ-Induced HLA Class I Expression in HER2-Positive Breast Cancer Cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Female; Flow Cytometry; Humans; Interferon-gamma; Lapatinib; Receptor, ErbB-2; Signal Transduction | 2022 |
Western Blot Analysis of Lapatinib-Mediated Inhibition of the Epidermal Growth Factor Receptor 2 (HER2) Pathway in Breast Cancer Cells.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2022 |
Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Neoadjuvant Therapy; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2022 |
Efficacy and safety of pyrotinib-containing regimen in the patients with HER2-positive metastatic breast cancer: A multicenter real-world study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Neoplasms, Second Primary; Receptor, ErbB-2; Trastuzumab | 2023 |
pH-responsive albumin-coated biopolymeric nanoparticles with lapatinab for targeted breast cancer therapy.
Topics: Albumins; Breast Neoplasms; Female; Humans; Hydrogen-Ion Concentration; Lapatinib; Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer | 2022 |
Lapatinib- and fulvestrant-PAMAM dendrimer conjugates promote apoptosis in chemotherapy-induced senescent breast cancer cells with different receptor status.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Dendrimers; Female; Fulvestrant; Humans; Lapatinib | 2022 |
Noncirrhotic Portal Hypertension after Trastuzumab Emtansine in HER2-positive Breast Cancer as Determined by Deep Learning-measured Spleen Volume at CT.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deep Learning; Female; Humans; Hypertension, Portal; Lapatinib; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Spleen; Splenomegaly; Tomography, X-Ray Computed | 2022 |
AMPK activation attenuates HER3 upregulation and Neuregulin-Mediated rescue of cell proliferation in HER2-Overexpressing breast cancer cell lines exposed to lapatinib.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatin; Female; Humans; Lapatinib; Ligands; Neuregulin-1; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Up-Regulation | 2022 |
ALKBH5-Mediated m6A Demethylation of GLUT4 mRNA Promotes Glycolysis and Resistance to HER2-Targeted Therapy in Breast Cancer.
Topics: AlkB Homolog 5, RNA Demethylase; Breast Neoplasms; Demethylation; Female; Glycolysis; Humans; Lapatinib; RNA, Messenger; Trastuzumab | 2022 |
PIK3CA Mutation is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer Patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Lapatinib; Mutation; Quinazolines; Retrospective Studies; Trastuzumab | 2023 |
Differences in sensitivity to new therapies between primary and metastatic breast cancer: A need to stratify the tumor response?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2023 |
Clinical Profile and Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer With Brain Metastases: Real-World Experience.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2022 |
Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage.
Topics: Acrylamides; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Insurance Coverage; Lapatinib; Neoplasms, Second Primary; Trastuzumab | 2022 |
Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation.
Topics: Animals; Autophagy; Breast Neoplasms; Cell Line, Tumor; Chloroquine; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mice; Neoplasm Recurrence, Local; Proteomics; Receptor, ErbB-2; Zebrafish | 2022 |
Expanding the role of systemic therapy for patients with active, HER2-positive breast cancer brain metastases.
Topics: Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib | 2022 |
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac Glycosides; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Letrozole; MCF-7 Cells; Ouabain; Precision Medicine; Sodium-Potassium-Exchanging ATPase; Tamoxifen | 2022 |
Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; China; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Lapatinib; Quality-Adjusted Life Years; Receptor, ErbB-2 | 2022 |
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer.
Topics: Adult; Biomarkers; Breast Neoplasms; Female; Humans; Lapatinib; Ovarian Reserve; Paclitaxel | 2023 |
PTX3 from vascular endothelial cells contributes to trastuzumab-induced cardiac complications.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Calcium; Cardiotoxicity; Endothelial Cells; Female; Heart Diseases; Humans; Induced Pluripotent Stem Cells; Lapatinib; Mice; Quinazolines; Rats; Receptor, ErbB-2; Trastuzumab | 2023 |
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Dasatinib; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2023 |
Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Humans; Lapatinib; Maytansine; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2023 |
Outcomes and Prognostic Factors in HER2-Positive Metastatic Breast Cancer Patients Who Had Developed Brain Metastasis in the Treatment Process.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Trastuzumab | 2023 |
Loss of Kmt2c in vivo leads to EMT, mitochondrial dysfunction and improved response to lapatinib in breast cancer.
Topics: Animals; Breast Neoplasms; Cell Transformation, Neoplastic; DNA-Binding Proteins; Epithelial-Mesenchymal Transition; Female; Genes, Tumor Suppressor; Humans; Lapatinib; Mice; Mice, Knockout; Mitochondria | 2023 |
Development of certain aminoquinazoline scaffolds as potential multitarget anticancer agents with apoptotic and anti-proliferative effects: Design, synthesis and biological evaluation.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Kidney Neoplasms; Lapatinib; Lung Neoplasms; Melanoma; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship | 2023 |
Novel Therapeutic Combination Targets the Growth of Letrozole-Resistant Breast Cancer through Decreased Cyclin B1.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cyclin B1; Drug Resistance, Neoplasm; Estrogens; Female; Humans; Lapatinib; Letrozole; Mitogen-Activated Protein Kinases; Nitriles; Triazoles | 2023 |
Lapatinib: A comprehensive profile.
Topics: Breast Neoplasms; Drug Compounding; Drug Stability; Female; Humans; Lapatinib; Pharmaceutical Preparations | 2023 |
The unexpected effect of the combination of lapatinib and capecitabin in cranial metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Lapatinib; Quality of Life; Quinazolines; Receptor, ErbB-2 | 2023 |
Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Quinolines; Receptor, ErbB-2 | 2023 |
HSD17B4 methylation enhances glucose dependence of BT-474 breast cancer cells and increases lapatinib sensitivity.
Topics: Breast Neoplasms; Cell Line, Tumor; Female; Glucose; Humans; Lapatinib; Methylation; Peroxisomal Multifunctional Protein-2; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2 | 2023 |
Novel Cytochrome P450-3A4 Enzymatic Nanobiosensor for Lapatinib (a Breast Cancer Drug) Developed on a Poly(anilino-co-4-aminobenzoic Acid-Green-Synthesised Indium Nanoparticle) Platform.
Topics: 4-Aminobenzoic Acid; Antineoplastic Agents; Biosensing Techniques; Breast Neoplasms; Cytochrome P-450 CYP3A; Electrochemical Techniques; Electrodes; Female; Humans; Indium; Lapatinib; Nanoparticles; Pharmaceutical Preparations | 2023 |
Dynamic ultrasound molecular-targeted imaging of senescence in evaluation of lapatinib resistance in HER2-positive breast cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Fluorescein-5-isothiocyanate; Humans; Lapatinib; Receptor, ErbB-2; Ultrasonography | 2023 |
Treatments During Pregnancy Targeting ERBB2 and Outcomes of Pregnant Individuals and Newborns.
Topics: Ado-Trastuzumab Emtansine; Adult; Antineoplastic Agents; Breast Neoplasms; Case-Control Studies; Female; Humans; Infant, Newborn; Lapatinib; Pregnancy; Receptor, ErbB-2; Trastuzumab | 2023 |
Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Oncogene Protein v-akt; Phenylenediamines; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Pyrimidines; Receptor, ErbB-2; Transcriptional Activation | 2020 |
Pyrotinib versus lapatinib in HER2-positive breast cancer.
Topics: Acrylamides; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Humans; Lapatinib; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2019 |
Comparative anti-proliferative effects of potential HER2 inhibitors on a panel of breast cancer cell lines.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Lapatinib; Molecular Docking Simulation; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2020 |
Early relapse of inflammatory breast carcinoma treated with lapatinib and capecitabine: Ten years of complete response.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Fluorouracil; Humans; Inflammatory Breast Neoplasms; Lapatinib; Neoplasm Recurrence, Local; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2020 |
Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cancer-Associated Fibroblasts; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mice; Mice, Nude; Neoplasm Recurrence, Local; Receptor, ErbB-2; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Survival Rate; Trastuzumab; Xenograft Model Antitumor Assays | 2020 |
HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies.
Topics: Animals; Antineoplastic Agents; Autophagy; Breast Neoplasms; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Heme Oxygenase-1; Humans; Lapatinib; Membrane Proteins; Mice; Mice, Transgenic; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2020 |
Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms.
Topics: Animals; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; DNA Damage; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Imidazoles; Lapatinib; Mice; Naphthoquinones; Protein Kinase Inhibitors; Pyridines; Quinolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2020 |
A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan.
Topics: Ado-Trastuzumab Emtansine; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Docetaxel; Female; Humans; Lapatinib; Markov Chains; Middle Aged; Neoplasm Metastasis; Quality-Adjusted Life Years; Receptor, ErbB-2; Taiwan; Trastuzumab | 2020 |
CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to HER2-Targeted Therapies.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; CD36 Antigens; Cell Line, Tumor; Drug Resistance, Neoplasm; Fatty Acids; Female; Humans; Lapatinib; Mice; Mice, Inbred NOD; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2019 |
ERRα activates SHMT2 transcription to enhance the resistance of breast cancer to lapatinib via modulating the mitochondrial metabolic adaption.
Topics: Antineoplastic Agents; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Energy Metabolism; ERRalpha Estrogen-Related Receptor; Female; Gene Expression Regulation, Neoplastic; Glycine Hydroxymethyltransferase; Humans; Lapatinib; Mitochondria; Promoter Regions, Genetic; Protein Kinase Inhibitors; Reactive Oxygen Species; Receptors, Estrogen; Signal Transduction | 2020 |
An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Middle Aged; Mutagenesis, Insertional; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Signal Transduction; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Invasiveness; Prognosis; Receptor, EphB4; Receptor, ErbB-2; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Pyrimidines; Signal Transduction; Thiophenes; TOR Serine-Threonine Kinases; Trastuzumab | 2020 |
Real-world data of lapatinib and treatment after lapatinib in patients with previously treated HER2-positive metastatic breast cancer: A multicenter, retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Trastuzumab | 2020 |
Transcriptional suppression of AMPKα1 promotes breast cancer metastasis upon oncogene activation.
Topics: AMP-Activated Protein Kinases; Animals; Breast; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Chromones; Disease-Free Survival; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lapatinib; Mice; Morpholines; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prognosis; Receptor, ErbB-2; Tissue Array Analysis; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2020 |
Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; China; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Survival Rate; Trastuzumab | 2020 |
Repeated courses of radiation treatment in an HER2-positive breast cancer patient with diffuse brain metastases: A case report.
Topics: Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2020 |
Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain; Brain Neoplasms; Breast; Breast Neoplasms; Capecitabine; Chemoradiotherapy, Adjuvant; China; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Progression-Free Survival; Receptor, ErbB-2; Trastuzumab; Vinorelbine; Young Adult | 2020 |
Lapatinib inhibits doxorubicin induced migration of HER2-positive breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Movement; Cell Survival; Doxorubicin; ErbB Receptors; Female; Fibroblasts; Humans; Lapatinib; Protein Kinase Inhibitors; Receptor, ErbB-2; Triple Negative Breast Neoplasms | 2020 |
HER2-targeted therapy influences CTC status in metastatic breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Trastuzumab | 2020 |
Lower concentrations of curcumin inhibit Her2-Akt pathway components in human breast cancer cells, and other dietary botanicals potentiate this and lapatinib inhibition.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Curcumin; Female; Humans; Lapatinib; Phytochemicals; Plant Extracts; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quercetin; Receptor, ErbB-2; Signal Transduction | 2020 |
Acetyltanshinone IIA is more potent than lapatinib in inhibiting cell growth and degrading HER2 protein in drug-resistant HER2-positive breast cancer cells.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mice; Mice, Nude; Phenanthrenes; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2020 |
Fibroblast-tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Female; Fibroblasts; Humans; Lapatinib; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Signal Transduction; TOR Serine-Threonine Kinases | 2020 |
Variation in pathological complete response in HER2-positive breast cancers with intrinsic subtypes assessed by PAM50 testing: secondary analysis from NSABP B-41 trial.
Topics: Breast Neoplasms; Female; Humans; Lapatinib; Neoadjuvant Therapy; Receptor, ErbB-2; Trastuzumab | 2020 |
The development and initial evaluation of the Diarrhoea Management Diary (DMD) in patients with metastatic breast cancer.
Topics: Breast Neoplasms; Diarrhea; Female; Humans; Lapatinib; Middle Aged; Quality of Life; Self Report | 2020 |
Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Lapatinib; Mice; Mice, Nude; Oncogene Proteins, Fusion; Receptor, ErbB-2; Signal Transduction; src-Family Kinases; Tamoxifen; Xenograft Model Antitumor Assays | 2020 |
Adipocyte-conditioned medium induces resistance of breast cancer cells to lapatinib.
Topics: Adipocytes; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Line; Culture Media, Conditioned; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mice, SCID; Protein Kinase Inhibitors | 2020 |
Combination of lapatinib and luteolin enhances the therapeutic efficacy of lapatinib on human breast cancer through the FOXO3a/NQO1 pathway.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Female; Forkhead Box Protein O3; Humans; Lapatinib; Luteolin; Mice; NAD(P)H Dehydrogenase (Quinone); Neoplasm Invasiveness; Receptor, ErbB-2; Signal Transduction | 2020 |
Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Italy; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2020 |
Crizotinib induced antitumor activity and synergized with chemotherapy and hormonal drugs in breast cancer cells via downregulating MET and estrogen receptor levels.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Crizotinib; Dose-Response Relationship, Drug; Drug Synergism; Estrogen Antagonists; Humans; Inhibitory Concentration 50; Lapatinib; Proto-Oncogene Proteins c-met; Receptor, ErbB-2; Receptors, Estrogen | 2021 |
Higher serum PD-L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial.
Topics: Antineoplastic Agents, Immunological; B7-H1 Antigen; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Lapatinib; Neoplasm Metastasis; Progression-Free Survival; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2020 |
Repurposing of Benzimidazole Scaffolds for HER2 Positive Breast Cancer Therapy: An
Topics: Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Computer Simulation; Drug Development; Drug Repositioning; Female; Humans; Lapatinib; MCF-7 Cells; Protein Kinase Inhibitors; Receptor, ErbB-2; Structure-Activity Relationship | 2021 |
Antioxidant functions of DHHC3 suppress anti-cancer drug activities.
Topics: Acyltransferases; Antineoplastic Agents; Antioxidants; Apoptosis; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Female; Gefitinib; Humans; Lapatinib; Male; Prostatic Neoplasms; RNA Interference | 2021 |
Lapatinib-loaded acidity-triggered charge switchable polycarbonate-doxorubicin conjugate micelles for synergistic breast cancer chemotherapy.
Topics: Animals; Breast Neoplasms; Doxorubicin; Humans; Hydrogen-Ion Concentration; Lapatinib; Mice; Micelles; Polycarboxylate Cement | 2020 |
Comparative effectiveness of trastuzumab emtansine versus lapatinib plus chemotherapy for HER2+ metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Humans; Lapatinib; Receptor, ErbB-2; Trastuzumab | 2021 |
Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Female; Fulvestrant; Gene Expression; Humans; Lapatinib; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; RNA-Binding Proteins; Signal Transduction; TOR Serine-Threonine Kinases | 2020 |
A quantitative systems pharmacological approach identified activation of JNK signaling pathway as a promising treatment strategy for refractory HER2 positive breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; MAP Kinase Signaling System; Network Pharmacology; Protein Interaction Maps; Protein Kinase Inhibitors; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2021 |
CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cyclic N-Oxides; Cyclin-Dependent Kinases; Databases, Genetic; Drug Resistance, Neoplasm; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Indolizines; Lapatinib; Mice, Inbred BALB C; Mice, Nude; Phosphatidylinositol 3-Kinase; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridinium Compounds; Receptor, ErbB-2; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Investigating mutations at the hotspot position of the ERBB2 and screening for the novel lead compound to treat breast cancer - a computational approach.
Topics: Breast Neoplasms; Drug Screening Assays, Antitumor; Female; Humans; Lapatinib; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Signal Transduction | 2021 |
IL-8 secreted by tumor associated macrophages contribute to lapatinib resistance in HER2-positive locally advanced breast cancer via activation of Src/STAT3/ERK1/2-mediated EGFR signaling.
Topics: Adult; Aged; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Interleukin-8; Lapatinib; MAP Kinase Signaling System; Mastectomy; Middle Aged; Receptor, ErbB-2; Signal Transduction; Tumor-Associated Macrophages | 2021 |
RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Neoadjuvant Therapy; NF-kappa B; Protein Binding; Receptor Activator of Nuclear Factor-kappa B; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2021 |
Discovering novel cancer bio-markers in acquired lapatinib resistance using Bayesian methods.
Topics: Algorithms; Antineoplastic Agents; Bayes Theorem; Biomarkers, Tumor; Breast Neoplasms; Computational Biology; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Ontology; Gene Regulatory Networks; Humans; Lapatinib; Models, Genetic; Signal Transduction | 2021 |
The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice, Inbred NOD; Neoplasms; Phosphorylation; Receptor, ErbB-2; Receptor, ErbB-3; Xenograft Model Antitumor Assays | 2021 |
Identification of lysosome-targeting drugs with anti-inflammatory activity as potential invasion inhibitors of treatment resistant HER2 positive cancers.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Autophagy; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Lysosomes; MCF-7 Cells; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Neoplasm Invasiveness; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2021 |
Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor, ErbB-2; RNA, Messenger; Trastuzumab; Up-Regulation | 2021 |
Case report: Secondary sclerosing cholangitis induced by lapatinib and vinorelbine in a metastasis breast cancer patient.
Topics: Breast Neoplasms; Cholangitis, Sclerosing; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Vinorelbine | 2021 |
MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; MicroRNAs; Prognosis; Survival Analysis; Trastuzumab; Up-Regulation | 2021 |
Tamoxifen overcomes the trastuzumab-resistance of SK-BR-3 tumorspheres by targeting crosstalk between cytoplasmic estrogen receptor α and the EGFR/HER2 signaling pathway.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Breast Neoplasms; Cell Line, Tumor; Cytoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Receptor, ErbB-2; Signal Transduction; Tamoxifen; Trastuzumab | 2021 |
Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Carbazoles; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Gain of Function Mutation; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; MAP Kinase Signaling System; Point Mutation; Protein Kinase Inhibitors; Pyrimidines; rac GTP-Binding Proteins; Receptor, ErbB-2; Spheroids, Cellular; Up-Regulation | 2021 |
HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Liver Neoplasms; Mice; Positron-Emission Tomography; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Tissue Distribution | 2021 |
Lapatinib enhances paclitaxel toxicity in MCF-7, T47D, and MDA-MB-321 breast cancer cells.
Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Therapy, Combination; Female; Humans; Lapatinib; Paclitaxel; Protein Kinase Inhibitors | 2021 |
Induction of EnR stress by Melatonin enhances the cytotoxic effect of Lapatinib in HER2-positive breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; DNA Damage; Endoplasmic Reticulum Stress; Female; Humans; Lapatinib; Melatonin; Mice; Mice, Nude; Protein Kinase Inhibitors; Receptor, ErbB-2; Unfolded Protein Response | 2021 |
Inhibition of Ras and STAT3 activity of 4-(
Topics: Antibodies, Monoclonal; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Ki-67 Antigen; Lapatinib; STAT3 Transcription Factor | 2021 |
Targeting Gi/o protein-coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy.
Topics: Animals; Antineoplastic Agents, Immunological; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Epithelium; ErbB Receptors; Female; Humans; Indazoles; Lapatinib; Mammary Glands, Animal; Mice, Transgenic; Neoplasm Metastasis; Pertussis Toxin; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, G-Protein-Coupled; Signal Transduction; Sulfonamides; Trastuzumab; Up-Regulation | 2021 |
Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA.
Topics: Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Molecular Targeted Therapy; Mutation; Neuregulin-1; Phosphatidylinositol Phosphates; Protein Domains; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Receptor, ErbB-2; Signal Transduction | 2021 |
Development of a stable and high loaded liposomal formulation of lapatinib with enhanced therapeutic effects for breast cancer in combination with Caelyx®: In vitro and in vivo evaluations.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Female; Humans; Lapatinib; Mice; Polyethylene Glycols; Quinazolines | 2021 |
miR-221 confers lapatinib resistance by negatively regulating p27
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Dasatinib; Down-Regulation; Drug Resistance, Neoplasm; Female; Forkhead Box Protein O3; Hepatocyte Nuclear Factor 3-gamma; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Microarray Analysis; MicroRNAs; NF-kappa B p50 Subunit; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; src-Family Kinases; Up-Regulation | 2021 |
Identification of Food-Derived Isoflavone Sulfates as Inhibition Markers for Intestinal Breast Cancer Resistance Proteins.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biomarkers; Breast Neoplasms; Chromatography, High Pressure Liquid; Drug Resistance, Neoplasm; Genistein; Humans; Induced Pluripotent Stem Cells; Isoflavones; Lapatinib; Mice; Mice, Knockout; Neoplasm Proteins; Sulfates; Tandem Mass Spectrometry | 2021 |
HR+HER2- breast cancers with growth factor receptor-mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells.
Topics: Aged; Antigens, Neoplasm; Biomarkers, Tumor; Breast Neoplasms; Cadherins; Disease-Free Survival; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Integrins; Kaplan-Meier Estimate; Lapatinib; Matrix Metalloproteinase 9; MCF-7 Cells; Middle Aged; Quinazolines; Receptor, ErbB-2; Snail Family Transcription Factors; Transforming Growth Factor beta1 | 2017 |
HER2 signaling regulates HER2 localization and membrane retention.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Calcium; Cell Line, Tumor; Cell Membrane; Cell Proliferation; ErbB Receptors; Gene Knockdown Techniques; Humans; Intracellular Space; Lapatinib; Plasma Membrane Calcium-Transporting ATPases; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA, Small Interfering; Ubiquitination | 2017 |
Identification and characterization of biomarkers and their functions for Lapatinib-resistant breast cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Female; Gene Ontology; Humans; Lapatinib; Protein Interaction Mapping; Quinazolines; Transcriptome | 2017 |
ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Nuclear Proteins; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction; Survival Analysis; Xenograft Model Antitumor Assays | 2017 |
Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Young Adult | 2017 |
Identification of potential new treatment response markers and therapeutic targets using a Gaussian process-based method in lapatinib insensitive breast cancer models.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines | 2017 |
Metabolic shifts in residual breast cancer drive tumor recurrence.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lipid Metabolism; Metabolic Networks and Pathways; Mice; Neoplasm Recurrence, Local; Neoplasm, Residual; Oxidative Stress; Progesterone; Quinazolines; Reactive Oxygen Species; Transcriptome; Xenograft Model Antitumor Assays | 2017 |
Effect of dose timing on the blood concentration of lapatinib in patients with breast cancer.
Topics: Administration, Metronomic; Adult; Aged; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2017 |
Identification and characterization of ErbB4 kinase inhibitors for effective breast cancer therapy.
Topics: Amino Acid Sequence; Binding Sites; Breast Neoplasms; Female; Humans; Lapatinib; Ligands; Molecular Conformation; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-4; Sequence Alignment | 2017 |
Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Lymphocytes, Tumor-Infiltrating; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Patient Selection; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Retrospective Studies; T-Lymphocytes, Cytotoxic; Taxoids; Time Factors; Trastuzumab; Treatment Outcome | 2017 |
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.
Topics: Animals; bcl-2 Homologous Antagonist-Killer Protein; bcl-X Protein; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Amplification; Humans; Lapatinib; Myeloid Cell Leukemia Sequence 1 Protein; Pyrimidines; Quinazolines; Receptor, ErbB-2; Survival Analysis; Taxoids; Thiophenes; Trastuzumab; Treatment Outcome; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer.
Topics: Breast Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2017 |
Breast cancer: T-DM1 - an important agent in the history of breast cancer management.
Topics: Ado-Trastuzumab Emtansine; Breast Neoplasms; Capecitabine; Humans; Lapatinib; Maytansine; Trastuzumab | 2017 |
Ferroptosis and autophagy induced cell death occur independently after siramesine and lapatinib treatment in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Breast Neoplasms; Cell Line, Tumor; Female; Ferritins; Humans; Indoles; Lapatinib; Quinazolines; Reactive Oxygen Species; Spiro Compounds | 2017 |
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Female; Humans; Lapatinib; Lymphocytes, Tumor-Infiltrating; Middle Aged; Models, Biological; Models, Statistical; Multicenter Studies as Topic; Neoadjuvant Therapy; Predictive Value of Tests; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2018 |
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Topics: Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Ligands; Maytansine; Mice; Mice, Nude; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Trastuzumab; Xenograft Model Antitumor Assays | 2017 |
Gene isoforms as expression-based biomarkers predictive of drug response in vitro.
Topics: Alternative Splicing; Antineoplastic Agents; Benzimidazoles; Biomarkers; Breast Neoplasms; Carrier Proteins; Cell Adhesion Molecules; Chemistry, Pharmaceutical; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Genome, Human; Humans; Integrin beta Chains; Lapatinib; Neoplasms; Paclitaxel; Pharmacogenetics; Protein Isoforms; Quinazolines; RNA-Binding Proteins; RNA, Messenger; Sequence Analysis, RNA; Transcriptome | 2017 |
Near-infrared remotely triggered drug-release strategies for cancer treatment.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; DNA; Docetaxel; Drug Delivery Systems; Drug Liberation; Female; Gold; Humans; Infrared Rays; Lapatinib; Lasers; Nanoshells; Quinazolines; Serum Albumin, Human; Taxoids | 2017 |
The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Female; Humans; Lapatinib; Mammography; Middle Aged; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2018 |
Emilia: use cunning to survive cancer.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Lapatinib; Maytansine; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Rate; Trastuzumab | 2018 |
Distribution analysis of epertinib in brain metastasis of HER2-positive breast cancer by imaging mass spectrometry and prospect for antitumor activity.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Drug Monitoring; Female; Humans; Lapatinib; Mass Spectrometry; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Tissue Distribution; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Foxo-dependent Par-4 Upregulation Prevents Long-term Survival of Residual Cells Following PI3K-Akt Inhibition.
Topics: Apoptosis Regulatory Proteins; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Female; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; MCF-7 Cells; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Signal Transduction; Up-Regulation | 2018 |
Comment on a meta-analysis evaluating the cardiac toxicity of lapatinib in patients with breast cancer and other HER2-positive cancers.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotoxicity; Female; Humans; Lapatinib; Meta-Analysis as Topic; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2018 |
Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Immunological; Brain Neoplasms; Breast Neoplasms; Cranial Irradiation; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Prognosis; Receptor, ErbB-2; Trastuzumab | 2018 |
Lapatinib Inhibits Breast Cancer Cell Proliferation by Influencing PKM2 Expression.
Topics: Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Membrane Proteins; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction; STAT3 Transcription Factor; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2018 |
Curcumin as an In Vivo Selective Intestinal Breast Cancer Resistance Protein Inhibitor in Cynomolgus Monkeys.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biological Availability; Breast Neoplasms; Caco-2 Cells; Cell Line, Tumor; Curcumin; Cytochrome P-450 CYP3A; Female; Humans; Intestinal Absorption; Intestinal Mucosa; Intestines; Lapatinib; Macaca fascicularis; Male; Midazolam; Neoplasm Proteins; Pantoprazole; Quinazolines; Rosuvastatin Calcium; Sulfasalazine; Terfenadine | 2018 |
Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Databases, Genetic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-2; High-Throughput Screening Assays; Humans; Lapatinib; MCF-7 Cells; Mice; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Increased autophagy blocks HER2-mediated breast tumorigenesis.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Autophagy; Beclin-1; Breast Neoplasms; Cell Line, Tumor; Female; Gene Knock-In Techniques; Humans; Lapatinib; Mice; Mice, Inbred C57BL; Mice, Transgenic; Molecular Targeted Therapy; Mutation; Neoplasm Proteins; Peptide Fragments; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Random Allocation; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2018 |
Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface.
Topics: Adenosine Triphosphate; Breast Neoplasms; Cell Proliferation; Female; Humans; Lapatinib; Neuregulin-1; Phosphorylation; Protein Conformation; Protein Kinase Inhibitors; Protein Multimerization; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Tumor Cells, Cultured | 2018 |
Heat shock factor 1 confers resistance to lapatinib in ERBB2-positive breast cancer cells.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Heat Shock Transcription Factors; HSP90 Heat-Shock Proteins; Humans; Lapatinib; Mice, Inbred C57BL; Proteolysis; Receptor, ErbB-2; Tumor Suppressor Protein p53 | 2018 |
Antitumor effect of lapatinib and cytotoxic agents by suppression of E2F1 in HER2‑positive breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cytotoxins; E2F1 Transcription Factor; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2018 |
Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Humans; Lapatinib; Molecular Targeted Therapy; Nanoparticles; Receptor, ErbB-2; RNA, Small Interfering; Trastuzumab | 2018 |
Inhibition of HER2 Increases JAGGED1-dependent Breast Cancer Stem Cells: Role for Membrane JAGGED1.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Jagged-1 Protein; Lapatinib; Mice; Neoplastic Stem Cells; Receptor, ErbB-2; Receptor, Notch1 | 2018 |
Design and development of PEGylated liposomal formulation of HER2 blocker Lapatinib for enhanced anticancer activity and diminished cardiotoxicity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cardiotoxicity; Cell Line, Tumor; Cell Proliferation; Chick Embryo; ErbB Receptors; Female; Humans; Lapatinib; Liposomes; Polyethylene Glycols; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2018 |
Adherence to prescribing restrictions for HER2-positive metastatic breast cancer in Australia: A national population-based observational study (2001-2016).
Topics: Aged; Anthracyclines; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Australia; Breast Neoplasms; Capecitabine; Cluster Analysis; Female; Gene Expression; Humans; Lapatinib; Middle Aged; Patient Compliance; Patient Selection; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Vinorelbine | 2018 |
HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
Topics: Afatinib; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Synergism; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinolines; Receptor, ErbB-2; Trastuzumab; Tumor Cells, Cultured | 2019 |
Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Immunological; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Chemotherapy, Adjuvant; Female; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Italy; Lactic Acid; Lapatinib; Magnetic Resonance Spectroscopy; Mice; Oncogene Addiction; Patient Selection; Precision Medicine; Protein Kinase Inhibitors; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome; Up-Regulation | 2019 |
Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Creatine Kinase; Creatinine; Drug Resistance, Neoplasm; Energy Metabolism; Energy Transfer; Female; Gene Knockdown Techniques; Humans; Lapatinib; Mice; Mice, Nude; Mitochondria; Mitochondrial Proteins; Phosphocreatine; Phosphorylation; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2018 |
Chemotherapy and targeted therapy for breast cancer patients with hepatitis C virus infection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Breast Neoplasms; Breast Neoplasms, Male; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lapatinib; Liver; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Trastuzumab; Virus Replication | 2019 |
Phosphoproteomic analysis reveals PAK2 as a therapeutic target for lapatinib resistance in HER2-positive breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; p21-Activated Kinases; Phosphoproteins; Phosphorylation; Protein Interaction Maps; Protein Kinase Inhibitors; Proteomics; Receptor, ErbB-2; Signal Transduction | 2018 |
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Lung Neoplasms; Mice; Mice, Nude; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors; Quinolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Forkhead Box Protein O3; Gene Expression; Genes, erbB-2; Humans; Lapatinib; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; TNF-Related Apoptosis-Inducing Ligand | 2018 |
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers.
Topics: Breast Neoplasms; Cell Death; Cell Line, Tumor; CRISPR-Cas Systems; Drug Resistance, Neoplasm; Female; Genetic Testing; HEK293 Cells; Humans; Lapatinib; Metabolic Flux Analysis; NADP; Pentose Phosphate Pathway; Receptor, ErbB-2; Synthetic Lethal Mutations; Transaldolase | 2018 |
Antitumor effects of berberine against EGFR, ERK1/2, P38 and AKT in MDA-MB231 and MCF-7 breast cancer cells using molecular modelling and in vitro study.
Topics: Antineoplastic Agents, Phytogenic; Berberine; Breast Neoplasms; Catalytic Domain; Enzyme Stability; ErbB Receptors; Female; Humans; Lapatinib; MCF-7 Cells; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Molecular Docking Simulation; Molecular Dynamics Simulation; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Structure-Activity Relationship | 2019 |
Failure to Accurately Disclose Conflicts of Interest in Articles Published in JAMA Oncology.
Topics: Breast Neoplasms; Conflict of Interest; Disclosure; Humans; Lapatinib; Lymphocytes, Tumor-Infiltrating; Progression-Free Survival; Trastuzumab | 2019 |
Inhibition of ezrin causes PKCα-mediated internalization of erbb2/HER2 tyrosine kinase in breast cancer cells.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cytoskeletal Proteins; Female; Humans; Lapatinib; Mammary Neoplasms, Animal; Protein Kinase C-alpha; Receptor, ErbB-2; Signal Transduction | 2019 |
Baby steps: Pregnancy outcomes after human epidermal growth factor receptor 2-targeted therapy.
Topics: Breast Neoplasms; Female; Humans; Lapatinib; Pregnancy; Pregnancy Outcome; Receptor, ErbB-2; Trastuzumab | 2019 |
Heterotelechelic polymer prodrug nanoparticles: Adaptability to different drug combinations and influence of the dual functionalization on the cytotoxicity.
Topics: Breast Neoplasms; Cell Survival; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Combinations; Drug Synergism; Female; Gemcitabine; Humans; Lapatinib; MCF-7 Cells; Nanoparticles; Polymerization; Prodrugs | 2019 |
Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Culture Media; Drug Resistance, Neoplasm; Female; Healthy Volunteers; Humans; Interferon-gamma; Lapatinib; Leukocytes, Mononuclear; Receptor, ErbB-2; Th1 Cells; Tumor Necrosis Factor-alpha | 2019 |
[Survival of patients with advanced HER2+ breast cancer. Analysis of a cancer center database].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chile; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Receptor, ErbB-2; Retrospective Studies; Time Factors; Trastuzumab; Young Adult | 2018 |
Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Prognosis; Radiosurgery; Receptor, ErbB-2; Retrospective Studies; Survival Rate | 2019 |
Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Lapatinib; Middle Aged; Radiosurgery; Receptor, ErbB-2; Retrospective Studies; Survival Rate | 2019 |
(-)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo.
Topics: Aldehydes; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cyclopentane Monoterpenes; Drug Therapy, Combination; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Humans; Lapatinib; Mice; Phenols; Receptor, ErbB-2 | 2019 |
Cholesterol content in cell membrane maintains surface levels of ErbB2 and confers a therapeutic vulnerability in ErbB2-positive breast cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cholesterol; Drug Synergism; Endocytosis; Female; Filipin; Humans; Lapatinib; Lovastatin; Mice, Nude; Models, Biological; Protein Kinase Inhibitors; Proteolysis; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2019 |
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Follow-Up Studies; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Lapatinib; Neoadjuvant Therapy; Phosphatidylinositol 3-Kinases; Prognosis; Receptor, ErbB-2; Remission Induction; Trastuzumab | 2019 |
Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Receptor, ErbB-2; Treatment Outcome; Young Adult | 2019 |
Glucose-6-phosphate dehydrogenase blockade potentiates tyrosine kinase inhibitor effect on breast cancer cells through autophagy perturbation.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum Stress; Female; Gene Expression; Glucosephosphate Dehydrogenase; Humans; Lapatinib; Prognosis; Protein Kinase Inhibitors; Recurrence | 2019 |
Changing pattern of recurrences in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy in the era of dual anti-HER2 therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Hong Kong; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Trastuzumab; Treatment Outcome | 2019 |
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Gene Expression; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Reproducibility of Results; Survival Analysis; Treatment Outcome | 2020 |
BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy.
Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Prognosis; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Receptor, ErbB-2; Republic of Korea; Survival Analysis; Treatment Outcome | 2019 |
How we treat locally advanced HER2-positive breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Female; Genes, erbB-2; Humans; Lapatinib; Mastectomy; Maytansine; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Micrometastasis; Quinolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab | 2019 |
A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Receptor, ErbB-2; Retrospective Studies; Spain; Trastuzumab; Treatment Outcome | 2020 |
The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Decision-Making; Clinical Trials, Phase III as Topic; Female; Gene Expression Profiling; Humans; Lapatinib; Multicenter Studies as Topic; Neoadjuvant Therapy; Patient Selection; Precision Medicine; Predictive Value of Tests; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Retrospective Studies; Risk Factors; Time Factors; Transcriptome; Trastuzumab; Treatment Outcome | 2019 |
Risk factors associated with the incidence and time to onset of lapatinib-induced hepatotoxicity.
Topics: Breast Neoplasms; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP3A Inducers; Drug Therapy, Combination; Female; Histamine H2 Antagonists; Humans; Incidence; Lapatinib; Multivariate Analysis; Neoplasm Metastasis; Retrospective Studies; Risk Factors | 2019 |
For breast cancer patients with brain mets, new drug combo may be option.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines; Treatment Outcome | 2012 |
Incorporation of lapatinib into lipoprotein-like nanoparticles with enhanced water solubility and anti-tumor effect in breast cancer.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Female; Humans; Lapatinib; Lipoproteins; Mice; Nanoparticles; Quinazolines; Solubility; Xenograft Model Antitumor Assays | 2013 |
Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Dosage; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Regression Analysis; ROC Curve | 2013 |
Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Genes, erbB-2; High-Throughput Screening Assays; Humans; Lapatinib; Quinazolines; RNA Interference; RNA, Small Interfering | 2014 |
MEK inhibition increases lapatinib sensitivity via modulation of FOXM1.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Breast; Breast Neoplasms; Cell Line, Tumor; Female; Forkhead Box Protein M1; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; MAP Kinase Signaling System; Mice; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Mas; Quinazolines | 2013 |
PUMA and BIM are required for oncogene inactivation-induced apoptosis.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Biphenyl Compounds; Breast Neoplasms; Cell Line, Tumor; Chromatin Immunoprecipitation; ErbB Receptors; Female; Flow Cytometry; Gene Silencing; Humans; Immunoblotting; Immunohistochemistry; Lapatinib; MAP Kinase Signaling System; Membrane Proteins; Mice; Nitrophenols; Oncogenes; Piperazines; Plasmids; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Signal Transduction; Sulfonamides | 2013 |
A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Immunoblotting; Lapatinib; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Nuclear Proteins; Phosphoprotein Phosphatases; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-mdm2; Quinazolines; Receptor, ErbB-2; RNA Interference; Signal Transduction; Substrate Specificity; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2013 |
Identifying the challenges of biomarkers that predict response to HER2-directed therapies.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Female; Gene Dosage; Genes, erbB-1; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2013 |
OSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: a role for Nck1 but not Nck2.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Immunoprecipitation; Lapatinib; Oncogene Proteins; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Transfection | 2013 |
Predicting drug responsiveness in human cancers using genetically engineered mice.
Topics: Animals; Animals, Genetically Modified; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Breast Neoplasms; Carboplatin; Cyclophosphamide; Doxorubicin; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Oligonucleotide Array Sequence Analysis; Paclitaxel; Quinazolines; Tumor Microenvironment | 2013 |
Hypertriglyceridemia in patients with metastatic breast cancer and treatment with capecitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diabetes Mellitus; Dyslipidemias; Female; Fluorouracil; Humans; Hypertriglyceridemia; Israel; Lapatinib; Middle Aged; Multivariate Analysis; Quinazolines; Regression Analysis; Retrospective Studies; Risk Factors | 2013 |
Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib.
Topics: Adenine; Apoptosis; Autophagy; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2013 |
RON confers lapatinib resistance in HER2-positive breast cancer cells.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Crizotinib; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Lapatinib; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyridines; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2013 |
A gene expression profile indicative of early stage HER2 targeted therapy response.
Topics: Afatinib; Breast Neoplasms; Cell Line, Tumor; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, ErbB-2; Time Factors | 2013 |
Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Disease-Free Survival; Female; Humans; Intracranial Hypertension; Kaplan-Meier Estimate; Lapatinib; Liver Neoplasms; Middle Aged; Molecular Targeted Therapy; Quinazolines; Radiosurgery; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Trastuzumab; Young Adult | 2013 |
Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response.
Topics: Animals; Antigens, Neoplasm; Breast Neoplasms; CD8-Positive T-Lymphocytes; Cell Movement; Cells, Cultured; Chemotaxis; Disease Models, Animal; Doxorubicin; ErbB Receptors; Female; Humans; In Vitro Techniques; Interferon-gamma; Lapatinib; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Protein Kinase Inhibitors; Quinazolines; Rats; Receptor, ErbB-2; STAT1 Transcription Factor | 2013 |
[Combined therapy of lapatinib and capecitabine effective against local recurrence of breast cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Intraductal, Noninfiltrating; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines; Recurrence; Tomography, X-Ray Computed | 2013 |
Personalised cancer management: closer, but not here yet.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Molecular Targeted Therapy; Precision Medicine; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
[Current possibilities of targeted therapy in the treatment of breast cancer with overexpression of HER-2/neu and metastatic lesions in the brain].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Quality of Life; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Up-Regulation | 2013 |
Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin E; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Mucin-1; Peptides; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; RNA Interference; RNA, Small Interfering; Trastuzumab; Xenograft Model Antitumor Assays | 2014 |
SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Blotting, Western; Brain; Brain Neoplasms; Breast Neoplasms; Cell Cycle; Cell Proliferation; Cells, Cultured; Electric Impedance; Endothelium, Vascular; ErbB Receptors; Female; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Lapatinib; Mice; Protein Array Analysis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; src-Family Kinases; Xenograft Model Antitumor Assays | 2013 |
Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Immunoblotting; Immunoprecipitation; Lapatinib; Mice; Phosphorylation; Protein Multimerization; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Survival Rate; Trastuzumab; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Clinical Trials, Phase I as Topic; Cytochrome P-450 CYP3A; Docetaxel; Doxorubicin; Drug Interactions; Female; Half-Life; Humans; Intestine, Small; Lapatinib; Membrane Transport Modulators; Mice; Mice, Inbred Strains; Neoplasm Metastasis; Quinazolines; Taxoids; Tissue Distribution; Topoisomerase II Inhibitors; Tubulin Modulators | 2013 |
Identification and quantification of AKT isoforms and phosphoforms in breast cancer using a novel nanofluidic immunoassay.
Topics: Breast Neoplasms; Cell Line, Tumor; Electrophoresis, Capillary; Female; Humans; Immunoassay; Isoenzymes; Lapatinib; Metabolic Networks and Pathways; Microfluidic Analytical Techniques; Nanotechnology; Oxadiazoles; Phosphorylation; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins c-akt; Quinazolines | 2013 |
Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.
Topics: Animals; Antibodies, Bispecific; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Computer Simulation; Feedback, Physiological; Female; Lapatinib; MAP Kinase Signaling System; Mice; Models, Biological; Neuregulin-1; Oncogene Protein v-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Trastuzumab | 2013 |
LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling.
Topics: Acinar Cells; Amino Acid Oxidoreductases; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Epithelial Cells; Epithelial-Mesenchymal Transition; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mammary Glands, Human; Morphogenesis; Neoplasm Metastasis; Phenotype; Prognosis; Quinazolines; Reactive Oxygen Species; Receptor, ErbB-2; Signal Transduction | 2013 |
Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; CD24 Antigen; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glycosylation; Humans; Hyaluronan Receptors; Integrin beta1; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Trastuzumab | 2013 |
Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy.
Topics: Animals; Anoikis; Antineoplastic Agents, Hormonal; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Brain Neoplasms; Breast Neoplasms; Cell Survival; Drug Resistance, Neoplasm; Epigenesis, Genetic; ErbB Receptors; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histone Deacetylase Inhibitors; Humans; Indoles; Lapatinib; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Neoplastic Stem Cells; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Valproic Acid; Xenograft Model Antitumor Assays | 2013 |
An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
Topics: Autocrine Communication; Breast Neoplasms; Cell Line, Tumor; Cell Survival; CSK Tyrosine-Protein Kinase; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression; Gene Knockdown Techniques; Humans; Lapatinib; Neuregulin-1; Phosphatidylinositol 3-Kinases; Phosphoprotein Phosphatases; Phosphorylation; Prognosis; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; src-Family Kinases; TOR Serine-Threonine Kinases | 2013 |
Dual HER2 targeting for early breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Lapatinib; Neoadjuvant Therapy; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2013 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies | 2014 |
Unsuspected allies: chemotherapy teams up with immunity to fight cancer.
Topics: Animals; Breast Neoplasms; CD8-Positive T-Lymphocytes; Doxorubicin; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; STAT1 Transcription Factor | 2013 |
[Effects of mammalian-target-of-rapamycin pathway on lapatinib resistance in breast cancer MDA-MB-231 cells].
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Quinazolines; TOR Serine-Threonine Kinases | 2013 |
Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Lapatinib; Markov Chains; Quality-Adjusted Life Years; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
Reversible slurred speech related to capecitabine and lapatinib combination in patients with breast cancer.
Topics: Antineoplastic Agents; Articulation Disorders; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines | 2015 |
Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Triazoles | 2014 |
Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Neoplasm Invasiveness; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, CXCR4; Signal Transduction; src-Family Kinases | 2014 |
Early-onset brain metastases in a breast cancer patient after pathological complete response to neoadjuvant chemotherapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Remission Induction; Trastuzumab | 2013 |
Lapatinib inhibits stem/progenitor proliferation in preclinical in vitro models of ductal carcinoma in situ (DCIS).
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cell Line, Tumor; Cell Proliferation; Female; Humans; In Vitro Techniques; Lapatinib; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2 | 2014 |
Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Class Ia Phosphatidylinositol 3-Kinase; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Phosphorylation; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2014 |
[Clinical value of trastuzumab in the treatment of lapatinib-resistant HER2-positive metastatic breast cancer].
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Trastuzumab | 2013 |
Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Rate | 2014 |
NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Growth Processes; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mice; Mice, Nude; NF-kappa B; Quinazolines; Receptor, ErbB-2; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
Managing breast cancers with low estrogen receptor and HER2 by drugging both.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Receptors, Estrogen; Receptors, Progesterone | 2014 |
Reduced annexin A6 expression promotes the degradation of activated epidermal growth factor receptor and sensitizes invasive breast cancer cells to EGFR-targeted tyrosine kinase inhibitors.
Topics: Annexin A6; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Gene Expression; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Lapatinib; Lysosomes; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Proteolysis; Quinazolines | 2013 |
Clinical outcomes and cardiac safety of continuous antiHer2 therapy in c-erbB2-positive metastatic breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Heart; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2013 |
Doxorubicin and lapatinib combination nanomedicine for treating resistant breast cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; L-Lactate Dehydrogenase; Lapatinib; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Microscopy, Fluorescence; Nanomedicine; Nanotechnology; Neoplasm Transplantation; Particle Size; Polyethylene Glycols; Polypropylenes; Quinazolines | 2014 |
Ki-67 index as a prognostic factor of subsequent lapatinib-based therapy in HER2-positive metastatic breast cancer with resistance to trastuzumab.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Ki-67 Antigen; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Quinazolines; Receptor, ErbB-2; Trastuzumab; Young Adult | 2014 |
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
Topics: Aminopyridines; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mice; Mice, Nude; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2014 |
shRNA kinome screen identifies TBK1 as a therapeutic target for HER2+ breast cancer.
Topics: Animals; Apoptosis; Autophagy; Autophagy-Related Protein-1 Homolog; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Female; Genes, p53; Humans; Intracellular Signaling Peptides and Proteins; Lapatinib; Mice; Mice, SCID; Mutation; Protein Serine-Threonine Kinases; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Transcription Factor RelA | 2014 |
Evaluating HER2 amplification status and acquired drug resistance in breast cancer cells using Raman spectroscopy.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Spectrum Analysis, Raman | 2014 |
Clinical outcome of Turkish metastatic breast cancer patients with currently available treatment modalities--single center experience.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Metastasis; Postmenopause; Premenopause; Pyrroles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Sunitinib; Survival Rate; Trastuzumab; Turkey; Young Adult | 2014 |
Longest progression-free survival with lapatinib and capecitabine combination followed by trastuzumab in HER2-positive brain metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2014 |
Photo-activated psoralen binds the ErbB2 catalytic kinase domain, blocking ErbB2 signaling and triggering tumor cell apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Catalytic Domain; Cell Line, Tumor; Cell Nucleus; Cross-Linking Reagents; Drug Resistance, Neoplasm; Female; Ficusin; Humans; Lapatinib; Molecular Targeted Therapy; Protein Kinase Inhibitors; PUVA Therapy; Quinazolines; Quinolines; Receptor, ErbB-2; Signal Transduction; Ultraviolet Rays | 2014 |
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; MCF-7 Cells; Mice; Mice, Nude; Quinazolines; Random Allocation; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Up-Regulation; Xenograft Model Antitumor Assays | 2014 |
miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer.
Topics: Anoikis; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; MicroRNAs; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, IGF Type 1 | 2014 |
HER2 aberrations in cancer: implications for therapy.
Topics: Ado-Trastuzumab Emtansine; Adult; Afatinib; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Male; Maytansine; Molecular Targeted Therapy; Mutation; Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Up-Regulation; Uterine Cervical Neoplasms | 2014 |
Human decellularized adipose tissue scaffold as a model for breast cancer cell growth and drug treatments.
Topics: Adipose Tissue; Animals; Antineoplastic Agents; Biomimetics; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Extracellular Matrix; Female; Humans; Immunohistochemistry; Lapatinib; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron, Scanning; Neoplasm Transplantation; Quinazolines; Regeneration; Tissue Engineering; Tissue Scaffolds | 2014 |
Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases.
Topics: Brain Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2014 |
[Lapatinib plus transtuzumab for HER-2 positiva metastatic breast cancer: experience of use].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2014 |
Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Lapatinib; Mice; Mice, Transgenic; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Quinolines; Receptor, ErbB-2; Signal Transduction; TOR Serine-Threonine Kinases; Trastuzumab; Tumor Cells, Cultured | 2014 |
Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathway.
Topics: Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mitogen-Activated Protein Kinase Kinases; Neuregulin-1; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA Stability; RNA, Messenger; Signal Transduction; Time Factors; Transcription, Genetic | 2014 |
[A case of trastuzumab-resistant breast cancer responding to lapatinib/capecitabine therapy].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Quinazolines; Trastuzumab | 2014 |
Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells.
Topics: Animals; Breast Neoplasms; CD24 Antigen; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lapatinib; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Investigation of antitumor effects of sorafenib and lapatinib alone and in combination on MCF-7 breast cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Evaluation, Preclinical; Drug Synergism; ErbB Receptors; Female; Humans; Lapatinib; MCF-7 Cells; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Vascular Endothelial Growth Factor A | 2014 |
Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA Interference; RNA, Small Interfering; Signal Transduction; src-Family Kinases; Transplantation, Heterologous | 2014 |
Lapatinib-incorporated lipoprotein-like nanoparticles: preparation and a proposed breast cancer-targeting mechanism.
Topics: Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Carriers; Drug Delivery Systems; ErbB Receptors; Female; Humans; Lapatinib; Lipoproteins; Mice; Mice, SCID; Nanoparticles; Quinazolines; Receptor, ErbB-2 | 2014 |
PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; bcl-Associated Death Protein; bcl-X Protein; Breast Neoplasms; Cyclic AMP-Dependent Protein Kinase Catalytic Subunits; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; HEK293 Cells; Humans; Lapatinib; Mitogen-Activated Protein Kinases; Open Reading Frames; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-pim-1; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Benzamides; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Lapatinib; Mice; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Elongation Factor 2 Kinase; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Phosphorylation; Protein Phosphatase 2; Proteomics; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2014 |
Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Health Care Costs; Health Resources; Health Services Research; Humans; Kaplan-Meier Estimate; Lapatinib; Medicare; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Risk Factors; SEER Program; Trastuzumab; United States | 2014 |
Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Brain Chemistry; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Prospective Studies; Quinazolines | 2015 |
Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Lapatinib; Middle Aged; Mutation; Neoplasm Metastasis; Odds Ratio; Paclitaxel; Phosphatidylinositol 3-Kinases; Prognosis; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2014 |
Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Immunohistochemistry; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2014 |
Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Case-Control Studies; Female; Follow-Up Studies; Humans; Lapatinib; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Translational Research, Biomedical; Trastuzumab | 2014 |
Dual targeting of HER2 with lapatinib and trastuzumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Neoadjuvant Therapy; Quinazolines; Trastuzumab | 2014 |
Lentiviral vector-based insertional mutagenesis identifies genes involved in the resistance to targeted anticancer therapies.
Topics: Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Genetic Vectors; Humans; Lapatinib; Lentivirus; Molecular Targeted Therapy; Mutagenesis, Insertional; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2014 |
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Exons; Female; Genotype; Humans; Lapatinib; Middle Aged; Mutation; Neoadjuvant Therapy; Phosphatidylinositol 3-Kinases; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2014 |
Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; MCF-7 Cells; Mutagenesis, Site-Directed; Mutation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transcription Factors | 2014 |
Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Adhesion; Cell Movement; Cell Proliferation; ErbB Receptors; Female; Humans; Lapatinib; MCF-7 Cells; Metformin; Middle Aged; Neoplasm Invasiveness; Neurotensin; Quinazolines; Receptor Cross-Talk; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Neurotensin; Signal Transduction; Time Factors; Transfection; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2014 |
Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Eruptions; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Retrospective Studies | 2014 |
Dynamic transcription factor activity and networks during ErbB2 breast oncogenesis and targeted therapy.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Breast Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Survival; Computer Simulation; Female; Humans; Lapatinib; Models, Biological; Molecular Targeted Therapy; Protein Array Analysis; Quinazolines; Transcription Factors; Transcriptional Activation | 2014 |
Treatment patterns among elderly patients with stage IV breast cancer treated with HER-2-targeted therapy.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Lapatinib; Mastectomy; Medicare; Quinazolines; Radiotherapy, Adjuvant; Receptor, ErbB-2; Retrospective Studies; Time Factors; Trastuzumab; Treatment Outcome; United States | 2014 |
A novel combined micellar system of lapatinib and Paclitaxel with enhanced antineoplastic effect against human epidermal growth factor receptor-2 positive breast tumor in vitro.
Topics: Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Combinations; Drug Compounding; Endocytosis; Female; Humans; Lactic Acid; Lapatinib; Micelles; Paclitaxel; Particle Size; Polyesters; Polyethylene Glycols; Polymers; Quinazolines; Receptor, ErbB-2; Solubility; Surface Properties | 2015 |
HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Computational Biology; Disease Progression; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Lapatinib; Mice, Nude; Mutant Proteins; Mutation; Phenotype; Phosphorylation; Prognosis; Protein Structure, Tertiary; Quinazolines; Treatment Outcome | 2015 |
Synthesis, physicochemical and biological evaluation of technetium-99m labeled lapatinib as a novel potential tumor imaging agent of Her-2 positive breast cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Female; Humans; In Situ Hybridization; Lapatinib; Male; Mass Spectrometry; Mice; Mice, Inbred BALB C; Organotechnetium Compounds; Quinazolines; Radionuclide Imaging; Receptor, ErbB-2; Tissue Distribution | 2014 |
Effects of anti-proliferative lichen metabolite, protolichesterinic acid on fatty acid synthase, cell signalling and drug response in breast cancer cells.
Topics: 4-Butyrolactone; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Fatty Acid Synthases; Female; Humans; Lapatinib; Lichens; Molecular Structure; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2014 |
Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Immunoenzyme Techniques; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Oxazoles; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Female; Gene Expression; Humans; Lapatinib; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2015 |
Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; DNA Copy Number Variations; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; High-Throughput Nucleotide Sequencing; Humans; In Situ Hybridization, Fluorescence; Lapatinib; Mutation; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2015 |
Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration.
Topics: Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Connective Tissue Growth Factor; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Hippo Signaling Pathway; Humans; Lapatinib; Mechanotransduction, Cellular; Neuregulin-1; Nuclear Proteins; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Receptor, ErbB-4; Transcription Factors | 2014 |
Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors.
Topics: Animals; Antibodies, Monoclonal, Humanized; Apoptosis; Autophagy; Breast Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mammary Neoplasms, Animal; Molecular Targeted Therapy; Protein Serine-Threonine Kinases; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Breast Neoplasms; Disease-Free Survival; Female; Humans; Japan; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Prognosis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2015 |
A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Inhibitory Concentration 50; Lapatinib; MAP Kinase Signaling System; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Receptor, ErbB-2; Signal Transduction; TOR Serine-Threonine Kinases; Trastuzumab | 2015 |
miR-1470 mediates lapatinib induced p27 upregulation by targeting c-jun.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; JNK Mitogen-Activated Protein Kinases; Lapatinib; MicroRNAs; Proliferating Cell Nuclear Antigen; Quinazolines; Receptor, ErbB-2; Signal Transduction; Up-Regulation | 2015 |
Are capecitabine and the active metabolite 5-Fu CNS penetrable to treat breast cancer brain metastasis?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cell Proliferation; Central Nervous System; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Quinazolines; Receptor, ErbB-2 | 2015 |
Mislocalization of p27 to the cytoplasm of breast cancer cells confers resistance to anti-HER2 targeted therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Cytoplasm; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Humans; Lapatinib; Mice; Molecular Targeted Therapy; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction | 2014 |
Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Lapatinib; Mice; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-4; Trastuzumab | 2015 |
Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
Topics: Apoptosis; Breast Neoplasms; Cell Hypoxia; Cell Line; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Dual Specificity Phosphatase 2; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoblotting; Kaplan-Meier Estimate; Lapatinib; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridones; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction | 2015 |
Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Central Nervous System Neoplasms; Disease Progression; Female; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Middle Aged; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Time Factors; Trastuzumab; Treatment Outcome | 2015 |
Identifying differentially expressed genes and screening small molecule drugs for lapatinib-resistance of breast cancer by a bioinformatics strategy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Computational Biology; Databases, Genetic; Drug Discovery; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Small Molecule Libraries | 2014 |
Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression; Gene Knockdown Techniques; Glucuronidase; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Neuregulin-1; Quinazolines; Random Allocation; Receptor, ErbB-2; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition.
Topics: Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Inhibitor of Apoptosis Proteins; Lapatinib; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; TOR Serine-Threonine Kinases | 2015 |
Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
Effective Treatment of Solitary Pituitary Metastasis with Panhypopituitarism in HER2-Positive Breast Cancer by Lapatinib.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Hypopituitarism; Lapatinib; Pituitary Neoplasms; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2016 |
Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer.
Topics: Animals; Apoptosis; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lapatinib; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2015 |
Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mass Spectrometry; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Protein Kinase Inhibitors; Proteomics; Quinazolines; Receptor, ErbB-2; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2015 |
Targeting connexin 43 with α-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Connexin 43; Drug Delivery Systems; Female; Humans; Lapatinib; Quinazolines; Tamoxifen; Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 2015 |
Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells.
Topics: Acyltransferases; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Estrogen Receptor alpha; Female; Gene Amplification; Hedgehog Proteins; Humans; Lapatinib; Protein Transport; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tamoxifen | 2015 |
Disentangling multidimensional spatio-temporal data into their common and aberrant responses.
Topics: Algorithms; Biomarkers, Tumor; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Lapatinib; Mutation; Neural Networks, Computer; Principal Component Analysis; Protein Array Analysis; Proto-Oncogene Proteins c-akt; Quinazolines | 2015 |
Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Mutation; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Trastuzumab | 2015 |
MicroRNA networks regulated by all-trans retinoic acid and Lapatinib control the growth, survival and motility of breast cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Carrier Proteins; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Female; Humans; Lapatinib; MicroRNAs; Phosphoinositide Phospholipase C; Polymerase Chain Reaction; Protein Serine-Threonine Kinases; Quinazolines; Receptor, ErbB-2; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Tretinoin | 2015 |
Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Retreatment; Retrospective Studies; Survival Rate; Trastuzumab; Young Adult | 2015 |
The aryl hydrocarbon receptor (AhR) mediates resistance to apoptosis induced in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cyclooxygenase 2; Doxorubicin; Female; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Lapatinib; Paclitaxel; Polychlorinated Dibenzodioxins; Quinazolines; Receptors, Aryl Hydrocarbon; RNA, Messenger; RNA, Small Interfering; Transcription Factor RelB; Ultraviolet Rays | 2015 |
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.
Topics: Animals; Antineoplastic Agents, Hormonal; Biomarkers; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Lapatinib; Mice; Molecular Targeted Therapy; Neoadjuvant Therapy; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Time Factors; Xenograft Model Antitumor Assays | 2015 |
Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Interactions; Female; Hepatocytes; Humans; Immunohistochemistry; Lapatinib; Mice; Paclitaxel; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2015 |
EGFR tyrosine kinase inhibitors promote pro-caspase-8 dimerization that sensitizes cancer cells to DNA-damaging therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Caspase 8; Cell Line, Tumor; DNA Damage; Doxorubicin; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoprecipitation; Lapatinib; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Transfection | 2015 |
Lapatinib sensitizes quiescent MDA-MB-231 breast cancer cells to doxorubicin by inhibiting the expression of multidrug resistance-associated protein-1.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; Doxorubicin; Drug Synergism; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; MAP Kinase Signaling System; Multidrug Resistance-Associated Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2015 |
Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Amplification; Gene Dosage; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Enzyme Activation; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Membrane Proteins; Neoplasm Proteins; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2015 |
Lapatinib: an oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Postmenopause; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; United States; Women's Health | 2015 |
Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Catechin; Cell Adhesion; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatty Acid Synthase, Type I; Female; Gallic Acid; Humans; Lapatinib; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Naphthalenes; Neoplasm Invasiveness; Neoplasm Transplantation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Sirolimus; Trastuzumab | 2015 |
Lapatinib-based therapy for women with advanced/metastatic HER2 positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Young Adult | 2015 |
Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Canada; Capecitabine; Delivery of Health Care; Female; Health Care Costs; Humans; Lapatinib; Maytansine; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
Sensitization of HER2 Positive Breast Cancer Cells to Lapatinib Using Plants-Derived Isothiocyanates.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Isothiocyanates; Lapatinib; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sulfides; Sulfoxides; Thiocyanates; TOR Serine-Threonine Kinases | 2015 |
Novel nanosystem to enhance the antitumor activity of lapatinib in breast cancer treatment: Therapeutic efficacy evaluation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Female; Humans; Lactic Acid; Lapatinib; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Mononuclear Phagocyte System; Nanoparticles; Phagocytosis; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Quinazolines; Tumor Burden; Vitamin E; Xenograft Model Antitumor Assays | 2015 |
miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; MicroRNAs; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2; Transcription Factors; Trastuzumab; Tumor Suppressor Proteins | 2015 |
[A Case of Effective Whole-Brain Irradiation and Lapatinib/Capecitabine Combination Therapy for HER2-Positive Breast Cancer with Multiple Brain Metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Quinazolines; Receptor, ErbB-2; Remission Induction | 2015 |
Trastuzumab Rechallenge After Lapatinib- and Trastuzumab-Resistant Disease Progression in HER2-Positive Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Salvage Therapy; Trastuzumab | 2015 |
Benefit of eribulin in a patient with HER2(+) breast cancer who progressed after trastuzumab and lapatinib: a case report.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Fatal Outcome; Female; Furans; Humans; Ketones; Lapatinib; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Retreatment; Trastuzumab | 2015 |
Label-free LC-MS analysis of HER2+ breast cancer cell line response to HER2 inhibitor treatment.
Topics: Afatinib; Breast Neoplasms; Cell Line, Tumor; Chromatography, Liquid; Female; Humans; Lapatinib; Mass Spectrometry; Protein Kinase Inhibitors; Proteomics; Quinazolines; Quinolines; Receptor, ErbB-2 | 2015 |
Effect of Oncoxin Oral Solution in HER2-Overexpressing Breast Cancer.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dietary Supplements; Female; Lapatinib; Mice, Inbred BALB C; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2015 |
Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; MCF-7 Cells; Mice; Mice, Transgenic; MicroRNAs; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinase; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA Interference; Signal Transduction; Time Factors; Transfection; Trastuzumab; Tumor Burden | 2015 |
Breast Cancer Anti-Estrogen Resistance 4 (BCAR4) Drives Proliferation of IPH-926 lobular Carcinoma Cells.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Lobular; Cell Line, Tumor; Cell Proliferation; Female; Humans; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA, Long Noncoding | 2015 |
Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Letrozole; Molecular Imaging; Neoadjuvant Therapy; Nitriles; Precision Medicine; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab; Triazoles | 2015 |
Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors.
Topics: Acyltransferases; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mice; Mice, Knockout; Mice, Nude; Nuclear Proteins; Porphyrins; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction; Transcription Factors; Tumor Microenvironment; Verteporfin; Xenograft Model Antitumor Assays | 2015 |
Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Transfection | 2016 |
Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study.
Topics: Antineoplastic Agents; Breast Neoplasms; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Humans; Israel; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Rate; Trastuzumab | 2015 |
High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Female; Humans; Lapatinib; Mass Spectrometry; Quinazolines; Receptor, ErbB-2; Survival Analysis; Trastuzumab | 2016 |
t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib.
Topics: Antineoplastic Agents; Breast Neoplasms; Dopamine and cAMP-Regulated Phosphoprotein 32; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
A novel dual EGFR/HER2 inhibitor KU004 induces cell cycle arrest and apoptosis in HER2-overexpressing cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; ErbB Receptors; G1 Phase; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Resting Phase, Cell Cycle; Signal Transduction; Stomach Neoplasms | 2015 |
Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydroxybutyrates; Lapatinib; Molecular Dynamics Simulation; Mutation; Protein Kinase Inhibitors; Purines; Quinazolines; Receptor, ErbB-2; Staurosporine | 2016 |
An Epigenetic Pathway Regulates Sensitivity of Breast Cancer Cells to HER2 Inhibition via FOXO/c-Myc Axis.
Topics: Animals; Benzodiazepines; Breast Neoplasms; Cell Line, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Epigenesis, Genetic; Female; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2015 |
A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; Cell Survival; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Carriers; Drug Combinations; Drug Compounding; Drug Synergism; Female; G2 Phase Cell Cycle Checkpoints; Humans; Hydrogels; Injections, Intralesional; Injections, Intravenous; Lapatinib; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Nanotechnology; Paclitaxel; Poloxamer; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Solubility; Technology, Pharmaceutical; Temperature; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cadherins; Capecitabine; Carcinoma, Lobular; Female; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Molecular Targeted Therapy; Mutation, Missense; Quinazolines; Radiography; Receptor, ErbB-2; Treatment Outcome | 2016 |
PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mammary Neoplasms, Experimental; Mice, Knockout; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Signal Transduction; Thiazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Phenol 8% solution for the treatment of epidermal growth factor receptor inhibitor-induced periungual pyogenic granulomas.
Topics: Administration, Topical; Antineoplastic Agents; Breast Neoplasms; Caustics; Cautery; ErbB Receptors; Female; Granuloma, Pyogenic; Humans; Lapatinib; Middle Aged; Nail Diseases; Neoplasm Proteins; Phenol; Protein Kinase Inhibitors; Quinazolines; Toes | 2015 |
Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Synergism; Humans; Imidazoles; Indoles; Lapatinib; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Multiprotein Complexes; Naphthyridines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA Interference; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2015 |
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Case-Control Studies; Clonal Evolution; Deoxycytidine; DNA, Neoplasm; Female; Gemcitabine; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Mutation; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Sequence Analysis, DNA; Spinal Neoplasms; Tamoxifen; Trastuzumab | 2015 |
Incorporation of lapatinib into human serum albumin nanoparticles with enhanced anti-tumor effects in HER2-positive breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Lapatinib; Nanoparticles; Powder Diffraction; Quinazolines; Receptor, ErbB-2; Serum Albumin; Spectrum Analysis, Raman | 2015 |
POINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
Medicine: Eyes on the target.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Neoadjuvant Therapy; Phosphatidylinositol 3-Kinases; Precision Medicine; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2015 |
Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer.
Topics: Animals; Breast Neoplasms; Collagen; ErbB Receptors; Female; Lapatinib; Mammary Neoplasms, Experimental; Mice; Neoplasm Recurrence, Local; Phenylurea Compounds; Pyrimidines; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Signal Transduction; Stromal Cells; Tenascin; Up-Regulation; Wnt1 Protein | 2015 |
Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Enzyme Induction; ErbB Receptors; Estradiol; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Genes, erbB-2; Humans; Lapatinib; MCF-7 Cells; Metformin; Neoplasm Proteins; Neuregulin-1; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA Interference; RNA, Small Interfering; Signal Transduction; Tamoxifen; Tumor Stem Cell Assay | 2016 |
The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Insulin-Like Growth Factor I; Lapatinib; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins pp60(c-src); Quinazolines; Receptor, ErbB-3; Receptor, IGF Type 1; Signal Transduction; Trastuzumab | 2016 |
Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cyclin E; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Mitogen-Activated Protein Kinases; Outcome Assessment, Health Care; Phosphorylation; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Ribosomal Protein S6 Kinases, 70-kDa; Young Adult | 2016 |
[PTEN loss correlates withthe clinical efficacy of lapatinib in HER2 positive metastatic breast cancer with trastuzumab-resistance].
Topics: Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Lapatinib; Neoplasm Metastasis; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2015 |
HER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK.
Topics: Afatinib; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Inhibitory Concentration 50; JNK Mitogen-Activated Protein Kinases; Lapatinib; MAP Kinase Signaling System; Morpholines; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Quinazolines; STAT5 Transcription Factor | 2016 |
Structural Uncertainty of Markov Models for Advanced Breast Cancer: A Simulation Study of Lapatinib.
Topics: Antineoplastic Agents; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Lapatinib; Markov Chains; Models, Economic; Quality-Adjusted Life Years; Quinazolines; Uncertainty | 2016 |
Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Predictive Value of Tests; Proportional Hazards Models; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2016 |
A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Cost-Benefit Analysis; Disease Progression; Female; Health Services; Humans; Lapatinib; Letrozole; Markov Chains; Models, Econometric; Neoplasm Metastasis; Nitriles; Quality-Adjusted Life Years; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Terminal Care; Trastuzumab; Triazoles | 2016 |
Clinical predictors of long-term survival in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2016 |
Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Humans; Lapatinib; Molecular Targeted Therapy; Prognosis; Protein Kinase Inhibitors; Proteomics; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2016 |
Therapeutic siRNA for drug-resistant HER2-positive breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mice; Mice, Nude; Phosphorylation; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction; Trastuzumab; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Inhibitor Response to HER2 G776(YVMA) In-frame Insertion in HER2-positive Breast Cancer.
Topics: Antineoplastic Agents; Binding Sites; Breast Neoplasms; Female; Humans; Lapatinib; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutagenesis, Insertional; Protein Binding; Protein Structure, Secondary; Quinazolines; Receptor, ErbB-2 | 2016 |
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Proportional Hazards Models; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab | 2016 |
[Hepatic toxicity in HER-2(+) breast cancer patient under treatment with capecitabine and lapatinib].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemical and Drug Induced Liver Injury; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2016 |
Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Immunohistochemistry; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Microarray Analysis; MicroRNAs; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; RNA, Long Noncoding; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Trastuzumab; Xenograft Model Antitumor Assays | 2016 |
Co-Targeting of JNK and HUNK in Resistant HER2-Positive Breast Cancer.
Topics: Antineoplastic Agents; Autophagy; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Genes, erbB-2; Humans; Lapatinib; MAP Kinase Kinase 4; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines | 2016 |
Inflammatory breast cancer in a previously treated case of breast cancer: a diagnostic dilemma for the clinician.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Neoplasms, Second Primary; Paclitaxel; Prognosis; Quinazolines | 2016 |
Bi-weekly very-high-dose lapatinib: an easy-to-use active option in HER-2-positive breast cancer patients with meningeal carcinomatosis.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diarrhea; Female; Humans; Lapatinib; Liver Neoplasms; Magnetic Resonance Imaging; Meningeal Carcinomatosis; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2016 |
Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; Isothiocyanates; Lapatinib; Quinazolines; Receptor, ErbB-2; Signal Transduction; Sulfides; Sulfoxides; Thiocyanates | 2017 |
MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclins; Disease Models, Animal; DNA Helicases; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Lapatinib; Male; Mice; MicroRNAs; Models, Biological; Promoter Regions, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Quinazolines; Receptor, ErbB-2; RNA Interference; RNA-Binding Proteins; Stomach Neoplasms; Trastuzumab | 2016 |
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Class I Phosphatidylinositol 3-Kinases; Clinical Trials as Topic; Disease-Free Survival; Female; Genotype; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2016 |
Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Italy; Lapatinib; Logistic Models; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Trastuzumab; Young Adult | 2016 |
Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Epidermal Growth Factor; Female; Gene Expression; Humans; Lapatinib; MAP Kinase Signaling System; Mice; Neuregulin-1; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Design, biological evaluation and 3D QSAR studies of novel dioxin-containing pyrazoline derivatives with thiourea skeleton as selective HER-2 inhibitors.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dioxins; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lapatinib; Molecular Docking Simulation; Protein Kinase Inhibitors; Pyrazoles; Quantitative Structure-Activity Relationship; Quinazolines; Receptor, ErbB-2; Thiourea | 2016 |
Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Letrozole; Middle Aged; Nitriles; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome; Triazoles | 2016 |
Porous Matrix Stiffness Modulates Response to Targeted Therapy in Breast Carcinoma.
Topics: Acrylic Resins; Breast Neoplasms; Cell Line, Tumor; Extracellular Matrix; Female; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; Integrin beta4; Lapatinib; Molecular Targeted Therapy; Porosity; Quinazolines; Receptor, ErbB-2 | 2016 |
Discovery of a Potential HER2 Inhibitor from Natural Products for the Treatment of HER2-Positive Breast Cancer.
Topics: Acetanilides; Area Under Curve; Binding Sites; Biological Products; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Half-Life; Humans; Lapatinib; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2; ROC Curve; Thiazolidinediones | 2016 |
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Disease-Free Survival; Female; Gene Frequency; Genotype; Humans; Lapatinib; Mastectomy; Middle Aged; Neoadjuvant Therapy; Pharmacogenetics; Pharmacogenomic Testing; Pharmacogenomic Variants; Phenotype; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, IgG; Retrospective Studies; Time Factors; Trastuzumab; Treatment Outcome | 2016 |
ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Drug Resistance, Neoplasm; ERRalpha Estrogen-Related Receptor; Humans; Lapatinib; Mammary Neoplasms, Experimental; Mammary Tumor Virus, Mouse; MCF-7 Cells; Mice; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Retroviridae Infections; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Virus Infections | 2016 |
Berberine reverses lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS.
Topics: Antineoplastic Combined Chemotherapy Protocols; Berberine; Breast Neoplasms; Cell Line, Tumor; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; NF-E2-Related Factor 2; Quinazolines; Reactive Oxygen Species; Receptor, ErbB-2; Signal Transduction | 2016 |
Suppression of breast cancer cell growth by Her2-reduced AR serine 81 phosphorylation.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Humans; Lapatinib; Metribolone; Molecular Targeted Therapy; Phosphorylation; Quinazolines; Receptor, ErbB-2; Receptors, Androgen | 2016 |
Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib.
Topics: Alternative Splicing; Animals; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Genetic Predisposition to Disease; Humans; Inhibitory Concentration 50; Lapatinib; Mammary Neoplasms, Experimental; Mice, Transgenic; Phenotype; Protein Isoforms; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Receptor, ErbB-2; Signal Transduction; Time Factors | 2016 |
Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Female; Humans; Lapatinib; Markov Chains; Maytansine; Middle Aged; Quality-Adjusted Life Years; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; United States | 2016 |
A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer.
Topics: Adenovirus E1A Proteins; Animals; Apoptosis; Axl Receptor Tyrosine Kinase; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Therapy; Humans; Kaplan-Meier Estimate; Lapatinib; Mice; Mice, SCID; Neoplasm Transplantation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases | 2016 |
Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Mutation; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53 | 2016 |
Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.
Topics: Aminopyridines; Animals; Antibodies; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Lapatinib; Mice; Morpholines; ortho-Aminobenzoates; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; PTEN Phosphohydrolase; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Thiazoles; Xenograft Model Antitumor Assays | 2016 |
Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Female; Humans; Interleukin-6; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA Interference; RNA, Small Interfering; Signal Transduction; Spheroids, Cellular; STAT3 Transcription Factor; Up-Regulation | 2016 |
Epidermal growth factor receptor targeting alters gene expression and restores the adhesion function of cancerous cells as measured by single cell force spectroscopy.
Topics: Breast Neoplasms; Cell Adhesion; Cetuximab; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; MCF-7 Cells; Microscopy, Atomic Force; Neoplasm Proteins; Quinazolines | 2016 |
Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA-Activated Protein Kinase; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; MCF-7 Cells; Nuclear Proteins; Phosphorylation; Quinazolines; Radiation-Sensitizing Agents; Receptor, ErbB-2 | 2016 |
Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.
Topics: Ado-Trastuzumab Emtansine; Aged; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Inhibitor of Apoptosis Proteins; Lapatinib; Male; Maytansine; Middle Aged; Neuregulin-1; Oncogene Protein v-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Stomach Neoplasms; Survivin; Trastuzumab | 2016 |
ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Mutation; Protein Kinase Inhibitors; Proteolysis; Quinazolines; Receptor, ErbB-2; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2017 |
FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Fibroblast Growth Factor 2; Humans; Hyaluronan Receptors; Lapatinib; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nuclear Proteins; Phenotype; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Signal Transduction; Time Factors; Transforming Growth Factor beta; Twist-Related Protein 1; Xenograft Model Antitumor Assays | 2016 |
Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2017 |
Synergistic disruption of ERα/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells.
Topics: Activation, Metabolic; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cytochrome P-450 CYP3A; Drug Synergism; Estrogen Receptor alpha; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Tamoxifen | 2017 |
[A Case of Interstitial Pneumonitis Induced by Lapatinib plus Letrozole].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; ErbB Receptors; Female; Humans; Lapatinib; Letrozole; Lung Diseases, Interstitial; Nitriles; Quinazolines; Triazoles | 2016 |
Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4.
Topics: Afatinib; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cytochrome P-450 CYP3A; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab; Up-Regulation | 2017 |
Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
Topics: Apoptosis; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Computational Biology; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Proto-Oncogene Mas; Proto-Oncogene Proteins c-yes; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Signal Transduction; Trastuzumab | 2017 |
Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Brain Neoplasms; Breast Neoplasms; Cranial Irradiation; ErbB Receptors; Female; Humans; Lapatinib; Metastasectomy; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Trastuzumab | 2017 |
Lapatinib Resistance in Breast Cancer Cells Is Accompanied by Phosphorylation-Mediated Reprogramming of Glycolysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cellular Reprogramming; Drug Resistance, Neoplasm; Female; Glycolysis; Humans; Lapatinib; Phosphorylation; Proteomics; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2017 |
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Letrozole; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoadjuvant Therapy; Nitriles; Prospective Studies; Quinazolines; Receptor, ErbB-2; Receptors, Cell Surface; Treatment Outcome; Triazoles | 2017 |
Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lignans; Magnolia; Medicine, Chinese Traditional; Quinazolines; Signal Transduction; Sirolimus; Time Factors | 2008 |
Focus on ERBB2.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Genes, erbB-2; Genetic Predisposition to Disease; Humans; Lapatinib; Polymorphism, Genetic; Protein Binding; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2008 |
[New treatment approaches in breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Paclitaxel; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Vascular Endothelial Growth Factor A | 2008 |
Tufted hair folliculitis in a woman treated with lapatinib for breast cancer.
Topics: Alopecia; Antineoplastic Agents; Breast Neoplasms; Female; Folliculitis; Granuloma, Pyogenic; Humans; Lapatinib; Middle Aged; Quinazolines | 2008 |
Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2008 |
As metastasis yields its biological secrets, researchers hope to apply findings.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Denosumab; Drug Design; ErbB Receptors; Female; Humans; Lapatinib; Male; Mice; Neoplasm Metastasis; Prostatic Neoplasms; Quinazolines; RANK Ligand; Receptor, ErbB-2; Trastuzumab | 2008 |
Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Immunoblotting; Immunochemistry; Lapatinib; Mice; Mice, Inbred BALB C; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Research Design; RNA, Small Interfering; Signal Transduction; Transfection; Xenograft Model Antitumor Assays | 2008 |
Drug development in the targeted therapy era.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Disclosure; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Lapatinib; Maximum Tolerated Dose; Quinazolines; Receptor, ErbB-2 | 2008 |
Are volumetric changes of brain metastases the best evaluation of efficacy?
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Breast Neoplasms; Clinical Trials, Phase II as Topic; Cranial Irradiation; Endpoint Determination; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Research Design; Treatment Outcome | 2008 |
Monitoring circulating epithelial tumour cells (CETC) to gauge therapy: in patients with disease progression after trastuzumab persisting CETC can be eliminated by combined lapatinib treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Breast Neoplasms; Disease Progression; Epithelial Cells; Female; Gene Amplification; Humans; Lapatinib; Monitoring, Physiologic; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2009 |
Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2008 |
HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Amplification; Genes, erbB-2; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Laboratories, Hospital; Lapatinib; Medical Laboratory Personnel; Pathology, Clinical; Physicians; Quinazolines; Receptor, ErbB-2; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2008 |
Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor.
Topics: Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Insulin-Like Growth Factor I; Lapatinib; Leptin; Neoplasm Invasiveness; Quinazolines; Receptor Cross-Talk; Receptor, IGF Type 1; Receptors, Leptin; Signal Transduction; Transcriptional Activation | 2008 |
An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}meth
Topics: Animals; Antineoplastic Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Biological Transport; Blood-Brain Barrier; Brain; Breast Neoplasms; Central Nervous System; Cricetinae; Disease Models, Animal; Drug Synergism; Female; Humans; Lapatinib; Male; Mice; Mice, Knockout; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Tissue Distribution | 2009 |
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Cell Membrane; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Neoplasm Transplantation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Remission Induction; Signal Transduction; Trastuzumab | 2009 |
How should we prescribe lapatinib to our patients: once daily or twice daily, and at what dose?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lapatinib; Polyethylene Glycols; Quinazolines; Recombinant Proteins; Taxoids | 2009 |
tabAnti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra-Virgin Olive Oil (EVOO).
Topics: Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Flavonoids; Humans; Lapatinib; Leupeptins; Lignans; Olive Oil; Phenols; Phosphorylation; Plant Oils; Polyphenols; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Trastuzumab | 2008 |
Better translation from bench to bedside: breakthroughs in the individualized treatment of cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Gene Expression Profiling; Humans; Lapatinib; Multicenter Studies as Topic; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2009 |
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Diphosphonates; Everolimus; Female; Humans; Imidazoles; Lapatinib; Letrozole; Nitriles; Quinazolines; Sirolimus; Tamoxifen; Trastuzumab; Triazoles; Zoledronic Acid | 2009 |
Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quality of Life; Quinazolines; Sensitivity and Specificity | 2009 |
Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cyclin D1; Epidermal Growth Factor; Epiregulin; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Precancerous Conditions; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; RNA, Messenger; Signal Transduction | 2009 |
Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Base Sequence; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Cell-Free System; Cisplatin; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Female; Glioma; Glutathione S-Transferase pi; Humans; Lapatinib; Mice; Mice, Nude; Models, Molecular; Molecular Sequence Data; Neoplasm Transplantation; Phosphorylation; Protein Conformation; Quinazolines; Recombinant Proteins; RNA, Small Interfering; Signal Transduction; Static Electricity; Transplantation, Heterologous; Tyrosine | 2009 |
Lapatinib plus paclitaxel as first-line therapy for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: inappropriate conclusions from a company-sponsored study?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Genes, erbB-2; Humans; Lapatinib; Paclitaxel; Quinazolines | 2009 |
microRNA-205 regulates HER3 in human breast cancer.
Topics: Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Combined Modality Therapy; Gefitinib; Genes, Tumor Suppressor; Genetic Therapy; Humans; Lapatinib; MicroRNAs; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Quinazolines; Receptor, ErbB-3; Transfection | 2009 |
[Position statement of the (Hungarian) College of Oncology and Radiotherapy regarding the financing of Tyverb (lapatinib) based on individual discretionary compassionate care].
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Hungary; Immunohistochemistry; Insurance, Health, Reimbursement; Lapatinib; Medical Oncology; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Societies, Medical; Up-Regulation | 2009 |
Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Female; Heart; Heart Failure; Humans; Lapatinib; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2009 |
Unilateral taxane-induced onychopathy in a patient with a brain metastasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carboplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Fluorouracil; Hand; Humans; Lapatinib; Middle Aged; Onycholysis; Paclitaxel; Paresis; Peripheral Nervous System Diseases; Quinazolines; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2009 |
The "win-win" initiative: a global, scientifically based approach to resource sparing treatment for systemic breast cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Lapatinib; Pharmacogenetics; Quinazolines; Trastuzumab | 2009 |
No cure in sight for the world's drug problem.
Topics: Antineoplastic Agents; Breast Neoplasms; Cost-Benefit Analysis; Drug Costs; Drug Utilization; Female; Humans; Lapatinib; Quinazolines; United Kingdom | 2009 |
Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lapatinib; Male; Mice; Middle Aged; Mitogen-Activated Protein Kinase 7; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2009 |
Lapatinib for inflammatory breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Genes, erbB-2; Humans; Inflammation; Lapatinib; Quinazolines | 2009 |
Targeted therapies: Combined lapatinib and paclitaxel in HER2-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Lapatinib; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2009 |
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Enzyme Inhibitors; Humans; Indazoles; Lapatinib; Mice; Mice, Nude; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Sulfonamides; Taxoids; Trastuzumab; Xenograft Model Antitumor Assays | 2009 |
FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Female; Forkhead Box Protein M1; Forkhead Transcription Factors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Mice, Transgenic; Middle Aged; Paraffin Embedding; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA Interference; RNA, Messenger; Signal Transduction; Transcription, Genetic; Transfection; Up-Regulation | 2009 |
Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Calreticulin; Cell Line, Tumor; Cell Nucleus; Cetuximab; Endoplasmic Reticulum; ErbB Receptors; Green Fluorescent Proteins; Humans; Lapatinib; Membrane Proteins; Protein Kinase Inhibitors; Quinazolines; Recombinant Fusion Proteins; SEC Translocation Channels; Signal Transduction; Transfection | 2009 |
Severe drug-induced thrombocytopenia after treatment with trastuzumab but not with lapatinib.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoembryonic Antigen; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Immunohistochemistry; Lapatinib; Middle Aged; Mucin-1; Quinazolines; Receptor, ErbB-2; Thrombocytopenia; Trastuzumab | 2009 |
Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.
Topics: Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Breast Neoplasms; Cell Line, Tumor; Clone Cells; Drug Antagonism; Drug Resistance, Neoplasm; Female; Genes, erbB-2; Humans; Lapatinib; Oncogene Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Estrogen; RNA, Small Interfering; Trastuzumab | 2009 |
Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Lapatinib; Liposomes; Neoplasm Proteins; Quinazolines; RNA, Small Interfering | 2009 |
How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lapatinib; Nitriles; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Risk Assessment; Survival Analysis; Time Factors; Trastuzumab; Triazoles | 2009 |
Geographic distribution of lapatinib-induced skin rash: sparing of abdominal skin persists in the transverse rectus abdominis myocutaneous flap.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Eruptions; ErbB Receptors; Female; Humans; Lapatinib; Mammaplasty; Middle Aged; Quinazolines; Surgical Flaps | 2009 |
Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK.
Topics: Anthracenes; Breast Neoplasms; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Lapatinib; MAP Kinase Kinase 1; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 9; Mitogen-Activated Protein Kinase Kinases; Proto-Oncogene Proteins c-raf; Quinazolines; Radiation Tolerance; Receptor, ErbB-2; Tumor Cells, Cultured | 2009 |
Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.
Topics: Adenoviridae; Animals; Blotting, Western; Breast Neoplasms; Cancer Vaccines; Cell Proliferation; Combined Modality Therapy; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Genetic Therapy; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Information for patients. I have HER2 positive metastatic breast cancer: is my treatment working?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biopsy; Breast Neoplasms; Female; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2009 |
Information for patients. HER2: what you need to know.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Genetic Techniques; Humans; In Situ Hybridization, Fluorescence; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2009 |
Targeting breast cancer stem cells.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Isoenzymes; Lapatinib; Neoplasm Metastasis; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2; Receptors, Notch; Retinal Dehydrogenase; Signal Transduction | 2009 |
Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Synergism; ErbB Receptors; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Lapatinib; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Retinoblastoma-Like Protein p130; RNA Interference; RNA, Messenger; Signal Transduction; Time Factors; Trastuzumab | 2010 |
Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors.
Topics: Animals; Breast Neoplasms; Drug Discovery; Drug Industry; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Technology, Pharmaceutical | 2009 |
Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Papillary; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Invasiveness; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2010 |
Ras-induced resistance to lapatinib is overcome by MEK inhibition.
Topics: Antineoplastic Agents; Breast Neoplasms; Butadienes; Cell Line, Tumor; Cell Survival; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Genes, ras; Humans; Immunoblotting; Lapatinib; Mitogen-Activated Protein Kinase Kinases; Mutation; Nitriles; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2010 |
[New development in the treatment of breast cancer. II. Future anti-HER2 therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab | 2009 |
Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA.
Topics: Apoptosis; Biopsy; Breast Neoplasms; Calcium; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Humans; Immunohistochemistry; Lapatinib; NF-kappa B; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Transcription Factor RelA | 2010 |
Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
Topics: Adaptation, Physiological; Animals; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Female; Gene Expression Regulation, Neoplastic; GRB7 Adaptor Protein; Humans; Lapatinib; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Transplantation, Heterologous; Up-Regulation | 2010 |
Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromosomes, Human, Pair 17; Female; Gene Amplification; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Quinazolines; Treatment Outcome | 2010 |
Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Gene Expression; Gene Expression Profiling; Humans; Lapatinib; Quinazolines; Receptor Cross-Talk; Receptor, ErbB-2; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2010 |
Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Genes, erbB-2; Health Services Accessibility; Humans; Lapatinib; Middle Aged; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome; United Kingdom | 2010 |
Breast cancer drug approved for new indication.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Drug Approval; Drug Therapy, Combination; Female; Humans; Lapatinib; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quinazolines; Triazoles; United States; United States Food and Drug Administration; Women's Health | 2010 |
Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Female; Gene Amplification; Humans; Lapatinib; Mutation; Neuregulin-1; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; RNA, Messenger; Trastuzumab | 2010 |
Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antineoplastic Agents; Breast Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; Drug Synergism; Enzyme Activation; Focal Adhesion Protein-Tyrosine Kinases; Humans; Integrin alpha3beta1; Integrin alpha6beta4; Kalinin; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tetraspanin 24; Trastuzumab | 2010 |
HER2 as a cancer stem-cell target.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2010 |
Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Immunoblotting; Inhibitory Concentration 50; Lapatinib; Mice; Mice, Inbred BALB C; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2011 |
Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition.
Topics: Adenylate Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autophagy; Breast Neoplasms; Calcium; Cell Line, Tumor; Elongation Factor 2 Kinase; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Intercellular Signaling Peptides and Proteins; Lapatinib; Quinazolines; Signal Transduction; Trastuzumab | 2010 |
Reporting of studies on new medicines in major medical journals: a case study in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lapatinib; Paclitaxel; Periodicals as Topic; Quinazolines; United States; United States Food and Drug Administration | 2010 |
Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Carcinoma, Ductal, Breast; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Killer Cells, Natural; Lapatinib; Lung Neoplasms; Middle Aged; Prognosis; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Taxoids; Trastuzumab | 2011 |
Tyrosine kinase inhibitors gefitinib, lapatinib and sorafenib induce rapid functional alterations in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Benzenesulfonates; Breast Neoplasms; Calcium; Cell Division; Cell Line, Tumor; Cytosol; DNA Primers; Endoplasmic Reticulum; Flow Cytometry; Gefitinib; Humans; Lapatinib; Membrane Potentials; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib | 2010 |
Updates on therapeutic approaches in HER2-positive disease.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; HSP90 Heat-Shock Proteins; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2010 |
Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.
Topics: 3T3 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Humans; Immunoblotting; In Situ Hybridization, Fluorescence; Lapatinib; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Analysis; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts.
Topics: Animals; Breast Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Mice; Mitogen-Activated Protein Kinase 3; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Receptor, ErbB-2; Transplantation, Heterologous | 2010 |
Targeting alternative pathways in HER2-positive breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2010 |
A case of metastatic breast cancer successfully treated with lapatinib plus capecitabine therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Quinazolines | 2011 |
Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Activation; Female; Humans; Lapatinib; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2010 |
Novel targeted therapies in inflammatory breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Delivery Systems; Fluorouracil; Humans; Inflammation; Lapatinib; Protein Kinase Inhibitors; Quinazolines | 2010 |
NICE rejects drug for metastatic breast cancer because of cost and poor efficacy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Drug Recalls; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Quality-Adjusted Life Years; Quinazolines; Treatment Outcome; United Kingdom | 2010 |
Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel.
Topics: Algorithms; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Drug Therapy, Combination; ErbB Receptors; Europe; Evidence-Based Medicine; Female; Humans; Lapatinib; Neoplasm Staging; Neoplasms, Hormone-Dependent; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2010 |
Dynamic simulations of pathways downstream of ERBB-family, including mutations and treatments: concordance with experimental results.
Topics: Antineoplastic Agents; Breast Neoplasms; Butadienes; Cell Line, Tumor; Computational Biology; Computer Simulation; Female; G1 Phase; Humans; Lapatinib; Mitogen-Activated Protein Kinase Kinases; Models, Biological; Mutant Proteins; Nitriles; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; Receptor, ErbB-2; Receptors, Growth Factor; Resting Phase, Cell Cycle; Signal Transduction | 2010 |
Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Everolimus; Female; Humans; Lapatinib; Quinazolines; Sirolimus | 2011 |
Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2011 |
Human epidermal growth factor receptor 2 testing in 2010: does chromosome 17 centromere copy number make any difference?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Centromere; Chromosomes, Human, Pair 17; Clinical Trials as Topic; False Negative Reactions; False Positive Reactions; Female; Humans; Immunohistochemistry; Lapatinib; Practice Guidelines as Topic; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2010 |
Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Intracellular Signaling Peptides and Proteins; Lapatinib; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Receptor, ErbB-2 | 2010 |
Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome; Young Adult | 2011 |
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.
Topics: Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; Immunoconjugates; Immunotoxins; Lapatinib; Maytansine; Mice; Mice, Nude; Mice, Transgenic; Phosphatidylinositol 3-Kinases; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2011 |
[HER2 ASCO guidelines. The answer to everything?].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Drug Delivery Systems; Female; Formaldehyde; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Lapatinib; Practice Guidelines as Topic; Predictive Value of Tests; Prognosis; Quinazolines; Receptor, ErbB-2; Tissue Fixation; Trastuzumab; Treatment Outcome | 2010 |
Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Lapatinib; Neovascularization, Pathologic; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2010 |
Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flow Cytometry; Fluorouracil; Gene Expression Profiling; Genetic Markers; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2010 |
Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Blotting, Western; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Synergism; Electrophoresis, Polyacrylamide Gel; ErbB Receptors; Female; Flavonoids; Fluorescent Antibody Technique; Gene Knockout Techniques; Humans; Indoles; Lapatinib; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Molecular Targeted Therapy; Myeloid Cell Leukemia Sequence 1 Protein; Piperidines; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrroles; Quinazolines; Roscovitine | 2010 |
Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Confidence Intervals; Deoxycytidine; Female; Fluorouracil; Health Status Indicators; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2 | 2010 |
High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Cell Proliferation; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Logistic Models; Middle Aged; Quinazolines; Receptor, ErbB-2; Republic of Korea; Risk Assessment; Risk Factors; Time Factors; Transforming Growth Factor alpha; Treatment Outcome; Up-Regulation | 2011 |
Chemotherapy-associated recurrent pneumothoraces in lymphangioleiomyomatosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Lung Neoplasms; Lymphangioleiomyomatosis; Middle Aged; Neoplasms, Second Primary; Oxygen Inhalation Therapy; Pneumothorax; Quinazolines; Trastuzumab | 2010 |
Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.
Topics: 4-Butyrolactone; Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Fatty Acid Synthases; Female; Fluorescent Antibody Technique; Gene Expression; Humans; Lapatinib; Mass Spectrometry; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Neuregulin-1; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction | 2010 |
[Two cases of HER2-positive advanced or metastatic breast cancer, responding to lapatinib and capecitabine].
Topics: Adenocarcinoma, Scirrhous; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Lung Neoplasms; Lymph Node Excision; Mastectomy; Middle Aged; Quinazolines; Receptor, ErbB-2 | 2010 |
Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Female; HSP90 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Lapatinib; Mice; Mice, SCID; Pentacyclic Triterpenes; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab; Triterpenes; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Clinical Trials, Phase II as Topic; Docetaxel; Enzyme Activation; Female; Humans; Lapatinib; Middle Aged; Mutation; Neoadjuvant Therapy; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Taxoids; Transfection; Trastuzumab | 2011 |
Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Lapatinib; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2011 |
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Lapatinib; Mice; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinases; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction; Sorafenib; Survivin; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Chromosome 17 polysomy without HER2 amplification does not predict response to lapatinib in metastatic breast cancer--letter.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Chromosomes, Human, Pair 17; Female; Gene Amplification; Humans; Lapatinib; Neoplasm Metastasis; Polyploidy; Prognosis; Quinazolines; Receptor, ErbB-2 | 2010 |
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.
Topics: Animals; Benzylamines; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Therapy, Combination; Feedback, Physiological; Female; Forkhead Transcription Factors; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Models, Biological; Multiprotein Complexes; Neoplasms; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Quinoxalines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, IGF Type 1; Receptor, Insulin; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays | 2011 |
[Anti-HER2 therapy for breast cancer--an added increasing therapeutic option].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2010 |
HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer.
Topics: Aged; Alanine Transaminase; Antineoplastic Agents; Breast Neoplasms; Case-Control Studies; Female; Genetic Predisposition to Disease; Genotype; HLA-DQ alpha-Chains; HLA-DQ Antigens; Humans; Lapatinib; Liver; Liver Diseases; Liver Function Tests; Middle Aged; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors | 2011 |
Trastuzumab and chemotherapy after the treatment failure of lapatinib for HER2-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Failure | 2010 |
Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cells, Cultured; Female; Gene Expression; Gene Expression Profiling; Humans; Immunoblotting; Immunoprecipitation; Lapatinib; Middle Aged; Oligonucleotide Array Sequence Analysis; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2011 |
Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer.
Topics: Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Mastectomy; Meningeal Carcinomatosis; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Skin Neoplasms | 2011 |
Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib.
Topics: Breast Neoplasms; Disease Progression; Female; Humans; Immediate-Early Proteins; Lapatinib; Quinazolines; Tumor Suppressor Proteins | 2011 |
The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?
Topics: Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Indoles; Lapatinib; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sunitinib | 2011 |
Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Amplification; Humans; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, Fibroblast Growth Factor, Type 2; Salvage Therapy; Treatment Failure | 2011 |
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase.
Topics: Animals; Breast Neoplasms; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Mice, Nude; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Transcription, Genetic; Transplantation, Heterologous; Up-Regulation | 2011 |
Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Amplification; Humans; Inhibitor of Apoptosis Proteins; Lapatinib; Quinazolines; Receptor, ErbB-2; RNA Interference; Survivin; Trastuzumab | 2011 |
Hints of future progress for HER-2 breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoadjuvant Therapy; Off-Label Use; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab | 2011 |
Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2011 |
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
Topics: Antibodies, Monoclonal; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lapatinib; Phosphorylation; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Signal Transduction; Staining and Labeling; Treatment Outcome | 2011 |
Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016).
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Gene Knockdown Techniques; Humans; Imatinib Mesylate; Lapatinib; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2011 |
Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Inhibitor of Apoptosis Proteins; Lapatinib; MAP Kinase Kinase Kinases; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; RNA Interference; RNA, Small Interfering; Signal Transduction; Survivin | 2011 |
Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.
Topics: Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Maytansine; Mice; Mice, SCID; Mitosis; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2011 |
Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Models, Biological; Quinazolines; Vinblastine; Vinorelbine | 2011 |
Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Genes, erbB-2; Humans; Kaplan-Meier Estimate; Lapatinib; Maytansine; Middle Aged; Neoplasm Staging; Quinazolines; Retrospective Studies; Trastuzumab; Young Adult | 2012 |
Autophagy facilitates the Lapatinib resistance of HER2 positive breast cancer cells.
Topics: Antineoplastic Agents; Autophagy; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Models, Biological; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2011 |
[Breast cancer therapy with combination of endocrine and target drugs].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Sirolimus; Trastuzumab | 2011 |
Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2.
Topics: Antibodies; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Ligands; Male; Neoplasms; Neurokinin-1 Receptor Antagonists; Piperidines; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2; Receptors, Neurokinin-1; Signal Transduction; Substance P; Trastuzumab | 2012 |
Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Capecitabine; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Female; Fluorouracil; Humans; Lapatinib; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Thymidine Phosphorylase; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2012 |
Can patients with metastatic breast cancer be cured after introduction of newer and more effective agents?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Rate; Survivors; Taxoids; Trastuzumab; Treatment Outcome | 2012 |
Lapatinib-induced hepatitis: a case report.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Female; Humans; Jaundice; Lapatinib; Middle Aged; Quinazolines | 2011 |
Assessment of PTEN and PI3K status in primary breast cancer and corresponding metastases: is it worthwhile?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Quinazolines; Trastuzumab | 2011 |
Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; GTPase-Activating Proteins; Humans; Lapatinib; Mice; Mice, Inbred NOD; Mice, SCID; Models, Biological; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2011 |
Antitumor activity of NRC-AN-019 in a pre-clinical breast cancer model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Humans; Lapatinib; Male; Mice; Mice, Nude; Mice, SCID; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2011 |
Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Female; Humans; Lapatinib; Mice; Mice, Nude; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cells, Cultured; Disease Progression; ErbB Receptors; Female; Humans; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Predictive Value of Tests; Prognosis; Quinazolines; Trastuzumab | 2011 |
HER2-targeted therapies: how far we've come--and where we're headed.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Delivery Systems; Female; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Trastuzumab | 2011 |
Trastuzumab and lapatinib modulation of HER2 tyrosine/threonine phosphorylation and cell signaling.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Female; Humans; Lapatinib; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Threonine; Trastuzumab; Tyrosine | 2012 |
Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; Female; Humans; Lapatinib; Neuregulin-1; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2011 |
Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications.
Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Morpholines; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab | 2012 |
Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence.
Topics: Amyloid Precursor Protein Secretases; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Cyclic S-Oxides; Drug Resistance, Neoplasm; Female; Gene Targeting; Genes, erbB; Genes, erbB-2; Humans; Lapatinib; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Receptor, ErbB-2; Receptors, Notch; Recurrence; Signal Transduction; Thiadiazoles; Trastuzumab | 2011 |
FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Female; Forkhead Box Protein M1; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Histone Deacetylase 2; Humans; Lapatinib; Quinazolines; Vascular Endothelial Growth Factor A | 2012 |
β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.
Topics: Antibodies; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Focal Adhesion Kinase 1; Humans; Integrin beta1; Lapatinib; Phosphorylation; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; RNA, Small Interfering; Signal Transduction; src-Family Kinases; Trastuzumab; Up-Regulation | 2011 |
BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Breast Neoplasms; CD24 Antigen; Cell Line, Tumor; Claudin-4; Female; Humans; Hyaluronan Receptors; Lapatinib; Membrane Proteins; Mice; Mice, Inbred BALB C; Mitochondrial Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Neoplastic Stem Cells; Paclitaxel; Promoter Regions, Genetic; Proto-Oncogene Proteins c-bcl-2; Quinazolines | 2011 |
Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Heart; Humans; Lapatinib; Ovarian Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Razoxane; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2011 |
Effect of the tyrosine kinase inhibitor lapatinib on CUB-domain containing protein (CDCP1)-mediated breast cancer cell survival and migration.
Topics: Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; Cell Movement; Cell Survival; Female; Humans; Lapatinib; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2; Thymidine Kinase | 2011 |
Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Cetuximab; DNA; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, Reporter; Green Fluorescent Proteins; Humans; Hypoxia; Hypoxia-Inducible Factor 1; Lapatinib; Molecular Sequence Data; Neoplasm Metastasis; Quinazolines; Transcription, Genetic | 2011 |
The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclin D1; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genetic Association Studies; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Proportional Hazards Models; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Treatment Outcome | 2012 |
The clinical utility of HER2-targeted therapy in the neoadjuvant setting: recent results from the San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Texas; Trastuzumab; Treatment Outcome | 2011 |
Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Injections, Intravenous; Lapatinib; Mice; Quinazolines; Receptor, ErbB-2; Up-Regulation | 2012 |
Lapatinib ditosylate: expanding therapeutic options for receptor tyrosine-protein kinase erbB-2-positive breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lapatinib; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2 | 2011 |
The role of lapatinib in the preoperative therapy of breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Neoplasm Proteins; Preoperative Care; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2012 |
Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Failure | 2012 |
Surrogate markers for targeted therapy-based treatment activity and efficacy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Ki-67 Antigen; Lapatinib; Molecular Targeted Therapy; Neoadjuvant Therapy; Phosphoinositide-3 Kinase Inhibitors; Poly(ADP-ribose) Polymerase Inhibitors; Precision Medicine; Predictive Value of Tests; Quinazolines; Randomized Controlled Trials as Topic; Trastuzumab; Treatment Outcome; Validation Studies as Topic | 2011 |
Neoadjuvant chemotherapy and targeted therapies: a promising strategy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Repair; Drug Discovery; Everolimus; Female; Genetic Predisposition to Disease; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Neoadjuvant Therapy; Nitriles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; Trastuzumab; Triazoles | 2011 |
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Ki-67 Antigen; Lapatinib; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoadjuvant Therapy; Nitriles; Predictive Value of Tests; Preoperative Period; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; TOR Serine-Threonine Kinases; Trastuzumab | 2012 |
Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2011 |
Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Oncogene Protein v-akt; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Xenograft Model Antitumor Assays | 2012 |
Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Amplification; Humans; Lapatinib; Phosphorylation; Quinazolines; Receptor, ErbB-2; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Smad3 Protein; Transcription, Genetic; Transcriptome; Transforming Growth Factor beta; Tretinoin | 2012 |
Quercetin-3-methyl ether inhibits lapatinib-sensitive and -resistant breast cancer cell growth by inducing G(2)/M arrest and apoptosis.
Topics: Apoptosis; Breast Neoplasms; Caspase 3; Caspase 7; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cyclin B1; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; G2 Phase Cell Cycle Checkpoints; Humans; Lapatinib; M Phase Cell Cycle Checkpoints; MAP Kinase Signaling System; Poly(ADP-ribose) Polymerases; Protein Kinases; Proto-Oncogene Proteins c-akt; Quercetin; Quinazolines; Signal Transduction | 2013 |
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Lapatinib; Mice; Mice, Nude; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Estrogen; Trastuzumab; Xenograft Model Antitumor Assays | 2011 |
[A case of breast cancer liver metastases responding to lapatinib and capecitabine therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Fatal Outcome; Female; Fluorouracil; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Quinazolines | 2011 |
Don't pick the loser: lessons from the GeparQuinto trial.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Trastuzumab | 2012 |
Select interviews from the 2011 San Antonio Breast Cancer Symposium (SABCS) and American Society of Hematology (ASH) Annual Meeting.
Topics: Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast Neoplasms; Cyclophosphamide; Dacarbazine; Doxorubicin; Female; Fertility Preservation; Humans; Lapatinib; Lymphoma; Molecular Targeted Therapy; Prednisone; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Quinazolines; Receptor, ErbB-2; Rituximab; Trastuzumab; Vinblastine; Vincristine | 2011 |
Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2012 |
Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence.
Topics: Adult; Animals; Antineoplastic Agents; Breast Neoplasms; Case-Control Studies; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cytochrome P-450 CYP3A; Dexamethasone; Drug Interactions; Female; Hepatocytes; Humans; Lapatinib; Mice; Middle Aged; Quinazolines; Retrospective Studies; Risk Factors | 2012 |
Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Benzoxazoles; Blotting, Western; Breast Neoplasms; Cell Cycle; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Lapatinib; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Multiprotein Complexes; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Receptor, ErbB-2; TOR Serine-Threonine Kinases; Transcription Factors; Trastuzumab; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Die and let live: harnessing BikDD to combat breast cancer stem cells.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; CD24 Antigen; Female; Humans; Hyaluronan Receptors; Lapatinib; Membrane Proteins; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondrial Proteins; Neoplastic Stem Cells; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Quinazolines; RNA Interference; RNA, Small Interfering | 2012 |
A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells.
Topics: Breast Neoplasms; Butadienes; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; MAP Kinase Signaling System; Matrix Metalloproteinase 1; Matrix Metalloproteinase 9; MCF-7 Cells; Neuregulin-1; Nitriles; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Protein Multimerization; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3 | 2012 |
Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estrogen Antagonists; Female; Gene Expression; Humans; Lapatinib; Mice; Mice, Nude; Molecular Targeted Therapy; Mucin-4; Oligonucleotide Array Sequence Analysis; Phenotype; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Statistics, Nonparametric; Tamoxifen; Transcriptome; Trastuzumab; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
Topics: Animals; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; ErbB Receptors; Female; Humans; Lapatinib; MAP Kinase Signaling System; Myoblasts, Cardiac; Myocytes, Cardiac; Protein Binding; Proto-Oncogene Mas; Quinazolines; Rats; Receptor, ErbB-2; Receptor, ErbB-4; Trastuzumab | 2012 |
Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Female; Follow-Up Studies; Humans; Lapatinib; Metabolome; Metabolomics; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Analysis; Time Factors; Treatment Outcome | 2012 |
HER2 testing in patients with breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Immunohistochemistry; Lapatinib; Maytansine; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2012 |
Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Transcription Factors | 2012 |
Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: a single center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Female; Genes, erbB-2; Heart; Heart Diseases; Humans; Incidence; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2 | 2012 |
Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Amplification; Humans; Inhibitory Concentration 50; Lapatinib; Neoplasms, Hormone-Dependent; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; Quinazolinones; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Trastuzumab | 2012 |
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Hepatocyte Growth Factor; Humans; Indoles; Lapatinib; Ligands; Melanoma; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Signal Transduction; Sulfonamides; Vemurafenib | 2012 |
[A case of HER2-positive breast cancer receiving lapatinib+capecitabine chemotherapy with ventriculoperitoneal shunting for hydrocephalus associated with brain metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Fatal Outcome; Female; Fluorouracil; Humans; Hydrocephalus; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Ventriculoperitoneal Shunt | 2012 |
Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Multivariate Analysis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Tamoxifen; Trastuzumab; Turkey | 2012 |
The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gene Expression Profiling; Genomics; Glucose; Humans; Hypoglycemic Agents; Lapatinib; Macrolides; Metformin; Models, Biological; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2012 |
FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Knockdown Techniques; Humans; Kaplan-Meier Estimate; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-raf; Quinazolines; RNA Interference; Signal Transduction; Tyrphostins; Xenograft Model Antitumor Assays | 2012 |
BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Long Noncoding; RNA, Messenger; RNA, Untranslated; Signal Transduction; Tamoxifen | 2012 |
Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Young Adult | 2012 |
Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Costs and Cost Analysis; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; France; Health Services; Humans; Lapatinib; Middle Aged; Models, Econometric; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
Neoadjuvant treatment for HER-2-positive and triple-negative breast cancers.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Taxoids; Trastuzumab | 2012 |
Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Breast Neoplasms; Cell Line, Tumor; eIF-2 Kinase; Endoplasmic Reticulum Stress; Female; HSP70 Heat-Shock Proteins; Humans; Indoles; Lapatinib; Membrane Proteins; Mice; Mice, Nude; Mitochondria; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase 9; p38 Mitogen-Activated Protein Kinases; Pyrroles; Quinazolines; Reactive Oxygen Species | 2012 |
Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Blotting, Western; Breast Neoplasms; Cell Proliferation; Drug Synergism; Female; Flow Cytometry; Fluorescent Antibody Technique; Genes, erbB-1; HSP90 Heat-Shock Proteins; Humans; Immunoenzyme Techniques; Immunoglobulin Fab Fragments; Lactams, Macrocyclic; Lapatinib; Male; Mice; Mice, Inbred BALB C; Quinazolines; Receptor, ErbB-2; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Lapatinib or trastuzumab in combination with an aromatase inhibitor for first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Cost-Benefit Analysis; Drug Costs; Female; Guideline Adherence; Humans; Lapatinib; Practice Guidelines as Topic; Quality-Adjusted Life Years; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; United Kingdom; Up-Regulation | 2012 |
Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Brain Neoplasms; Breast Neoplasms; Cell Death; Cell Proliferation; Diagnostic Imaging; Disease Models, Animal; Female; Gene Amplification; Humans; Killer Cells, Natural; Lapatinib; Mice; Molecular Targeted Therapy; Necrosis; Neovascularization, Pathologic; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Survival Analysis; Trastuzumab; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; BRCA1 Protein; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Survival; DNA Breaks, Double-Stranded; Drug Synergism; ErbB Receptors; Female; Humans; Lapatinib; Mice; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Binding; Protein Transport; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Recombinational DNA Repair; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Mutation; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Phosphorylation; Proteins; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; TOR Serine-Threonine Kinases | 2012 |
Ulcerated plaques in the pelvic region of an adult female.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Genital Neoplasms, Female; Humans; Lapatinib; Middle Aged; Neoplasm Invasiveness; Quinazolines; Skin Neoplasms; Skin Ulcer | 2012 |
Primary systemic treatment of breast-cancer brain metastases.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2013 |
Adherence with oral oncologic treatment in cancer patients: interest of an adherence score of all dosing errors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Male; Medication Adherence; Medication Errors; Middle Aged; Patient Compliance; Pilot Projects; Prognosis; Prospective Studies; Quinazolines | 2013 |
[Efficacy and toxicity of lapatinib plus capecitabine therapy in HER2-positive metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Retrospective Studies | 2012 |
[A case of effective lapatinib/capecitabine therapy for HER2-positive breast cancer with multiple brain metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Remission Induction | 2012 |
Novel dithiocarbamic acid esters derived from 6-aminomethyl-4-anilinoquinazolines and 6-aminomethyl-4-anilino-3-cyanoquinolines as potent EGFR inhibitors.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; ErbB Receptors; Esters; Female; HCT116 Cells; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Quinolines; Structure-Activity Relationship | 2013 |
Lapatinib plus capecitabine for brain metastases in patients with human epidermal growth factor receptor 2-positive advanced breast cancer: a review of the Anatolian Society of Medical Oncology (ASMO) experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Prevalence; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Survival Rate; Treatment Outcome; Turkey | 2012 |
Activating HER2 mutations in HER2 gene amplification negative breast cancer.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line; Drug Resistance, Neoplasm; Female; Gene Amplification; Gene Expression; Humans; Lapatinib; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice; Mice, Nude; Models, Molecular; Molecular Sequence Data; Mutation; NIH 3T3 Cells; Protein Structure, Tertiary; Quinazolines; Quinolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Sequence Homology, Amino Acid; Transplantation, Heterologous | 2013 |
Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Lapatinib inhibits the activation of NF-κB through reducing phosphorylation of IκB-α in breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Chromones; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; I-kappa B Proteins; Lapatinib; Morpholines; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Time Factors | 2013 |
Lapatinib in early breast cancer--questions to be resolved.
Topics: Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2013 |
[Lapatinib is useful for metastatic breast cancer patients who cannot be treated with trastuzumab-report of a case].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biopsy, Needle; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Lapatinib; Liver Neoplasms; Mastectomy; Neoplasm Staging; Quinazolines; Trastuzumab | 2012 |
Brain metastases from HER2-positive breast cancer.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2013 |
Brain metastases from HER2-positive breast cancer.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2013 |
Brain metastases from HER2-positive breast cancer - authors' reply.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2013 |
Impacts of HER2-overexpression and molecular targeting therapy on the efficacy of stereotactic radiosurgery for brain metastases from breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Prognosis; Quinazolines; Radiosurgery; Receptor, ErbB-2; Retrospective Studies; Survival Rate | 2013 |
Targeting the human epidermal growth factor receptor 2 pathway in breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2012 |
Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 12; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Humans; Lapatinib; Mice; Mice, Nude; Molecular Targeted Therapy; Oligonucleotide Array Sequence Analysis; Phenotype; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; RNA Interference; Small Ubiquitin-Related Modifier Proteins; Time Factors; Transfection; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Lapatinib; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Tissue Inhibitor of Metalloproteinase-1; Trastuzumab; Tumor Cells, Cultured | 2013 |
[Supports for the toxicity of the molecular target medicine].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Female; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Trastuzumab | 2012 |
Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cyclooxygenase 2; ErbB Receptors; Female; Gene Expression Regulation, Enzymologic; Humans; Lapatinib; Mice; Neoplasm Invasiveness; Quinazolines; Receptor, ErbB-2; Severe Combined Immunodeficiency; Up-Regulation; Xenograft Model Antitumor Assays | 2013 |
Psoriasis aggravation due to lapatinib.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Disease Progression; ErbB Receptors; Female; Humans; Lapatinib; Psoriasis; Quinazolines | 2013 |
Targeting HER2 in brain metastases from breast cancer.
Topics: Animals; Brain Neoplasms; Breast Neoplasms; Female; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Rats; Rats, Nude; Receptor, ErbB-2 | 2003 |
Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.
Topics: Breast Neoplasms; Cell Line, Tumor; Dimerization; Enzyme Inhibitors; Humans; Lapatinib; Neuregulin-1; Phosphorylation; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3 | 2004 |
Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.
Topics: Breast Neoplasms; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Neoplasm Proteins; Phosphorylation; Quinazolines; Radiation Tolerance; Receptor, ErbB-2; Signal Transduction; Tumor Stem Cell Assay | 2004 |
The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
Topics: Breast Neoplasms; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Estrogen Receptor Modulators; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Tamoxifen | 2005 |
Early success of combined EGFR and Her2 receptor blockade as a clinical strategy in breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase I as Topic; ErbB Receptors; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2004 |
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.
Topics: Antibodies, Monoclonal; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2005 |
Highlights From ECCO 13-The European Cancer Conference Paris, France October 30 to November 3, 2005.
Topics: Administration, Oral; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diphosphonates; Docetaxel; Europe; Female; Humans; Ibandronic Acid; Lapatinib; Quinazolines; Taxoids; Trastuzumab | 2005 |
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Drug Interactions; Drug Screening Assays, Antitumor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Lapatinib; Mice; Mice, SCID; Oncogene Protein v-akt; Phosphorylation; Quinazolines; raf Kinases; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2006 |
Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; ErbB Receptors; Humans; Inhibitor of Apoptosis Proteins; Lapatinib; Microtubule-Associated Proteins; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA Interference; Signal Transduction; Survivin | 2006 |
A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; RNA, Small Interfering; Signal Transduction | 2006 |
Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Dihydrouracil Dehydrogenase (NADP); Drug Synergism; ErbB Receptors; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Thymidine Phosphorylase; Thymidylate Synthase; Trastuzumab | 2006 |
Delivery of a healthy baby after first-trimester maternal exposure to lapatinib.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Infant, Newborn; Lapatinib; Live Birth; Neoplasm Metastasis; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, First; Quinazolines | 2006 |
Targeted therapy for metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2006 |
Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzopyrans; Breast Neoplasms; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Humans; Indoles; Lapatinib; Nitriles; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Quinazolines; Receptor, ErbB-2 | 2007 |
Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Humans; Lapatinib; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2007 |
Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Immunoblotting; Immunoprecipitation; Insulin-Like Growth Factor I; Lapatinib; Quinazolines; Receptor, ErbB-2; Receptor, IGF Type 1; Signal Transduction; Trastuzumab | 2007 |
Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Drug Approval; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Inflammation; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Research Design; Trastuzumab; United States | 2007 |
TEACH: Tykerb evaluation after chemotherapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2007 |
Lapatinib plus capecitabine in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Time Factors; Trastuzumab | 2007 |
Closing in on a cure.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2; United States | 2006 |
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Division; Cell Line, Tumor; Cloning, Molecular; DNA, Complementary; Female; Genes, erbB-2; Genetic Vectors; Humans; Lapatinib; Mice; Mice, Nude; Quinazolines; Receptor, ErbB-2; Sequence Deletion; Signal Transduction; Transfection; Transplantation, Heterologous; Trastuzumab | 2007 |
Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Lapatinib; Models, Biological; Oligonucleotide Array Sequence Analysis; Proteomics; Quinazolines; Time Factors | 2007 |
Lapatinib shows promise for inflammatory breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase II as Topic; Female; Humans; Inflammation; Lapatinib; Multicenter Studies as Topic; Quinazolines | 2007 |
Lapatinib.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Breast Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2007 |
Why are promising new drugs for dying patients still out of reach?
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Drug Approval; Female; Health Services Accessibility; Humans; Lapatinib; Quinazolines; Terminal Care; United States; United States Food and Drug Administration | 2007 |
Development of new targeted therapies for breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Delivery Systems; Female; Humans; Lapatinib; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Trastuzumab | 2008 |
Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Drug Resistance; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Protein Kinases; Proteome; Proteomics; Quinazolines; Receptor, ErbB-2; Ribosomal Protein S6 Kinases, 70-kDa; TOR Serine-Threonine Kinases | 2008 |
Advances in HER2-positive breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2008 |
Treatment of breast cancer with trastuzumab during pregnancy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Infant, Low Birth Weight; Infant, Newborn; Infant, Premature; Lapatinib; Lung Neoplasms; Mastectomy, Modified Radical; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Quinazolines; Trastuzumab | 2008 |
Cerebellar toxicity with capecitabine in a patient with metastatic breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cerebellar Ataxia; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines | 2008 |
FDA approves new drug for specific type of advanced breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Approval; ErbB Receptors; Female; Humans; Lapatinib; Quinazolines; United States; United States Food and Drug Administration | 2007 |
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flow Cytometry; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Research Design | 2008 |
Mathematics in the realm of lapatinib: 500 + 500 = 1,500?
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2008 |
Ten years of HER2-directed therapy: still questions after all these years.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Drug Delivery Systems; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Forecasting; Humans; Lapatinib; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab | 2009 |
Lapatinib study supports cancer stem cell hypothesis, encourages industry research.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; CD24 Antigen; Down-Regulation; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Lapatinib; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Up-Regulation | 2008 |